<SEC-DOCUMENT>0001171843-24-002274.txt : 20240426
<SEC-HEADER>0001171843-24-002274.hdr.sgml : 20240426
<ACCEPTANCE-DATETIME>20240426084824
ACCESSION NUMBER:		0001171843-24-002274
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		30
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240426
DATE AS OF CHANGE:		20240426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		24879052

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>anik20231231_10ka.htm
<DESCRIPTION>FORM 10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:anik="http://www.anik.com/20231231"><head>
	<title>anik20231231_10ka.htm</title>

	<!-- Generated by ThunderDome Portal - 4/26/2024 11:00:07 AM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d202410KA" name="dei:AmendmentFlag" id="ixv-6612">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d202410KA" name="dei:EntityCentralIndexKey" id="ixv-6613">0000898437</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="anik-20231231.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d202410KA">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d202410KABYX">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d202410KAWEJ">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2024-04-22</xbrli:instant>
</xbrli:period>
</xbrli:context>


<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>

</ix:resources>
</ix:header>
</div>

<div class="hidden-ix-covertags" style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; display: none;"><ix:nonNumeric contextRef="d202410KA" name="dei:CurrentFiscalYearEndDate" id="ixv-6637">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="d202410KA" name="dei:DocumentFiscalPeriodFocus" id="ixv-6638">FY</ix:nonNumeric><ix:nonNumeric contextRef="d202410KA" name="dei:DocumentFiscalYearFocus" id="ixv-6639">2023</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>UNITED STATES</b><br/>
<b>SECURITIES AND EXCHANGE COMMISSION</b><br/>
<b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>FORM <ix:nonNumeric contextRef="d202410KA" name="dei:DocumentType" id="ixv-17"><b>10-K/A</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(Amendment No. 1)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(Mark One)</b></div>
			</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-6640">&#9746;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION</b>&#160;<b>13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF</b>&#160;<b>1934</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the fiscal year ended <ix:nonNumeric contextRef="d202410KA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-43"><b>December</b>&#160;<b>31, 2023</b></ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-6641">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION</b>&#160;<b>13 OR 15 (d)</b>&#160;<b>OF THE SECURITIES EXCHANGE ACT OF</b>&#160;<b>1934</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from&#160; &#160; &#160; &#160;&#160;&#160;</b>&#160;<b>to</b>&#160;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Commission File Number</b> <ix:nonNumeric contextRef="d202410KA" name="dei:EntityFileNumber" id="ixv-68"><b>001-14027</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d202410KA" name="dei:EntityRegistrantName" id="ixv-72"><b>Anika Therapeutics,</b> <b>Inc.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>(Exact Name of Registrant as Specified in Its Charter)</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-83"><b>Delaware</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(State or Other Jurisdiction of Incorporation or Organization)</i></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" name="dei:EntityTaxIdentificationNumber" id="ixv-89"><b>04-3145961</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(IRS Employer Identification No.)</i></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><ix:nonNumeric contextRef="d202410KA" name="dei:EntityAddressAddressLine1" id="ixv-96"><b>32 Wiggins Avenue</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d202410KA" name="dei:EntityAddressCityOrTown" id="ixv-98"><b>Bedford</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d202410KA" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-100"><b>Massachusetts</b></ix:nonNumeric> <ix:nonNumeric contextRef="d202410KA" name="dei:EntityAddressPostalZipCode" id="ixv-102"><b>01730</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>(Address of Principal Executive Offices) (Zip Code)</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(<ix:nonNumeric contextRef="d202410KA" name="dei:CityAreaCode" id="ixv-109"><b>781</b></ix:nonNumeric>)</b> <ix:nonNumeric contextRef="d202410KA" name="dei:LocalPhoneNumber" id="ixv-111"><b>457-9000</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>(Registrant</i>&#8217;<i>s Telephone Number, Including Area Code)</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Securities registered pursuant to Section</b> <b>12(b) of the Act:</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Title of Each Class</i></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Trading Symbol</i></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Name of Each Exchange on Which Registered</i></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" name="dei:Security12bTitle" id="ixv-6642">Common Stock, par value $0.01 per share</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" name="dei:TradingSymbol" id="ixv-6643">ANIK</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-6644">NASDAQ</ix:nonNumeric> Global Select Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="d202410KA" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-6645">No</ix:nonNumeric> &#9746;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="d202410KA" name="dei:EntityVoluntaryFilers" id="ixv-6646">No</ix:nonNumeric> &#9746;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="d202410KA" name="dei:EntityCurrentReportingStatus" id="ixv-6647">Yes</ix:nonNumeric> &#9746; No &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="d202410KA" name="dei:EntityInteractiveDataCurrent" id="ixv-6648">Yes</ix:nonNumeric> &#9746; No &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Large accelerated filer &#9744;</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d202410KA" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-6649">Accelerated filer</ix:nonNumeric> &#9746;</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Non-accelerated filer &#9744;</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smaller reporting company <ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-6650">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-6651">&#9744;</ix:nonNumeric></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-6652">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-6653">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="d202410KA" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="ixv-6654">&#9744;</ix:nonNumeric> No &#9746;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The aggregate market value of voting common stock held by non-affiliates of the registrant as of June 30, 2023, the last day of the registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction contextRef="d202410KABYX" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" unitRef="USD" scale="0" decimals="0" id="ixv-6655">370,427,535</ix:nonFraction> computed by reference to the closing price of common stock on such date. The registrant does not have any non-voting stock outstanding.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At April 22, 2024, there were <ix:nonFraction contextRef="d202410KAWEJ" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" unitRef="Share" scale="0" decimals="0" id="ixv-6656">14,828,456</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>EXPLANATORY NOTE</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<ix:nonNumeric contextRef="d202410KA" name="dei:AmendmentDescription" id="ixv-200"><div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:24pt;">This Amendment No. 1 on Form 10-K/A, or the Amendment, amends the Annual Report on Form 10-K of Anika Therapeutics, Inc., a Delaware corporation, or we, our, us, Anika, or the Company, for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission, or the SEC, on March 15, 2024, or the Original Filing. This Amendment is being filed to amend Part III of the Original Filing to include the information required by and not included in Part III of the Original Filing. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 4 and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:24pt;">Except for the matters described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing other than as expressly indicated in this Amendment. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company&#8217;s other filings made with the SEC on or subsequent to March 15, 2024.</div>

</ix:nonNumeric><div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART III</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Directors</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth certain information about the current directors of our Company. Directors are elected for three-year terms, to hold office until the annual meeting of stockholders or special meeting in lieu of such annual meeting at the end of their term, or until their successors are elected and qualified or until their earlier deaths, resignations, or removal.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our Board of Directors, or Board, is committed to maintaining a diverse and inclusive membership with varying experience, characteristics, and expertise that complement our business strategy. On an annual basis, the Board of Directors reviews the cumulative skill set of our Board members to insure we have the skills and experience we believe are required for Board oversight and governance of the Company and we undergo periodic Board refreshment accordingly. 6 of our 8 directors have a tenure of less than 5 years, including 2 of 8 directors being appointed in the last three years. Our directors, individually and as a group, possess a wide range of skills and experiences that are highly relevant as we transform our company, expand our business into new treatment areas and develop, manufacture, and launch new products. Our directors are strategic thinkers with high expectations for our performance. Our directors are attuned to the value and importance of diversity in all of its forms and the demands of proper Board oversight and good governance practices.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following provides information regarding our directors as of April 22, 2024:</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(0, 102, 153);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#ffffff;"><b>Director Name</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Age</b></span></b></div>
			</td>
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Director</b></span></b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Since</b></span></b></div>
			</td>
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Term</b> </span></b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Expires</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Class</i></b> <b><i>I Directors</i></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Sheryl L. Conley</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">63</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2021</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2024</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stephen O. Richard</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">61</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2020</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2024</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Jeffery S. Thompson</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">58</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2011</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2024</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Class</i></b> <b><i>II Directors</i></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">59</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2018</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2025</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Glenn R. Larsen, Ph.D.</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">70</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2015</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2025</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Class</i></b> <b><i>III Directors</i></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>&#160;</b></i></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Gary P. Fischetti</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">63</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2023</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2026</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">John B. Henneman, III</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">62</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2020</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2026</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Susan L. N. Vogt</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">70</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2018</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2026</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following biographical descriptions set forth certain information with respect to the directors of our Board, based on information furnished to us by each director.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
4
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Cheryl R. Blanchard, Ph.D.</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="blanchard.jpg" src="blanchard.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since August 2018</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>PRESIDENT and<br/>
			CHIEF EXECUTIVE OFFICER</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 59&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer of Anika since April 2020, and Interim Chief Executive Officer of Anika from February 2020 through April 2020</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Principal at Blanchard Consulting, LLC, a provider of scientific, regulatory, and business strategy consulting services to medical device companies and private equity clients, from 2012 to 2020</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed biotechnology company developing regenerative medicine and drug delivery products, from 2014 until its sale to Dar&#233;&#160;Bioscience, Inc. in November 2019</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Various offices, including Senior Vice President, Chief Scientific Officer, and general manager of Zimmer Biologics, of Zimmer, Inc., a medical device company focused on musculoskeletal products, from 2000 to 2012</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Current Public Company Board Service </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dar&#233;&#160;Bioscience, Inc. (NASDAQ: DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health, from November 2019 &#8211;&#160;present</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company that went public in January 2022, committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, from December 2020 &#8211;&#160;present</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Former Recent Public Company Board Service </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on products for psychiatric disorders, from February 2019 to June 2020</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, from June 2015 &#8211;&#160;May 2019</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ph.D. and M.S. in Materials Science and Engineering from the University of Texas-Austin</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.S. in Ceramic Engineering from Alfred University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
5
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience, Commercialization/ Marketing Expertise, M&amp;A/Business Development Expertise, Manufacturing Experience, R&amp;D/Innovation Experience, Regulatory Expertise, and International/Global Business Experience</b>&#160;&#8211;&#160;acquired over her career in positions of leadership at multiple companies in the life science industry, where she gained extensive experience in business development, developing and commercializing products, including building from scratch a high-growth $100 million-plus regenerative medicine business while at Zimmer, and regenerative medicine and drug delivery products while at multiple companies in the life science industry</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise</b>&#160;&#8211;&#160;obtained through her experience serving on boards of directors, including publicly held medical technology and biopharmaceutical companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr.&#160;Blanchard also brings <b>Human Capital Management Expertise</b>&#160;to the Board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
6

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Sheryl L. Conley</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="conley.jpg" src="conley.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since October 2021</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Committees:</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Audit</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 63&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Board Member of AcceLINX, Inc., a musculoskeletal health business accelerator, from March 2017 to December 2022</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer of OrthoWorx, Inc., a community-based initiative that works strategically and collaboratively with the orthopedic industry, from September 2012 to May 2017</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Group President and Chief Marketing Officer (December 2005 to May 2008) and various management roles at Zimmer, Inc., a medical device company focused on musculoskeletal products, from June 1983 to May 2008</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Public Company Board Service </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on transforming patient lives with the best neurohealth therapies in the world, from October 2019 &#8211;&#160;present</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, from May 2021 &#8211;&#160;December 2023</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">M.B.A. from Ball State University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.S. in Biology and Chemistry from Ball State University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience, Commercialization/Marketing Expertise, M&amp;A/Business Development Expertise, R&amp;D/Innovation Expertise, Financial Oversight/Accounting Expertise, Regulatory Expertise, and International/Global Business Experience </b>&#8211;&#160;gained during more than 35 years in the orthopedic medical device and healthcare industries, including her significant executive leadership experience running full profit-and-loss business segments, global brand management, marketing, sales, product development, operations, and in global medical device development and commercialization</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing Expertise</b>&#160;&#8211;&#160;developed while at Zimmer, where she held roles with responsibility for oversight of business divisions that included manufacturing segments</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise </b>&#8211;&#160;obtained through her corporate section 16 officer roles at Zimmer, an NYSE public company, in addition to her experience serving on boards of directors, including boards of publicly held medical technology companies, gaining experience serving as a board chair and a chair of a nominating and governance committee</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ms.&#160;Conley also brings <b>Human Capital Management Expertise</b>&#160;to the Board through her multiple and globally expansive executive leadership roles</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
7

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Gary P. Fischetti</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="fischetti.jpg" src="fischetti.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since April 2023</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Committees:</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capital Allocation</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 63&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Spent 35 years at Johnson &amp; Johnson, a multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods, in positions of increasing responsibility, including Company Group Chairman &#8211;&#160;North American Medical Devices from May 2015 to January 2018, Company Group Chairman &#8211;&#160;DePuy Synthes North America from January 2014 to June 2015, Company Group Chairman &#8211;&#160;DePuy Orthopaedic from February 2011 to May 2015, and Worldwide President of DePuy Spine from 2005 to 2011</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Public Company Board Service </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Conformis (NASDAQ: CFMS), a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain, from May 2022 through completion of the acquisition by Restor3d in September 2023</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">M.B.A. from Rutgers University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.S.B.A. in Finance from Villanova University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience, Commercialization/Marketing Expertise, M&amp;A/Business Development Expertise, R&amp;D/Innovation Expertise, Financial Oversight/Accounting Expertise, Regulatory Expertise, and International/Global Business Experience</b>&#160;&#8211;&#160;acquired during his 35 years at Johnson &amp; Johnson serving in executive leadership positions for multiple medical device businesses and divisions of the company, with both domestic and worldwide responsibilities, overseeing all aspects of strategic planning, product and business development, and commercial operations, with full P&amp;L responsibility, as well as oversight of sales and marketing initiatives</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise</b>&#160;&#8211;&#160;obtained through his experience serving on boards of directors, including the board of publicly held medical technology company, Conformis</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
8

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>John B. Henneman, III</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="henneman.jpg" src="henneman.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since September 2020</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chair of the Board</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Committees:</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation (Chair)</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capital Allocation</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Governance and Nominating</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 62&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology company, from October 2014 to July 2018, and Chief Administrative Officer of NewLink from July 2018 through his retirement in November 2018</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Various offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including Chief Financial Officer from 2007 to 2014, and earlier as General Counsel and Chief Administrative Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Public Company Board Service </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aprea Therapeutics Inc. (NASDAQ: APRE), a biotechnology company focused on novel cancer therapeutics, from August 2019 &#8211;&#160;present</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">R1 RCM, Inc. (NASDAQ: RCM), a provider of revenue cycle management services to healthcare providers, from February 2016 &#8211;&#160;present (lead independent director from February 2022 &#8211; present)</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Orthofix Medical, Inc. (NASDAQ: OFIX), a leading global spine and orthopedics company, from January 2023 &#8211;&#160;present</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SeaSpine Holdings Corporation (NASDAQ: SPNE), a spinal implant and orthobiologics company, from July 2015 through completion of the merger and acquisition by Orthofix Medical Inc. in January&#160;2023</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">J.D. from University of Michigan Law School</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A.B. in Politics from Princeton University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience</b>&#160;and <b>M&amp;A/Business Development Expertise </b>&#8211;&#160;developed during his more than 25 years of senior management experience in the medical technology and biotechnology industries, including at Integra, where he led or executed more than 40 acquisitions and alliances and raised more than $1 billion in debt and equity financing &#160;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;"><b>Financial Oversight/Accounting Expertise</b> &#8211; acquired while serving as Executive Vice President and Chief Financial Officer of NewLink Genetics and as Chief Financial Officer of Integra, positions in which he was responsible for overseeing all the financial aspects of the company&#8217;s operations</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
9
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Human Capital Management Expertise</b>&#160;and <b>Regulatory Expertise</b>&#160;&#8211;&#160;gained in his role as General Counsel at Integra and his multiple roles as CFO, especially at Integra, where while serving in that role, he had the additional responsibility, at various times, for the company&#8217;s regulatory affairs and human resources functions</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise </b>&#8211;&#160;obtained through his significant experience serving on boards of directors, including boards of publicly held life science companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mr.&#160;Henneman also brings <b>International/Global Business Experience</b>&#160;to the Board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
10

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Glenn R. Larsen, Ph.D.</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="larsen.jpg" src="larsen.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 60pt; text-indent: -36pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since February 2015</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 60pt; text-indent: -36pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Committees:</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Governance and Nominating</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 70&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Chairman, President, Chief Executive Officer and cofounder of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused on the development of treatments for ALS, Alzheimer&#8217;s, and other neurodegenerative diseases, from February 2014 to present</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman, President, and Chief Executive Officer of 180 Therapeutics L.P., a clinical stage musculoskeletal drug development company, from 2013 until its merger with NASDAQ-listed 180 LifeSciences in 2020</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Scientific Officer and Executive Vice President of Research and Development of SpringLeaf Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 to 2013</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Operating Officer, Executive Vice President of Research and Development and director of Hydra Biosciences, Inc., a biopharmaceutical company focused on developing pain therapeutic drugs, from 2003 to 2010</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series of drug discovery and development leadership positions, including Global Development Board and Vice President Musculoskeletal Sciences, at Wyeth (now Pfizer)/Genetics Institute, where he directed Wyeth&#8217;s second-largest therapeutic area with responsibility for Enbrel, an anti-TNF therapeutic for arthritic pain with multi-billion dollar annual sales, and the development of Infuse Bone Graft, the 1<sup style="vertical-align:top;line-height:120%;">st</sup>&#160;regenerative biologic medicine approved for numerous orthopedic bone regeneration indications</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ph.D. in Biochemistry from Stony Brook University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">P.M.D. from Harvard University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;"><b>Medical Devices/Pharmaceutical Experience, R&amp;D/Innovation Expertise, M&amp;A/Business Development Expertise, Regulatory Expertise, </b>and<b> International/Global Business Experience</b> &#8211; acquired during his extensive background in management, product development and business development at multiple companies in the life science industry as well as significant experience in innovative research and product development and commercial development, including leading groups that advanced 15 drugs to clinical development, resulting in 5 commercial approvals</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility </b>&#8211;&#160;obtained through his service on the Company&#8217;s board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr.&#160;Larsen also brings <b>Manufacturing, Financial Oversight/Accounting </b>and <b>Human Capital Management Expertise </b>to the Board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
11

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Stephen O. Richard</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="richard.jpg" src="richard.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since September 2020</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Committees:</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Audit (Chair) (Financial Expert)</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capital Allocation (Chair)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 61&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Senior Vice President, Chief Risk Officer from May 2019 to present, and Chief Audit Executive from 2016 to present, of Becton, Dickinson and Company, an $18 billion, global medical technology company</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Various executive positions in the areas of finance, operations and business development of the National Basketball Association from 1998 to 2016, including Senior Vice President, Business Development and Global Operations of NBA Properties, Inc. from 2013 to 2016, Chief Financial Officer of NBA China from 2010 to 2013, and Interim Chief Executive Officer of NBA China from 2010 to 2011</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Earlier in his career, Mr.&#160;Richard served as, among other positions, Regional Audit Director, U.S. Consumer Businesses at Citigroup Inc., District Manager, Financial Planning and Analysis at AT&amp;T Corporation, and Senior Manager at Deloitte&#160;&amp; Touche LLP</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">M.B.A. in Finance from Columbia Business School</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.S. in Accounting from Northeastern University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience and Commercialization/Marketing Expertise </b>&#8211;<b>&#160;</b>acquired through his senior management roles at Becton, Dickinson and Company and the National Basketball Association</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise </b>and <b>M&amp;A/Business Development Expertise</b>&#160;&#8211;&#160;gained as Chief Risk Officer of Becton, Dickinson and Company and Senior Vice President, Business Development and Global Operations of NBA Properties; <b>NACD Directorship Certified</b>, having completed examination and continuing recertification requirements through the National Association of Corporate Directors (NACD)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Oversight/Accounting Expertise</b>&#160;and <b>International/Global Business Experience</b>&#160;&#8211;&#160;first gained through his education and further developed during his experience serving as Chief Risk Officer and Chief Audit Executive of Becton, Dickinson, Chief Financial Officer and interim Chief Executive Officer of NBA China, and Regional Audit Director, U.S. Consumer Businesses at Citigroup, as well as all prior professional positions and as the Chairman of the Committee on Governance, Risk and Compliance of Financial Executives International, an association of financial executives serving public and private companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mr.&#160;Richard also brings <b>Human Capital Management Expertise </b>to the Board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mr. Richard is a <b>Certified Public Accountant</b>&#160;with an active license in the State of New Jersey</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
12

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Jeffery S. Thompson</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="thompson.jpg" src="thompson.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since January 2011</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 58&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Partner with HealthEdge Investment Partners, LLC, or HealthEdge, a private equity firm providing strategic capital exclusively to the healthcare industry, where he sits on the investment team and serves as a director for numerous HealthEdge affiliated companies, including Legacy Xspire Holdings, LifeSync and Westone, from 2008 to present</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Previously, Chairman, Chief Executive Officer and President of Advanced Bio-Technologies, Inc. and Enaltus LLC, both HealthEdge portfolio companies specializing in skincare solutions sold to consumers and direct to physicians from 2008 to 2017</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-executive director of Sinclair Pharma, plc, a publicly traded international aesthetic dermatology company from September 2014 until its acquisition by China Grand in November 2018</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Director and Chief Operating Officer of Stiefel Laboratories, Inc., an independent pharmaceutical company with wholly-owned global operations specializing in dermatology in 100 plus markets, and President of Glades Pharmaceuticals, both of which were sold to GlaxoSmithKline in 2008</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Earlier in his career, Mr.&#160;Thompson held sales and business management positions at Bausch&#160;&amp; Lomb Pharmaceuticals and SmithKline Beecham</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.S. in General Science from University of Pittsburgh</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience, Manufacturing Expertise, R&amp;D/Innovation Expertise, Regulatory Expertise</b>&#160;and <b>Commercialization/Marketing Expertise</b>&#160;&#8211;&#160;gained over his extensive career in leadership roles, including as CEO, at multiple life science and healthcare services companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>M&amp;A/Business Development Expertise </b>&#8211;&#160;acquired during more than a decade spent advising HealthEdge portfolio and other life sciences companies on business development strategies and transactions</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise </b>&#8211;&#160;developed during his extensive experience serving on boards of directors of numerous life science, biotechnology, and healthcare services companies, including Sinclair Pharma and Stiefel Laboratories</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mr.&#160;Thompson also brings <b>Human Capital Management Expertise </b>and <b>International Global/Business Experience</b>&#160;to the Board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
13

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(0, 102, 153);">
			<td colspan="2" style="vertical-align: middle; width: 100%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><span style="color:#ffffff;"><b>Susan L. N. Vogt</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div><img alt="vogt.jpg" src="vogt.jpg"/></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Anika Board Service:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Director since October 2018</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Committees:</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Audit (Financial Expert)</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 66pt; text-indent: -18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Governance and Nominating (Chair)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%; padding: 0px; background-color: rgb(204, 238, 255);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>INDEPENDENT</b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Age: 70&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 0%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Professional Experience </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer and President of Aushon Biosystems, Inc., a developer of a multiplex immunoassay platform, from 2013 until its acquisition in January 2018</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer, President, and a director of SeraCare Life Sciences, Inc., a NASDAQ-listed life sciences developer of products facilitating human diagnostics and therapeutics, from 2006 to 2011</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Former director of Andor Technology (LSE:AND) from 2010 to 2013</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">From 1981 to 2005, various management and officer positions at Millipore Corporation (now part of MilliporeSigma, the life science business of Merck KGaA), an NYSE-listed developer of technologies for life science research, drug development and manufacturing for the biotechnology and pharmaceutical industries, including, among other leadership roles, President of the Biopharmaceutical Division, Vice President and General Manager of the Laboratory Water Division, and Vice President and General Manager of the Analytical Products Division</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Public Company Board Service </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sharps Compliance, Inc. (NASDAQ: SMED) a leading full-service national provider of comprehensive waste management services, including medical, pharmaceutical, and hazardous waste, from October 2019 through completion of the merger and acquisition by an affiliate of Aurora Capital Partners, a private equity firm, in August 2022</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">Charlotte&#8217;s Web Holdings, Inc. (TSX: CWEB) a leading provider of CBD wellness products, from September 2020 &#8211; February 2024</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Education </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">M.B.A. from Boston University, concentration in Finance</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A.B. in Art History from Brown University</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Relevant Skills </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices/Pharmaceutical Experience, R&amp;D/Innovation Experience, Manufacturing Experience </b>and <b>Commercialization/Marketing Expertise </b>&#8211;&#160;gained through her more than thirty-five years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics industries, including senior roles at MilliporeSigma, SeraCare Life Sciences and Aushon Biosystems and her proven record of driving operational efficiency and productivity, successfully scaling commercial operations, enhancing profitability by streamlining, restructuring and consolidating operations, and delivering sustained revenue and cash flow growth at multiple companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
14
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Oversight/Accounting Expertise</b>&#160;&#8211;&#160;as a result of her education, financial-based roles during her career and serving on audit committees of several companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Company Governance/Corporate Responsibility Expertise </b>&#8211;&#160;obtained through her significant experience in serving on the boards of directors of other public companies</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</div>
			</td>
			<td style="vertical-align:top;width:52.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ms.&#160;Vogt also brings <b>Regulatory Expertise, Human Capital Management Expertise, </b>and <b>International/Global Business Experience </b>to the Board</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
15

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Executive Officers</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table sets forth certain information regarding our executive officers as of April 22, 2024:</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align:bottom;width:28.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Name</b></span></div>
			</td>
			<td style="vertical-align:bottom;width:62.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Position</b></span></div>
			</td>
			<td style="vertical-align:bottom;width:9.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Age</b></span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:28.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;">Cheryl&#160;R.&#160;Blanchard,&#160;Ph.D.</div>
			</td>
			<td style="vertical-align:bottom;width:62.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</div>
			</td>
			<td style="vertical-align:bottom;width:9.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">59</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align:top;width:28.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;">Michael L. Levitz</div>
			</td>
			<td style="vertical-align:bottom;width:62.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Vice President, Chief Financial Officer and Treasurer</div>
			</td>
			<td style="vertical-align:bottom;width:9.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">50</div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:28.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;">David B. Colleran</div>
			</td>
			<td style="vertical-align:bottom;width:62.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Vice President, General Counsel and Secretary</div>
			</td>
			<td style="vertical-align:bottom;width:9.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">52</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align:top;width:28.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;">Anne M. Nunes</div>
			</td>
			<td style="vertical-align:bottom;width:62.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Senior Vice President, Chief Operations Officer</div>
			</td>
			<td style="vertical-align:bottom;width:9.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our executive officers are appointed by, and serve at the discretion of, our Board. The business experience for the past five years, and in some instances, for prior years, of each of our executive officers is as follows. <i>Dr.</i>&#160;<i>Blanchard</i>&#8217;<i>s</i> biography is included above in the section titled &#8216;Directors&#8217;.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Michael L. Levitz </i>was appointed Executive Vice President, Chief Financial Officer and Treasurer in August 2020. Mr.&#160;Levitz served as the Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a publicly traded, global medical device and drug delivery company, from 2015 to May 2019. From 2009 to 2015, Mr.&#160;Levitz was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging, and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic), Mr.&#160;Levitz served in various capacities including Vice President and Corporate Controller. Mr.&#160;Levitz began his career in the high technology audit practice at Arthur Andersen LLP. Mr.&#160;Levitz earned his Bachelor of Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>David B. Colleran </i>was appointed Executive Vice President, General Counsel and Secretary in March 2020. Most recently, Mr.&#160;Colleran served as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer at Insulet Corporation, a publicly traded, global medical device and drug delivery company, from July 2015 through March 2019. Prior to that, from 2010 to 2015, he held the role of Vice President and General Counsel of the Medical Supplies segment, and from 2006 to 2010, he held the role of Associate General Counsel, both at Covidien, a global manufacturer of medical devices and supplies acquired by Medtronic in 2015. Prior to that, he was Corporate Counsel at Ocean Spray Cranberries. Mr.&#160;Colleran began his career as a corporate attorney at the law firm Choate, Hall&#160;&amp; Stewart. Mr.&#160;Colleran holds a B.A. in Political Science from Boston College and a J.D. from Boston College Law School.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Anne M. Nunes</i> was appointed Senior Vice President, Chief Operations Officer in June 2023. Prior to her appointment as Senior Vice President, Chief Operations Officer, Ms. Nunes was our Vice President of Operations since September 2021. Prior to joining the Company, from 2019 to 2021, Ms. Nunes served as Senior Vice President of Global Operations at Smith &amp; Nephew, a global portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. From 2012 to 2019, Ms. Nunes held roles of increasing responsibility with Smith &amp; Nephew, including Senior Vice President of Process Optimization, Vice President of Supply Chain for the Advance Surgical Devices division, and Chief Information Officer of the Sports Medicine business. Prior to 2012, Ms. Nunes held positions at Biogen Idec, a global biotechnology company that pioneers science and drives innovations for complex and devastating diseases, and Eli Lilly &amp; Co., a pharmaceutical company. Ms. Nunes holds a Bachelor of Science in Chemistry from the University of Illinois and a Masters of Business Administration from Boston University.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Family Relationship</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There are no family relationships among any of our directors and executive officers.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
16
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corporate Governance and Board Matters</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Board of Directors annually reviews the independence of all non-employee directors. In 2020, the Board established categorical standards consistent with the corporate governance standards of NASDAQ to assist the Board in making determinations of the independence of Board members. A copy of our Standards for Director Independence, which was adopted by the Board in April 2020, is available on the investor relations portion of our website at <i>https://ir.anika.com/governance-documents</i>. These categorical standards require that, to be independent, a director may not have a material relationship with our Company. Even if a director meets all categorical standards for independence, the Board reviews other relationships with Anika in order to conclude that each independent director has no material relationship with Anika either directly or indirectly.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board has determined that each of the continuing directors and director nominees, other than our President and Chief Executive Officer, Cheryl R. Blanchard, Ph.D., is &#8220;independent&#8221; within the meaning of the director independence standards of NASDAQ and the SEC. The Board based these determinations primarily on a review of the responses of each director and director nominee to questions regarding employment and compensation history, affiliations, and family and other relationships, and on other relevant discussions with the directors and director nominees.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Independent directors meet regularly in executive sessions without management participation. The executive sessions generally occur in connection with regularly scheduled meetings of the Board and committees of the Board, and at other times the independent directors deem appropriate. The executive sessions are chaired either by the Chair of the Board or by the Chair of the Board committee, as applicable.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board and its committees review matters related to our corporate governance periodically at regularly scheduled meetings. The Board&#8217;s review process includes an evaluation of our bylaws, committee charters, diversity programs, corporate social and environmental responsibility initiatives, and other matters related to our governance. During this review, the Board assesses input from management and outside consultants as appropriate to discern whether any actions should be taken on any of these topics. Furthermore, the Board conducts periodic evaluations that focus on the effectiveness of the Board as a whole and of its committees. Board members complete a detailed questionnaire that provides for quantitative rankings in key areas and seeks subjective comments in each of those areas. In addition, members of each Board committee complete a detailed questionnaire to evaluate how well their committee is operating and to make suggestions for improvement. The evaluation process is managed by the Chair of the Governance and Nominating Committee, with advice and assistance from outside counsel. Outside counsel may conduct separate, confidential interviews with some or all of the directors to follow-up on responses and comments reflected in the questionnaires to the extent it is determined helpful or necessary. An anonymized summary of the principal findings from the evaluation process is prepared by outside counsel and is used as the basis for self-assessment discussions by the Board and its committees.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Board met 13 times during 2023. Each of the directors attended at least 75% of the of the Board meetings in 2023 during the director&#8217;s term.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our annual meetings of stockholders are generally held to coincide with one of the Board&#8217;s regularly scheduled meetings.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The Board</b>&#8217;<b>s Leadership Structure </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In connection with Jeffery Thompson&#8217;s announcement in February 2024 of his planned retirement from the Board effective as of the end of his current term at the 2024 Annual Meeting, John B. Henneman, III was appointed as the Chair of the Board effective February 24, 2024. Separating the roles of Chair of the Board and Chief Executive Officer allows our Chief Executive Officer to focus on the strategic management of our day-to-day business, while allowing the Chair of the Board to focus on leading the Board of Directors in its fundamental role of providing advice to, and independently overseeing, management. The Board recognizes the time, effort, and energy that the Chief Executive Officer is required to devote to the position in the current business environment, as well as the commitment required to serve as Chair of the Board, particularly as the Board&#8217;s oversight responsibilities continue to grow. The Board believes that having separate positions, with an independent, non-executive director serving as Chair of the Board, is the appropriate leadership structure for our Company at this time and allows the Board to fulfill its role in maintaining independence from management.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
17
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The Board</b>&#8217;<b>s Role in Environmental, Social and Governance (ESG) Oversight </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Board of Directors believes that our Company has a broad responsibility that takes into account the positive effect we seek to have on the people we employ, serve and support, and the environment and the communities where we live and work. The full Board has oversight of our environmental, social and governance, or ESG, initiatives, which are the direct responsibility of a cross-functional group comprised of members of our senior management team under the leadership of our Vice President, Investor Relations, ESG and Corporate Communications.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The Board</b>&#8217;<b>s Role in Risk Oversight </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The role of the Board of Directors in our risk oversight process includes receiving reports from management and the Chairs of Board committees on areas of material risk to our Company, including operational, financial, commercial, legal, regulatory, strategic, cybersecurity and reputational risks. The Board has delegated primary responsibility to the Audit Committee to review these matters and discuss with management the process by which management assesses and manages our risk exposure, risk management, and risk mitigation strategies. The Audit Committee also works with other committees to assess areas of risk under the particular purview of those committees. When the Audit Committee receives a report from management or another committee, the Chair of the Audit Committee reviews the matter and then summarizes the review in a presentation to the full Board. This enables the Board and its committees to coordinate the risk oversight role to ensure that all directors receive all significant risk-related information. The Board also administers its risk oversight function through the required approval by the Board (or a committee of the Board) of significant transactions and other material decisions and through regular periodic reports from our independent registered public accounting firm and other outside consultants regarding various areas of potential risk, including, among others, those relating to our internal controls and financial reporting. In addition, as part of its charter, the Audit Committee discusses with management significant financial and operational risks and exposures, as well as the steps management has taken to minimize those risks. This includes the oversight and management of cybersecurity risks through the review of data management and security initiatives and significant existing and emerging cybersecurity risks, including material cybersecurity incidents and their impact on the Company.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Board Committees </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board of Directors currently has four standing committees:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Audit Committee;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation Committee;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Governance and Nominating Committee; and</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-18pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capital Allocation Committee.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The membership of each standing committee was as follows as of April&#160;22, 2024:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Director</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Audit</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Compensation</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Governance</b></span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>and</b></span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Nominating</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Capital</b>&#160;</span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Allocation</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Independent</b></span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Under</b></span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>SEC Rules</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Financial</b></span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Expert</b><br/>
			&#160;<b>Under</b>&#160;<b>SEC</b>&#160;</span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Rules</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Sheryl L. Conley</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Gary P. Fischetti</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">John B. Henneman, III</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chair</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Glenn R. Larsen, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Stephen O. Richard</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chair</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chair</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Jeffery S. Thompson</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Susan L. N. Vogt</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chair</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">&#160;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#10003;</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
18
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Board has adopted a written charter for the Audit Committee, Capital Allocation Committee, Compensation Committee, and Governance and Nominating Committee, each of which is reviewed yearly by that committee. You can find these charters on the investor relations portion of our website at<i> </i><i>https://ir.anika.com/board-committees</i>.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Audit Committee </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><span style="color:#ffffff;"><b>Role and Key Responsibilities</b></span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Overseeing accounting and financial reporting processes</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Overseeing audits of our financial statements and internal controls</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Taking, or recommending that the Board of Directors take, appropriate action to oversee the qualifications, independence and performance of our independent registered public accounting firm</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Leading the review of our risk management processes and exposure to financial and operational risks</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Overseeing the management of cybersecurity risks through the review of data management and security initiatives and significant existing and emerging cybersecurity risks, including material cybersecurity incidents, the impact on the Company and its stakeholders of any significant cybersecurity incident, and any disclosure obligations arising from any such incidents</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Preparing an Audit Committee report, as required by the SEC, for inclusion in our annual Proxy Statement</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Selecting, retaining, overseeing, and, when appropriate, terminating our independent registered public accounting firm</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Conferring with the independent registered public accounting firm and reporting to the Board regarding the scope, method, and result of the audit of our books and records</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Reviewing and discussing proposed earnings press releases and financial information and guidance proposed to be provided to investors</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Establishing, overseeing and periodically reviewing procedures for complaints regarding accounting or auditing matters</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Establishing and monitoring a policy relative to non-audit services provided by the independent registered public accounting firm in order to ensure the firm&#8217;s independence</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Audit Committee held 8 meetings in 2023. Each of the members attended all of the Audit Committee meetings held in 2023 while the member served on the Audit Committee. The Audit Committee holds separate sessions of its meetings, outside the presence of management, with our independent auditor in conjunction with each regularly scheduled Audit Committee meeting in which the independent auditor participates. During 2023, the Audit Committee regularly met privately with our management and held executive sessions with only non-employee directors in attendance as appropriate. No director is eligible to serve on the Audit Committee if that director simultaneously serves on the audit committees of three or more other public companies.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The current members of the Audit Committee are Stephen O. Richard, who serves as Chair, Sheryl L. Conley, and Susan L. N. Vogt. The Board has determined that each member is independent, as defined for purposes of the SEC and NASDAQ, is financially literate, and has the requisite financial sophistication to serve on the Audit Committee. The Board has also determined that each of Mr.&#160;Richard and Ms.&#160;Vogt qualifies under SEC rules as an &#8220;audit committee financial expert,&#8221; which designation is an SEC disclosure requirement related to their experience and understanding of certain accounting and auditing matters. The designation does not impose upon either of the members any duties, obligations, or liabilities that are greater than those otherwise imposed on them as members of the Audit Committee and the Board.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
19
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Capital Allocation Committee </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><span style="color:#ffffff;"><b>Role and Key Responsibilities</b></span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Supporting and making recommendations to the Board regarding capital allocation across business segments and between internal investments and return of capital to stockholders</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing and discussing with management the capital structure and debt levels of the Company</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing and discussing with management short- and long-term financing plans, including debt and equity financing and use of securitization facilities</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing and discussing with management capital allocation priorities with a view to enhance long-term stockholder value, including use of available funds for business and/or capital investments, stock repurchases, or dividends</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Serving as an advisory group to the Board and providing the Board with regular updates</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Capital Allocation Committee held 2 meetings in 2023. Each of the members attended all of the Capital Allocation Committee meetings held in 2023 while the member served on the Capital Allocation Committee.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In 2023, the members of the Capital Allocation Committee were Jeffery S. Thompson, who served as Chair, Gary P. Fischetti, and John B. Henneman, III. The current members of the Capital Allocation Committee are Stephen O. Richard, who serves as Chair, Gary P. Fischetti, and John B. Henneman, III.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Compensation Committee </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><span style="color:#ffffff;"><b>Role and Key Responsibilities</b></span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Managing our overall compensation philosophy, structure, policies, processes, procedures, and programs</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing the performance of and determining the compensation of the Chief Executive Officer</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing the performance of and determining, with the advice and assistance of the Chief Executive Officer, the compensation of our executive officers other than the Chief Executive Officer</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Annually reviewing and recommending to the Board of Directors compensation for non-employee directors</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Overseeing our overall compensation programs, including the granting of awards under our equity incentive plans</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Preparing a report on executive compensation for inclusion in our annual Proxy Statement or other corporate governance filing, as applicable</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Reviewing, discussing with management and any compensation consultant, and recommending the inclusion of disclosures under &#8220;Compensation Discussion and Analysis&#8221; in our Proxy Statement or other corporate governance filing, as applicable</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Periodically conducting a risk assessment to evaluate whether forms of pay encourage unnecessary or excessive risk taking and assisting the Audit Committee in assessing and managing potential risks created by our compensation practices, policies and programs</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
20
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; vertical-align: top;">&#9745;</td>
			<td style="width: 97%;">Reviewing, approving, recommending to the Board for approval, and considering the results of stockholder advisory &#8220;say-on-pay&#8221; and &#8220;say-on-frequency&#8221; votes and reviewing and recommending to the Board whether to submit a stockholder advisory vote on certain acquisition-related compensation arrangements</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Appointing, retaining, compensating, terminating, and overseeing the work of any compensation consultant or other compensation advisor, as well as considering the independence of any compensation consultant or other compensation advisor</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee held 7 meetings in 2023. Each of the members attended at least 75% of the Compensation Committee meetings held in 2023 while the member served on the Compensation Committee. During 2023, the Compensation Committee regularly held executive sessions with only non-employee directors in attendance as appropriate, including when evaluating the performance of Dr.&#160;Cheryl&#160;R. Blanchard.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The current members of the Compensation Committee are John B. Henneman, III, who serves as Chair, Sheryl L. Conley, Gary P. Fischetti and Glenn R. Larsen, Ph.D. The Board has determined that each current member of the Compensation Committee is independent, as defined in the listing standards of NASDAQ.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Governance and Nominating Committee </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><span style="color:#ffffff;"><b>Role and Key Responsibilities</b></span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Recommending to the Board of Directors the criteria for Board and committee membership</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Identifying, evaluating, and recommending nominees to stand for election as directors at each Annual Meeting of Stockholders, including incumbent directors and candidates recommended by stockholders</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Developing succession plans for the Board, the Chief Executive Officer and other executives</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Coordinating performance evaluations of the Board and its standing committees</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Recommending to the Board assignments of directors to each Board committee and monitoring compliance with Board and committee membership criteria</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Overseeing and administering Board education programs</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Overseeing corporate governance affairs of the Board and our Company</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Governance and Nominating Committee held 2 meetings in 2023. Each of the members attended all of the of the Governance and Nominating Committee meetings held in 2023 while the member served on the Governance and Nominating Committee. During 2023, the Governance and Nominating Committee regularly held executive sessions with only non-employee directors in attendance as appropriate. In 2023, the Governance and Nominating Committee focused on reviewing the skill set of the Board members as a whole to ensure that the Board represents a balanced skill set enabling appropriate Board oversight of our Company in relation to our industry, strategic plan and stockholder alignment.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The current members of the Governance and Nominating Committee are Susan L. N. Vogt, who serves as Chair, John B. Henneman, III, and Glenn R. Larsen, Ph.D. The Board has determined that each current member of the Governance and Nominating Committee is independent, as defined in the listing standards of NASDAQ.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Board Membership Qualifications and Procedures </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When considering candidates for director, the Governance and Nominating Committee takes into account a number of factors, including the following minimum qualifications: the nominee (a)&#160;shall have the highest personal and professional integrity, (b)&#160;shall have demonstrated exceptional ability and judgment, and (c)&#160;shall be most effective, in conjunction with the other members of the Board of Directors, in collectively serving the long-term interests of the stockholders. In addition, the Governance and Nominating Committee takes into consideration such other factors as it deems appropriate, including any direct and applicable experience in the biotechnology, pharmaceutical, medical device, and/or life sciences industries, or in the markets in which we operate. The Governance and Nominating Committee may also consider, among other things, the skills of the candidate, his or her availability based on other commitments, including those related to other boards or committees that the candidate is involved with, the candidate&#8217;s depth and breadth of experience or other background characteristics, and his or her independence.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
21
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the considerations above, the Board strongly believes that diversity is an important component of a successful and effective board of directors and good corporate governance, including diversity of background, skills, experience, gender, race, and ethnicity. The Governance and Nominating Committee, guided by its charter, assesses and considers the diversity of the Board prior to nominating candidates and seeks to identify director candidates who will enhance the Board&#8217;s overall diversity. The Governance and Nominating Committee and the Board select candidates on the basis of qualifications and experience without discriminating on the basis of race, color, national origin, gender, sex, sexual preference, or religion. Accordingly, it is the practice of the Governance and Nominating Committee to include, and we request that any search firms we engage include, candidates with diversity in gender and demographic backgrounds in any pool from which the Governance and Nominating Committee selects director candidates. We believe that our current Board members collectively reflect a broad range of knowledge, expertise, and experience in the disciplines that impact our business.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our bylaws include a procedure that stockholders must follow to nominate a person for election as a director at an annual meeting of stockholders. The bylaws require that timely notice of the nomination in proper written form, including all required information as specified in the bylaws, be mailed to the Governance and Nominating Committee in care of our Chief Executive Officer, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. A copy of our bylaws can be viewed on the investor relations portion of our website at <i>https://ir.anika.com/governance-documents. </i>The Governance and Nominating Committee will consider director nominees recommended by stockholders in accordance with the Anika Therapeutics, Inc. Policy and Procedures for Stockholder Nominations to the Board, a copy of which is available on the investor relations portion of our website at <i>https://ir.anika.com/governance-documents</i>. Recommendations should be submitted to our Secretary in writing at Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730, along with additional required information about the nominee and the stockholder making the recommendation. The Governance and Nominating Committee may solicit recommendations for candidates for directors from non-management directors, the Chief Executive Officer, other executive officers, third-party search firms, and such other sources as it deems appropriate, including stockholders. The Governance and Nominating Committee will review and evaluate the qualifications of all such proposed candidates in the same manner and without regard to the source of the recommendation.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Communications with Directors </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board of Directors seeks input from a wide variety of sources to inform their work, including from stockholders. The Board welcomes stockholder input via voting, via participating in our annual meetings of stockholders, via our stockholder engagement program, and, more formally, via mail. If you wish to communicate with any of our directors, or the Board as a group, you may do so by writing to the individual director or to the Board, in care of our Chief Executive Officer, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. We recommend that all correspondence be sent via certified U.S. mail, return receipt requested. All correspondence received by the Chief Executive Officer will be forwarded to the appropriate addressee. Communications involving substantive accounting or auditing matters will be forwarded to the Chair of the Audit Committee. Communications that pertain to non-financial matters will be forwarded to the relevant director.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Code of Business Conduct and Ethics </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Board of Directors has adopted the Anika Therapeutics, Inc. Code of Business Conduct and Ethics to clarify, disseminate, and enforce the requirement and expectation that all of our officers, directors, and employees worldwide conduct our business in an honest and ethical manner and in compliance with all applicable laws and regulations. The Code of Business Conduct and Ethics applies to all of our officers, directors, and employees worldwide, including our Chief Executive Officer and Chief Financial Officer. It is our goal to aid our employees and Board members in making ethical and legal decisions when conducting Company business and performing daily duties. We cannot anticipate every situation an employee or Board member may face when conducting business on behalf of our Company, and we therefore encourage our employees and Board members to speak with any one of several Company representatives when he or she encounters situations giving rise to a question or concern regarding compliance with our Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics can be viewed on the investor relations portion of our website at <i>https://ir.anika.com/governance-documents</i>.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
22
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section 16(a) of the Exchange Act requires the Company&#8217;s Directors, executive officers and holders of more than 10% of the Company&#8217;s common stock (the Reporting Persons) to file with the SEC initial reports of ownership and reports of changes in ownership of common stock of the Company. Such persons are required by regulations of the SEC to furnish the Company with copies of all such filings. Based on its review of the copies of such filings received by it from January 1, 2023 to the present, the Company believes that no Reporting Person filed a late report during the referenced timeframe. While we are not aware of any late filings, the Form 3 filing for Anne M. Nunes made on June 26, 2023 incorrectly reported the Amount of Securities Beneficially Owned under Table I, Column 2 as 3,293 shares. That amount was corrected to 4,777 shares in a Form 3/A filed on January 12, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 11. EXECUTIVE COMPENSATION</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Compensation Discussion and Analysis </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This section describes and analyzes the material elements of the 2023 compensation for our named executive officers, or NEOs, determined in accordance with SEC rules, as follows:</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align:middle;width:37.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Name</b></span></div>
			</td>
			<td style="vertical-align:middle;width:63.4%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#ffffff;"><b>Title (as of December 31, 2023)</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:37.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;"><b>Cheryl</b>&#160;<b>R.</b>&#160;<b>Blanchard,</b>&#160;<b>Ph.D.</b></div>
			</td>
			<td style="vertical-align:bottom;width:63.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">President and Chief Executive Officer</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align:bottom;width:37.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;"><b>Michael L. Levitz</b></div>
			</td>
			<td style="vertical-align:bottom;width:63.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">EVP, Chief Financial Officer, and Treasurer</div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:37.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;"><b>David B. Colleran</b></div>
			</td>
			<td style="vertical-align:bottom;width:63.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">EVP, General Counsel, and Secretary</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align:bottom;width:37.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:-12pt;"><b>Anne M. Nunes</b></div>
			</td>
			<td style="vertical-align:bottom;width:63.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Senior Vice President, Chief Operations Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Company </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Founded in 1992, Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Based on our collaborations with clinicians to understand what they need most to treat their patients, we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis, or OA, pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have more than thirty years of global expertise developing, manufacturing and commercializing products based on our hyaluronic acid, or HA, technology platform. In early 2020, we enhanced our overall technology platform, product portfolio, and significantly expanded our commercial infrastructure, especially in the United States, through our strategic acquisitions of Parcus Medical, LLC, or Parcus Medical, a sports medicine and instrumentation solutions provider, and Arthrosurface Incorporated, or Arthrosurface, a company specializing in bone preserving partial and total joint replacement solutions. These acquisitions have been part of the transformation of our company by augmenting our HA-based OA pain management and regenerative products with a broad suite of products and capabilities focused on early intervention joint preservation primarily in upper and lower extremities such as shoulder, foot/ankle, knee and hand/wrist. In addition, these acquisitions expanded our product development expertise in the regenerative solutions space.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
23
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Executive Summary </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our Fiscal Year 2023 Business Performance </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our 2023 key accomplishments included:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Increased revenue for fiscal 2023 by 7% to $166.7&#160;million, above the $158 to $163 million guidance for the year;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Achieved Adjusted EBITDA margin for the year of 9%, above the low single-digit percent guidance for the year;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Generated record annual revenues of $101.9 million in OA Pain Management on global growth of our Monovisc single injection viscosupplement;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Continued double-digit international growth of our Cingal next generation non-opioid single injection pain product;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Successfully initiated the limited market release of the Integrity Implant System, our HA-based regenerative rotator cuff patch system;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center; vertical-align: top;">&#8226;</td>
			<td style="width: 97%;">Fully enrolled Phase III clinical trial for Hyalofast, our HA, off-the-shelf, single-stage cartilage repair product, designated as a breakthrough device by the FDA, with a modular PMA submission with break-through device designation commencing in 2024, and a final PMA module filing expected in 2025 with product launching by 2026;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center; vertical-align: top;">&#8226;</td>
			<td style="width: 97%;">Launched the PEEK version of our X-Twist Fixation System, followed by our Biocomposite version launched in early 2024, which together address the more than $600 million U.S. rotator cuff market;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center; vertical-align: top;">&#8226;</td>
			<td style="width: 97%;">Conducted a Type C meeting with the FDA in early 2023, with ongoing interactions with the FDA regarding proposed non-clinical next steps toward Cingal U.S. regulatory approval;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center; vertical-align: top;">&#8226;</td>
			<td style="width: 97%;">Entered full market release of our RevoMotion Reverse Shoulder Arthroplasty System in September 2023, expanding our shoulder arthroplasty portfolio into the more than $1 billion U.S. reverse shoulder market; and</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Announced planned cost reductions, executed in the first quarter of 2024, to accelerate our pivot to profitability and expansion of Adjusted EBITDA following improved operational progress in 2023, including launching key products and addressing EU Medical Device Regulations, MDR, requirements.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>2023 Compensation Highlights </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As described more fully below, we made compensation decisions for our NEOs for 2023 that reflect our ongoing commitment to align our executive compensation program with the interests of our stockholders.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; vertical-align: top; text-align: center;"><i>&#8226;</i></td>
			<td style="width: 97%;"><i>Our Executive Compensation Program is Predominantly At-Risk and Performance-Based </i>&#8211; Approximately 83% of our CEO&#8217;s and approximately 69% of our other NEOs&#8217; actual 2023 compensation* was variable and at risk, tied to our stock price performance or achievement of rigorous performance objectives that are important to the creation of long-term stockholder value.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
24
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="margin-left: 9pt;">
<div style="text-align: center;"><img alt="graph1.jpg" src="graph1.jpg"/></div>
</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 56pt; text-indent: -19pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 56pt; text-indent: -19pt;">* Ms. Nunes was promoted to Senior Vice President, Chief Operations Officer in June 2023 and her compensation data is excluded.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td>
			<td style="width: 94%;"><i>Significant Ratio of Incentives are Long-Term Focused to Foster Alignment with Our Stockholders </i>&#8211; 2023 equity awards granted to the CEO and other NEOs, except Ms. Nunes who became a named executive officer mid-year, were evenly split between performance-based stock options in the form of premium-priced stock options with an exercise price set at 110% of fair market value on the grant date, and time-vesting restricted stock units. The Compensation Committee believes the structure of the long-term incentives balances retention, the motivation of long-term value creation and the alignment of executive interests with those of our stockholders.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 94%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td>
			<td style="width: 94%;"><i>Annual Bonuses for 2023 Performance Paid Out Below Target Reflecting Commitment to Pay for Performance </i>&#160;&#8211; In approving the payout under the 2023 annual bonus program, the Compensation Committee considered financial performance results achieved in 2023, as described above, including revenue growth, strong balance sheet management, adjusted EBITDA growth, our strategic investments in the development and rollout of a growing product portfolio, process and system improvements, and delivering on our commitment to improved employee engagement and culture throughout the organization. As part of its assessment, the Compensation Committee also considered that target performance was not achieved under one Customer and Product metric and one People and Culture metric. On balance, the Compensation Committee approved a corporate bonus payout of 94.5% of target for our NEOs, which it viewed to be aligned with financial and operational results achieved in 2023. Based on the individual performance results, final bonus payouts were 95.6% of target for each of Messrs. Colleran and Levitz, 93.1% of target for Ms. Nunes, and there were no adjustments for Dr. Blanchard.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 94%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td>
			<td style="width: 94%;"><i>CEO Realizable Compensation on a One- and Three-Year Basis is Significantly Below Reported Compensation Values</i> &#8211; Consistent with our commitment to aligning executive compensation with our stockholders&#8217; experience, our CEO&#8217;s realizable compensation on a one- and three-year basis was 40% and 42% below the reported compensation levels.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160; &#160; &#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
25
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="margin-left: 36pt;">
<div style="text-align: center;">
<div><img alt="graph2.jpg" src="graph2.jpg"/></div>
</div>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 37pt;"><b>Reported Compensation Value reflects</b>: Base salary, target annual bonus values, and reported grant date fair values of annual equity awards.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 37pt;"><b>Realizable Compensation Value reflects</b>: Base salary earned, actual annual bonus payout values, and the value of equity compensation realized upon vesting based on the closing stock price on the vest date, with those tranches not yet vested valued at the 12/29/2023 closing stock price of $22.66. Premium-priced options, both vested and unvested portions, for all three years were &#8220;underwater&#8221; as of 12/29/2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Advisory Vote to Approve Executive Compensation and Stockholder Outreach </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the 2023 Annual Meeting of Stockholders, approximately 89% of votes cast were in favor of our executive compensation program. The Board and the Compensation Committee viewed this strong support as an indicator of general approval of our approach to executive compensation.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We maintain an annual stockholder engagement program to provide regular updates to our stockholders about our performance and to solicit their feedback, including outreach specifically on our executive compensation program. In May and June 2023, we contacted stockholders collectively representing over 80% of our outstanding common stock and engaged with stockholders representing approximately 40% of our outstanding common stock. During those engagements, we discussed our compensation philosophy, performance, strategy, capital allocation, corporate governance and ESG initiatives, and our stockholders were generally supportive of our approach to our executive compensation program.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We welcome, appreciate and will continue to solicit feedback from our stockholders, and will continue to consider this feedback as we seek to enhance our compensation program and related narrative disclosure, including the information provided in the following discussion.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Compensation Philosophy </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee oversees our overall compensation program and approves our compensation policies. The overriding goal of our compensation program is to drive long-term high performance and increase stockholder value through our pay programs and corporate culture. As a result, the Compensation Committee incorporates performance into many aspects of our compensation program, including pay levels, incentive payouts, and pay opportunities. Corporate and individual goals are set through our yearly budgeting and strategic planning processes and these goals are ultimately reviewed and approved by the Board of Directors prior to, or at the beginning of, each year.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee, utilizing the structure of our compensation program and, as appropriate, its discretion, implements our executive compensation program to reward our NEOs when their performance meets or exceeds established goals. A significant portion of each NEO&#8217;s incentive compensation is weighted towards the management team&#8217;s achievement against targeted goals (rather than individual performance), so that if we meet or exceed our goals, the team earns compensation at or above target levels. Conversely, if the team fails to meet the minimum thresholds, they will not be awarded the targeted components of the performance-based compensation.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
26
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a general matter, the Compensation Committee uses compensation data from the annual compensation study of competitive peer companies to inform its decisions about overall compensation opportunities and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing targeted compensation levels, and it does not benchmark specific elements or total compensation to a specific level or percentile relative to peer companies or the broader market.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rather than rely on a specific formula-based model, the Compensation Committee applies judgment and discretion in establishing targeted pay levels, considering not only competitive market data, but also factors such as company, business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession planning. The Compensation Committee believes that retaining this discretion gives the Compensation Committee the ability to more accurately reflect factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers our primary physical location near Boston, Massachusetts, the high level of competition for highly qualified life sciences employees in that geographic area, and the need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment and retention of top performing executives and employees, all of which have become more challenging in recent years.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have designed our compensation program to:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Motivate and reward our executives to achieve or exceed our financial and operating performance objectives;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Propel our business forward through a focus on operational excellence and execution of our business strategy;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Link each NEO&#8217;s compensation with specific business objectives;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Align each NEO&#8217;s compensation with the interests of long-term stockholders by tying a significant portion of total compensation opportunity to the value of our stock;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Reinforce accountability and cooperation by tying a significant portion of total NEO compensation to overall Company performance;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Attract and retain talented leaders who can drive and implement our growth, transformation, and operational excellence strategies;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Reward individual performance and accomplishments; and</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Keep the compensation packages competitive with those of our peers and other companies with whom we compete for highly-skilled top talent.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Key Compensation Policies and Practices </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Key Features </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We believe that our executive compensation program includes key features that align the performance and objectives of the NEOs and our Company with the interests of our stockholders and does not include features that misalign NEO and corporate objectives with stockholder interests. During 2023, we arranged our compensation program in accordance with the practices set forth below:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
27
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="width: 100%; text-align: center;"><span style="color:#ffffff;"><b>What We Do</b></span></td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Link a significant portion of NEO compensation to Company performance</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Align a significant portion of NEO compensation with stockholders&#8217; interests through long-term incentives, including historical grants of performance-based awards with exclusively multi-year performance metrics and grants in 2023 of performance-based awards in the form of premium-priced stock options with a 3-year vesting period</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Structure our equity grants to the NEOs to be evenly divided between time-vesting and performance-based awards (excepting the equity grants made to Ms. Nunes in March 2023, prior to her appointment as an NEO, which grants were divided 67% time-vesting and 33% performance-based awards)</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Balance short-term and long-term incentives</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Require NEOs to own significant amounts of stock through robust stock ownership guidelines</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Include minimum vesting requirements for equity awards in our equity incentive plan, subject to certain exceptions</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Incorporate double-trigger vesting upon a change in control for all equity awards to NEOs</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Cap annual cash bonus payouts at 1.5x target</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Utilize an independent compensation consultant annually to assist our assessment of our compensation program</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#9745;</td>
			<td style="width: 97%;">Solicit say-on-pay votes annually</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="width: 100%; text-align: center;"><span style="color:#ffffff;"><b>What We Don</b>&#8217;<b>t Do</b></span></td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No automatic or guaranteed annual salary increases</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No guaranteed short-term or long-term incentive awards</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No repricing of stock options or SARs without stockholder approval</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No hedging/pledging of our stock per our Insider Trading Policy</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No &#8220;golden parachute&#8221; excise tax gross ups</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No granting of stock options or SARs with an exercise price less than fair market value on the grant date</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No pension or other special benefits</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">
			<div><img alt="xbullet.jpg" src="xbullet.jpg"/></div>
			</td>
			<td style="width: 97%;">No perquisites</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Key Performance Factors </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In setting the compensation for our NEOs, the Compensation Committee relies primarily on our overall financial performance and an assessment of each individual&#8217;s performance and contribution to the achievement of our goals. The Compensation Committee seeks to align the metrics it uses in evaluating our executive compensation with the metrics that we use to evaluate our performance more generally, including those metrics that we publicly disclose.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In 2021, to reflect best market practice and preferences of our stockholders, the Compensation Committee began to use premium-priced stock options as a performance-based equity award to further align individual performance with our goals for growth and stockholder value appreciation. This practice was continued in 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
28
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Compensation Committee balances corporate goals and objectives, including certain financial metrics, product development, share price performance and individual performance, including, but not limited to, completion of strategic projects/transactions and new product releases, in making decisions on annual cash bonus payments. Additionally, the Compensation Committee considers the recommendations of the Chief Executive Officer in its review with regard to other NEO performance (other than the Chief Executive Officer) and resulting compensation decisions. In 2023, following the determination of the corporate bonus payout at 94.5% of target, to foster alignment with our stockholders, the Compensation Committee determined to apply certain individual performance adjustments to the bonus payouts for the NEOs, resulting in a total bonus payout of 94.5% of target for Dr. Blanchard, 95.6% of target for each of Messrs. Colleran and Levitz, and 93.1% of target for Ms. Nunes. The Committee recognized the commitment and leadership that the NEOs demonstrated throughout the year maintaining a healthy balance sheet with a focus on revenue and adjusted EBITDA, managing our strategic investments in the development and rollout of a growing product portfolio, driving process and system improvements, and delivering on our commitment to improve employee engagement and culture throughout the organization.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>The Role of Compensation Consultant </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to corporate and individual performance metrics, the Compensation Committee weighs other quantitative factors, such as general compensation trends, in making compensation decisions. In this regard, the Compensation Committee periodically reviews surveys of executive compensation and information concerning compensation in general and at similarly situated companies. For the 2023 compensation cycle, the Compensation Committee elected to engage a new compensation consultant, Willis Towers Watson, or WTW, in 2022 to provide executive compensation consulting services to the Compensation Committee, to assist the Compensation Committee in selecting an appropriate peer group for compensation comparisons, and to perform an executive compensation review. The Compensation Committee assessed the independence of WTW under the applicable SEC and NASDAQ Listing Rules and concluded that the continued engagement of WTW did not raise any conflicts of interest and did not adversely affect WTW&#8217;s independence.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In completing its analysis for 2023, the Compensation Committee reviewed competitive data compiled by WTW from a peer group comprised of 17 companies in related businesses at similar stages of development and of similar size in terms of market capitalization and employee population (see <i>Determination of the Compensation Peer Group</i> below). The Compensation Committee also reviewed market data from the 2022 Radford Global Life Sciences Survey, or the Radford Survey, covering public biopharmaceutical and medical device companies. The Compensation Committee uses competitive compensation data from these peer company and industry reviews to inform its decisions about overall compensation opportunities and specific compensation elements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the Compensation Committee uses multiple reference points when establishing targeted compensation levels. While the Compensation Committee considers benchmarking data and may factor certain benchmarking data elements into its compensation decisions, it does not generally seek to benchmark specific compensation elements or total compensation to a specific level or percentile relative to the peer companies or the broader United States market. Rather than rely on a specific formula-based model, the Compensation Committee applies its judgment in establishing targeted pay levels, considering not only competitive market data, but also factors such as company, business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession planning.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee believes this approach gives the committee the ability to more accurately reflect factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers our primary locations near Boston, Massachusetts, the high level of competition for highly qualified life sciences employees in that area, and the need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment and retention of top performing executives and employees.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
29
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Determination of the Compensation Peer Group</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">With our compensation consultant&#8217;s assistance, the Compensation Committee reviews and adjusts our peer group annually to ensure that the industry data we review is relevant to our current and near-term future activities and goals. We believe that the adjustments we made to our 2023 peer group are appropriate to better reflect changes in our Company over time, based on our history of strong financial performance, growing product pipeline, commercial strategies, and our Global Industrial Classification System, or GICS, Code as a Biotechnology company. Given this dynamic, the Compensation Committee determined it was appropriate to blend biotechnology companies with medical device companies in a ratio of approximately 2/3 to 1/3, as we did for 2022. The Compensation Committee adopted the following peer group in November 2022 for use in 2023 compensation decisions:</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 60%; margin-right: 20%; margin-left: 20%;">

		<tbody><tr style="font-size: 10pt; background-color: rgb(55, 94, 169);">
			<td colspan="2" style="width: 50%; font-size: 10pt; text-align: center;"><span style="color:#ffffff;"><b><i>&#160;Peer Group Companies&#160;</i></b></span></td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;<span style="text-decoration: underline;"><i>Biotechnology Companies</i></span></td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;<span style="text-decoration: underline;"><i>Medical Device Companies</i></span></td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Avid Bioservices, Inc.</td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;Artivion, Inc.</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Collegium Pharmaceutical, Inc.</td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;Atrion Corporation</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Heron Therapeutics, Inc.</td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;AxoGen, Inc.</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Karyopharm Therapeutics, Inc.</td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;Bioventus Inc.</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;MacroGenics, Inc.</td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;Orthofix, Inc.</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;MiMedx Group, Inc.</td>
			<td style="font-size: 10pt; width: 50%; padding-left: 72pt;">&#160;SurModics, Inc.</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Organogenesis Holdings Inc.</td>
			<td style="font-size: 10pt; width: 50%;">&#160;</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Rigel Pharmaceuticals, Inc.</td>
			<td style="font-size: 10pt; width: 50%;">&#160;</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Travere Therapeutics, Inc.</td>
			<td style="font-size: 10pt; width: 50%;">&#160;</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Vanda Pharmaceuticals, Inc.</td>
			<td style="font-size: 10pt; width: 50%;">&#160;</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="font-size: 10pt; width: 50%;">&#160;Vericel Corporation</td>
			<td style="font-size: 10pt; width: 50%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2023 Compensation Decisions </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our 2023 NEO compensation was made up of three key components:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Base salary;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Annual cash bonus; and</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Equity-based long-term incentive awards, generally in the form of performance-based stock options and time-based restricted stock units.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aside from Cheryl R. Blanchard, Ph.D., each of the current NEOs is an at-will employee with terms of employment documented on our standard form of offer letter. For additional detailed information regarding the compensation of Dr.&#160;Blanchard resulting from her employment agreement with us, please see the section captioned &#8220;<i>Other Compensation Matters </i>&#8211;<i> Dr.</i>&#160;<i>Blanchard</i>&#8217;<i>s Employment Agreement</i>&#8221; below.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Base Salary </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The first principal component of compensation for our executive officers is base salary, which is paid to our NEOs in recognition of the talents and the unique skills each NEO possesses and which are required to drive our Company toward achievement of its goals and objectives. Base salaries for our NEOs are subject to annual review by the Compensation Committee. For this purpose, the Compensation Committee considers a number of factors, including the individual&#8217;s level of responsibility, experience, and performance. The Compensation Committee also considers market practices as described above, taking into account any contractual obligations. Salaries are reviewed and determined at the discretion of the Compensation Committee on an annual basis, and there is no guaranteed year-over-year increase to any of the NEOs&#8217; salaries.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">For 2023, annualized base salaries and compensation increases, as applicable, for the NEOs are set forth below. All NEOs, except Ms. Nunes, received a limited 4.5% merit-based salary increase, which was consistent with our annual merit budget and largely in line with the rest of our employees. Ms. Nunes received a 6% merit-based salary increase in her role as Vice President, Operations, and a subsequent base salary increase in connection with her promotion to Senior Vice President, Chief Operations Officer in June 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
30
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023 Annualized Base Salary </b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(55, 94, 169);">
			<td style="width: 43%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Name</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>2022 Salary</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>2023 Salary</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>% Change</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cheryl R. Blanchard, Ph.D.</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">695,100</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">726,000</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(206, 229, 245);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Michael L. Levitz</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">474,600</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">496,000</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>David B. Colleran</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">449,700</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">469,900</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(206, 229, 245);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Anne M. Nunes</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">378,500</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">440,000</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16.0</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 20%; margin-right: 20%;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></div>
			</td>
			<td style="vertical-align: top; width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">In February 2023, the Committee approved a 6% merit-based salary increase for Ms. Nunes in her role as Vice President, Operations, bringing her annualized 2023 salary to $401,200. In June 2023, Ms. Nunes was promoted to Senior Vice President, Chief Operations Officer and received a 9.6% increase, bringing her base salary to $440,000.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Annual Cash Bonus </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The second principal component of our compensation policy for executive officers consists of cash bonuses, which are generally paid to our NEOs to motivate attainment of our near-term goals that are consistent with our long-term strategic plan.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Each NEO has a target annual bonus amount established by the Compensation Committee at the beginning of each year that is expressed as a percentage of the NEO&#8217;s base salary. In 2023, with the exception of the target for Anne M. Nunes, which changed from 35% to 45% in connection with her June 2023 promotion, these targets were unchanged from the prior year&#8217;s targets for individuals in similar positions. The Compensation Committee establishes the target bonus amounts consistent with the compensation philosophy described above, including consideration of market practices, and to provide, in its view, an appropriate balance between fixed (salary) and variable (bonus) cash compensation. The 2023 target bonus amounts for the NEOs were as follows:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023 Annual Cash Bonus Targets </b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color: rgb(255, 255, 255);"><b>Name</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>%</b> <b>of</b> <b>Salary</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Amount</b> <b>at</b> <b>Target</b></span></b></div>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cheryl R. Blanchard, Ph.D.</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">85</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">617,100</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Michael L. Levitz</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">45</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">223,200</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>David B. Colleran</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">45</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">211,455</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Anne M. Nunes</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">45</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">171,000</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 20%; margin-right: 20%;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></div>
			</td>
			<td style="vertical-align: top; width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">Represents target annual bonus percentage for Ms. Nunes in her role of Senior Vice President, Chief Operations Officer.</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></div>
			</td>
			<td style="vertical-align: top; width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">Represents a blended target bonus amount in connection with the promotion of Ms. Nunes in June 2023 to Senior Vice President, Chief Operations Officer.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Actual bonus amounts awarded are not formulaic and depend on the Compensation Committee&#8217;s assessment of both our business and individual NEO performance after the completion of each year. The Compensation Committee considers factors such as our financial performance, our overall operational performance, and our contribution to increasing stockholder value to determine an appropriate level of baseline cash bonus compensation for our NEOs. Once the Compensation Committee has established this baseline, it considers the applicable individual performance with respect to individual goals and contribution to overall Company performance to adjust each individual NEO&#8217;s cash bonus award.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>2023 Annual Cash Bonus Payouts</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">After the completion of the 2023 fiscal year, the Compensation Committee, with the assistance of our Chief Executive Officer, reviewed the performance of the Company, as well as the individual performance of each executive officer (other than the CEO&#8217;s own performance). The accomplishments set forth in the Executive Summary section titled &#8220;<i>Our Fiscal Year 2023 Business Performance</i>&#8221; and below were considered in this review.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
31
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In 2023, we delivered strong financial results and achieved significant strategic and operational goals as set forth in the section captioned &#8220;<i>Our Fiscal Year 2023 Business Performance</i>&#8221; above, including among other achievements, the following:</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(i)</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delivered increased revenue for fiscal 2023 of 7% to $166.7 million, including delivering record annual revenues of $102 million in OA Pain Management on global growth of our Monovisc single injection viscosupplement, and continued double-digit international growth of our Cingal next generation non-opioid single injection pain product;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ii)</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">completed the launch of the PEEK version of the X-Twist Fixation System, followed by the launch of the X-Twist Biocomposite Fixation System in Q1 2024, and entered into full market release of our new RevoMotion Reverse Shoulder Arthroplasty System;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iii)</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">conducted a Type C meeting with the FDA with ongoing interactions between the Company and the FDA regarding proposed non-clinical next steps toward Cingal U.S. regulatory approval, and took steps to pursue potential commercial partnerships for Cingal in the U.S. and select Asian markets;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iv)</div>
			</td>
			<td style="vertical-align:top;">initiated the limited market release of the Integrity Implant System; and</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(v)</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fully enrolled the Phase III clinical trial for Hyalofast with a planned modular premarket approval submission with break-through device designation commencing in 2024.</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We entered 2024 with a healthy balance sheet having launched meaningful new products, achieved record annual revenue in OA pain management, made considerable progress in addressing the new MDR regulatory requirements in Europe and continued to dedicate our efforts toward driving value creation.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On balance, the Compensation Committee determined that while we outperformed on our financial goals and we continued to make strong overall business progress transforming our organization, especially in light of the ongoing impact of macroeconomic volatility and inflationary pressures, and continued disruption of our distributor and supply chain networks during 2023, we did not achieve expected performance levels on certain smaller components of our Customer and Product goals and People and Culture goals. As such, the Compensation Committee determined an initial corporate bonus payout of 94.5% of target appropriately reflected results achieved by the management team in 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Final bonus payouts for our NEOs were subject to adjustment based on individual performance achievement against individual goals, which included a range of financial, commercial, regulatory, and employee engagement objectives tailored to each executive&#8217;s responsibilities, as well as contributions to overall Company performance. Overall, our NEOs had strong performance during the year and significantly contributed to our business and financial performance results with demonstrated commitment and leadership navigating the macroeconomic uncertainties and accelerating our progress, and the Compensation Committee determined to apply certain incremental additional positive adjustments for the payout for certain individual performances. The bonus targets based on annualized salary and final actual bonus amounts paid are presented in the table below.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023 Cash Bonus Decisions </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color: rgb(255, 255, 255);"><b>Name</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Bonus</b> <b>Target</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>%</b> <b>Achieved</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Bonus</b> <b>Paid</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cheryl R. Blanchard, Ph.D.</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">617,100</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">94.5</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt; text-align: right;">583,160</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Michael L. Levitz</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">223,200</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">95.6</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt; text-align: right;">213,368</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>David B. Colleran</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">211,455</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">95.6</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt; text-align: right;">202,183</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Anne M. Nunes</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 16pt; text-align: right;">171,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">93.1</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 7pt; text-align: right;">159,183</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Long-Term Equity Incentive Program </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The third principal component of our compensation policy for executive officers consists of grants under our equity incentive plan, which are generally provided to our NEOs to align their goals and objectives with the interests of our stockholders, to motivate attainment of our long-term strategic vision, and for retention purposes. Under our equity incentive plan, NEOs may be granted stock options or other forms of equity awards, including restricted stock awards and units, performance-based equity awards, and stock appreciation rights. Equity awards typically are approved at regularly scheduled Compensation Committee meetings, generally during the first quarter of each year given the meeting&#8217;s proximity to the beginning of the performance period for performance-based awards, and generally granted effective on the third full business day following our announcement of financial and business results for the completed prior fiscal year.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
32
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The amount and form of equity-based grants each year are determined by the Compensation Committee using the compensation philosophy described above, including the Compensation Committee&#8217;s informed judgment, and taking into account our performance, competitive market practices, past and expected individual performance achievements, past and expected contributions to overall Company performance, and the need to attract and retain talented executives in an extremely competitive environment who can drive and implement our transformation, growth and operational excellence strategies. For the last several years, the Compensation Committee has increasingly used performance-based equity awards to align the interests of our NEOs with those of our stockholders.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In 2023, our Chief Executive Officer was granted equity awards, the value of which was split approximately evenly between performance-based stock options in the form of premium priced stock options priced at 110% of fair market value on the grant date and time-vesting restricted stock units. Other NEOs, with the exception of Ms. Nunes who was not an executive officer at the time of grant, received a similar split in value as the CEO between time-vesting restricted stock units and performance based time-vesting stock options in the form of the same premium-priced stock options. The value of equity awards granted to Ms. Nunes in 2023 was split approximately 2/3 in time-based vesting restricted stock units and 1/3 in performance based time-vesting stock options in the form of the same premium-priced stock options. The restricted stock units and the premium-priced stock options vest in three equal annual installments beginning one year from the grant date. We believe premium-priced stock options granted with an exercise price of 110% of the fair market value of our common stock on the grant date inherently drive individual and Company performance, while strongly aligning executive interests with stockholder interests by generating stockholder value through increased stock performance over time.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For 2023, the Compensation Committee awarded the following balanced mix of time-vesting restricted stock units and premium-priced stock options:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color: rgb(255, 255, 255);"><b>Name<span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></span></b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Time-Vesting</b> <b>RSUs</b></span></b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>($ Value)<span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></span></b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Premium-Priced</b> <b>Stock</b> <b>Options</b></span></b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>($ Value)<span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></span></b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cheryl R. Blanchard, Ph.D.</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt; text-align: right;">1,829,963</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt; text-align: right;">1,830,037</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Michael L. Levitz</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt; text-align: right;">537,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt; text-align: right;">537,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>David B. Colleran</b></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt; text-align: right;">500,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt; text-align: right;">500,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Anne M. Nunes</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(2)</sup></b></span></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 24pt; text-align: right;">301,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 43pt; text-align: right;">148,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 20%; margin-right: 20%;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></div>
			</td>
			<td style="vertical-align: top; width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">The Committee typically makes value-based annual equity awards to our NEOs in which 50% of the total award value is granted as RSUs and 50% of the total award is granted as performance-based awards in the form of premium-priced stock options. The Committee approved the awards on February 15, 2023, and the awards were granted with an effective date of March 9, 2023. The Company applies a 20-day trailing average stock price to the grant date fair value of the awards to determine the number of shares granted as RSUs and premium-priced stock options on the grant date. As a result, the actual grant date fair value reported in the Summary Compensation Table below is different from the value of the award reported in this table.</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></div>
			</td>
			<td style="vertical-align: top; width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">At the time of this award, Ms. Nunes was still in her role as Vice President, Operations. The mix of time-vesting RSUs and premium-priced stock options granted to Ms. Nunes in 2023 is reflective of the standard mix granted to Vice Presidents at the time of the award. We anticipate aligning the mix of future equity award grants to Ms. Nunes in her current role as Senior Vice President, Chief Operations Officer with the mix of equity awards granted to other NEOs.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
33
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Compensation Matters </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Employment and Executive Retention Agreements Effective at December</i>&#160;<i>31, 2023 </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prior to 2023, we had entered into an employment agreement with Cheryl R. Blanchard (as described below under &#8220;<i>Dr.</i>&#160;<i>Blanchard</i>&#8217;<i>s Employment Agreement</i>&#8221;) and executive retention agreements with each of the other NEOs. While the NEOs remain employed at-will, these agreements are intended to provide market-level severance compensation to be competitive with our peer group of comparable companies and to promote retention. We believe that these agreements are fair to the executives and to our stockholders because they provide relatively modest severance in exchange for the restrictive covenants that help protect our Company. These restrictive covenants include standard non-competition, non-solicitation, non-disparagement, and confidentiality restrictions. The agreements are discussed in connection with the &#8220;<i>Potential Payments Upon Termination or Change in Control</i>&#8221; table below.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each agreement provides for severance benefits that may be triggered by an involuntary termination of employment by us without &#8220;cause&#8221; or by the executive for &#8220;good reason&#8221; (as defined in each agreement), or a qualifying termination. The level of severance benefits depends on whether the involuntary termination occurs during or outside of a change in control protected period that runs from three months before until 12 months after a change in control (as defined in each agreement). In addition, the agreements provide for full vesting of outstanding equity awards upon a qualifying termination occurring during the period from three months before until 12 months after a change in control for awards granted after January&#160;29, 2019. Equity awards granted prior to January&#160;29, 2019 will continue to vest in full upon the occurrence of a change in control in accordance with the award terms. Except as described in this paragraph and for certain equity grants made to Dr.&#160;Blanchard upon her appointment as our President and Chief Executive Officer, none of the equity grants made to our NEOs provide for accelerated vesting upon termination of their employment by us without &#8220;cause&#8221; or by the executive for &#8220;good reason.&#8221; If &#8220;golden parachute&#8221; excise taxes would be triggered by payments due in connection with termination during a change in control protected period, the agreements provide for a cut-back in the payments to avoid the excise tax, if the cut-back would result in a greater after-tax benefit to the executive.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The following summarizes the cash and health benefits (i.e., Company payment of premiums under our health plans) severance provided to the NEOs as of December&#160;31, 2023:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Trigger</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Type of Severance</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>CEO</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>CFO</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>EVP, GC</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>SVP, COO</b></span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Termination without cause or with good reason, not in connection with a change in control</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash severance</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Health benefits</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">18 months&#8217;&#160;salary</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">18 months at active employee rates</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12 months&#8217;&#160;salary</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12 months at active employee rates</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12 months&#8217;&#160;salary</div>

			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12 months at active employee rates</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6 months&#8217;&#160;salary</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6 months at active employee rates</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 16%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Termination without cause or with good reason, within 3 months before or 12 months after a change in control</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash severance</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2x the sum of 12 months&#8217;&#160;salary plus target bonus</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1.5x the sum of 12 months&#8217;&#160;salary plus target bonus</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12 months&#8217;&#160;salary plus target bonus</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9 months&#8217;&#160;salary plus target bonus</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 16%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Health benefits</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">18 months at active employee rates</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">18 months at active employee rates</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 16%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12 months at active employee rates</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9 months at active employee rates</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
34
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Dr.</i>&#160;<i>Blanchard</i>&#8217;<i>s Employment Agreement </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dr.&#160;Blanchard was appointed our President and Chief Executive Officer effective April&#160;26, 2020. In connection with her appointment, we and Dr.&#160;Blanchard entered into an employment agreement effective as of April&#160;23, 2020, or the Agreement. The Agreement has an initial term of April&#160;26, 2020 through December&#160;31, 2021, which automatically renews for successive 1-year periods unless either party elects nonrenewal in accordance with the Agreement. The Agreement provided for an initial annual base salary of $625,000 and a target annual bonus opportunity equal to 85% percent of annual base salary. In addition, the Agreement provided for the following initial equity awards: (i)&#160;a time-based restricted stock unit grant covering 73,726 shares, eligible to vest in equal annual installments over three years; (ii)&#160;a performance-based restricted stock unit grant covering 80,620 shares at target, eligible to vest up to 150% of the target shares on February&#160;25, 2023; (iii) a time-based stock option grant covering 104,638 shares, eligible to vest in equal annual installments over three years; and (iv)&#160;a performance-based stock option grant covering 104,638 shares at target, eligible to vest up to 150% of the target shares based on our total stockholder return relative to a comparison group of companies set forth in the Agreement through December&#160;31, 2022. In each case, vesting generally required Dr.&#160;Blanchard&#8217;s continued employment through the relevant vesting date. The Agreement provides for (i)&#160;reimbursement of reasonable business expenses, (ii)&#160;the payment of up to $10,000 in legal fees incurred by Dr.&#160;Blanchard in connection with the Agreement, (iii)&#160;participation in our benefit plans, and (iv) 30 paid vacation days per year. Under the Agreement, if Dr.&#160;Blanchard&#8217;s employment is terminated due to death, disability (as defined in the Agreement), by us without &#8220;cause&#8221; (as defined in the Agreement and including our nonrenewal of the term of the Agreement), or by Dr.&#160;Blanchard for &#8220;good reason&#8221; (as defined in the Agreement), Dr.&#160;Blanchard would become entitled to (i) 18 months of base salary, (ii)&#160;continued payment of Company premiums under our benefit plans for 18 months and (iii)&#160;if such termination is not due to disability and occurs prior to December&#160;31, 2021, pro rata vesting of the time-based restricted stock unit grant and the time-based option grant described above. Notwithstanding the foregoing, if such a termination without cause or for good reason occurs within 3 months prior to or 12 months after a change in control (as defined in the Agreement), Dr.&#160;Blanchard would become entitled to (i) 2 times the sum of her base salary and her target annual bonus, (ii)&#160;continued payment of Company premiums under our benefit plans for 18 months and (iii)&#160;vesting of her equity awards. The performance-based restricted stock unit grant and each other award with a performance metric-based vesting condition (other than a total stockholder return-based vesting condition) would vest based on the greater of assumed target performance or actual performance measured through the date of termination. For the total stockholder return-based option grant (and any other award with a total stockholder return-based vesting condition), the applicable performance period would be shortened to end as of immediately prior to the change in control and performance would be measured at such time. Any such severance benefits under the Agreement are contingent on Dr.&#160;Blanchard entering into and not revoking a general release of claims in favor of our Company, our affiliates, and our service providers. Finally, the Agreement contains customary covenants related to non-competition and non-solicitation for 12 months following termination of employment, as well as customary covenants related to confidentiality, inventions and intellectual property rights.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Compensation </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The NEOs are eligible to participate in our health and welfare programs, 401(k) plan with Company matching, and other benefit programs on the same basis as other employees. This includes our Deferred Compensation Plan, Employee Stock Purchase Plan, or ESPP, which stockholders approved at our 2021 Annual Meeting. Our ESPP provides the opportunity for all eligible U.S. based employees, including our NEOs, to purchase Company stock, further aligning management and stockholder interests.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Deductibility of Executive Compensation and Accounting Considerations </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section&#160;162(m) of the Internal Revenue Code generally limits our annual corporate tax deduction for compensation paid to each of our &#8220;covered employees&#8221; to $1&#160;million. &#8220;Covered employees&#8221; include anyone who served as chief executive officer or chief financial officer during any part of a year and the next three most highly compensated named executive officers for that year. In addition, once a person is considered a &#8220;covered employee,&#8221; that person remains a covered employee in all subsequent years (including after the person leaves our service or changes roles). The American Rescue Plan Act of 2021 updated Section&#160;162(m) of the Internal Revenue Code, effective in 2026, to expand the number of &#8220;covered employees&#8221; subject to the $1&#160;million deduction limit to include the next five highest compensated employees; however this new group of employees will not retain the perpetual &#8220;covered employee&#8221; status and will be determined annually. Consequently, we generally will not be entitled to a U.S. tax deduction for compensation paid in any year to our named executive officers and our other &#8220;covered employees&#8221; in excess of $1&#160;million. While considering tax deductibility as only one of several considerations in determining compensation, we believe that the tax deduction limitation should not compromise our ability to structure compensation programs that provide benefits to us that outweigh the potential benefit of a tax deduction and, therefore, may approve compensation that is not deductible for tax purposes.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We follow the Financial Accounting Standard Board&#8217;s Accounting Standards Codification Topic 718 for our stock-based compensation awards, which requires us to measure the compensation expense for all share-based awards based on the grant date &#8220;fair value&#8221; of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards may realize no value from their awards.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
35
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have not provided or committed to provide any NEO with a gross-up or other reimbursement for tax amounts the executive might pay pursuant to Section&#160;280G or Section&#160;409A of the Internal Revenue Code. Section&#160;280G and related sections of the Internal Revenue Code provide that an executive officer and certain persons who hold significant stockholder interests and certain other service providers could be subject to significant additional taxes if they receive payments or benefits in connection with a change in control that exceeds certain limits, and that we or our successor could lose a deduction on the amounts subject to the additional tax. Section&#160;409A of the Internal Revenue Code also imposes additional significant taxes on the individual in the event that an executive officer, director or service provider of certain types receives &#8220;deferred compensation&#8221; that does not meet the requirements of Section&#160;409A of the Internal Revenue Code.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Role of Management in Determining Compensation </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee, which is comprised entirely of independent directors, is responsible for establishing and implementing our executive compensation philosophy and for ensuring that the total compensation paid to our NEOs and other executives is fair, competitive and motivates high performance. The Compensation Committee is solely responsible for compensation decisions regarding our Chief Executive Officer. When making compensation recommendations for NEOs other than the Chief Executive Officer, the Compensation Committee requests and considers the advice and counsel of the Chief Executive Officer, given her direct day-to-day working relationship with those executives. Taking this feedback into consideration, the Compensation Committee will engage in discussions and make final determinations related to compensation paid to the NEOs.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risk Considerations in Our Compensation Programs </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee believes that risks arising from our policies and practices for compensating employees are not reasonably likely to have a material adverse effect on our Company.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Deferred Compensation Plan </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We provide our U.S. based NEOs, as well as other key employees, with an opportunity to defer settlement of restricted stock unit awards granted to them in 2020 and thereafter. Participants may elect to defer up to 100% of their restricted stock unit awards. We implemented this program, and continue to maintain it, to remain competitive with market practices. No deferral elections have been made by NEOs.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Compensation Recovery Policy </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Historically, all awards, amounts or benefits received or outstanding under the equity incentive plan by the NEOs have been subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in accordance with the terms of any clawback or similar policy or any applicable law related to such actions, as may be in effect from time to time. In accordance with the SEC&#8217;s adoption of the final &#8220;clawback rule,&#8221; effective January 27, 2023, requiring public companies to develop and implement a policy to recover excess incentive-based compensation from executive officers if amounts were based on material misstatements in financial reports, the Board adopted a Compensation Recovery Policy, effective November 27, 2023. The Compensation Recovery Policy covers our current and former executive officers, including all of our NEOs. Under the Compensation Recovery Policy, in the event that we are required to prepare a restatement of our previously issued financial statements due to our material noncompliance with any financial reporting requirement under securities laws, we are required to recover (subject to certain limited exceptions described in the Compensation Recovery Policy and permitted under the final clawback rules) any cash and/or equity incentive-based compensation received by any current or former executive officer after the effective date of the Compensation Recovery Policy and in the three years prior to the date we are required to restate our financial statements that is in excess of the amount that would have been received based on the restated financial statements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
36
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Prohibition on Hedging, Pledging, and Short Sales </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Insider Trading Policy prohibits the NEOs from hedging or pledging our stock.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Retention Guidelines </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our stock retention guidelines generally require each NEO to beneficially own certain amounts of our common stock. Generally, these guidelines require the Chief Executive Officer to beneficially own, at a minimum, the number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of his or her base salary. They require any other NEO to beneficially own, at a minimum, the number of shares (or vested share equivalents) of common stock having a market value equal to the amount of his or her base salary. Any individual initially designated as an executive officer has five years to achieve compliance. Each NEO is currently in compliance or within the five-year grace period. See the section captioned &#8220;<i>Director and Executive Officer Stock Retention Guidelines</i>&#8221; below for additional information.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Compensation Committee Report </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee of the Board of Directors of Anika Therapeutics, Inc., or Anika, has reviewed and discussed with the management of Anika Therapeutics, Inc. the section entitled &#8220;Compensation Discussion and Analysis&#8221; contained in this Amendment. Based on its review and discussions with management, the Compensation Committee recommended to the Board that the section entitled &#8220;Compensation Discussion and Analysis&#8221; be included in this Amendment. This report is submitted by the following independent directors who comprised the Compensation Committee as of December 31, 2023:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">John B. Henneman, III, Chair</div>
			</td>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Sheryl L. Conley</div>
			</td>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gary P. Fischetti</div>
			</td>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Glenn R. Larsen, Ph.D.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Executive and Director Compensation </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Executive Compensation</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary Compensation Table </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the compensation information with respect to our NEOs for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Name and Principal Position</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#ffffff;"><b>Year</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Salary ($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Bonus ($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(2)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Stock Awards ($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(3)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Option Awards</b>&#160;<b>($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(3)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>All Other Compensation ($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(4)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Total ($)</b></span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;726,000</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;583,160</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,614,708</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,509,736</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;26,196</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;4,459,800</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;695,100</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;590,835</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;2,306,779</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;2,323,562</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;24,446</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;5,940,722</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Officer</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;668,400</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;568,140</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,470,806</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,471,831</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;23,431</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;4,202,608</div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael L. Levitz</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;496,000</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;213,380</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;474,262</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;443,420</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;24,756</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,651,818</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EVP, Chief Financial Officer</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;474,600</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;213,570</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;682,065</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;433,721</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;22,430</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,826,386</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">and Treasurer</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;456,400</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;205,362</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;452,710</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;453,004</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;21,380</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,588,856</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David B. Colleran</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;469,900</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;202,194</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;441,189</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;412,475</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;24,756</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,550,514</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EVP, General Counsel</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;449,700</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;202,365</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;588,033</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;399,061</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;12,476</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,651,635</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">and Secretary</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;432,400</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;194,597</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;375,598</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;375,853</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;22,064</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,400,513</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Anne M. Nunes</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;440,000</div>
			</td>
			<td style="vertical-align: top; width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">&#160;</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;158,859</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;266,032</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;122,498</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;26,196</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,013,585</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SVP, Chief Operations Officer</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 6%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 12%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 11%;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Unless otherwise stated, the amounts in this column represent the annual base salary approved for the executive by the Board of Directors. The base salary for Ms. Nunes represents her annual base salary upon her promotion to Senior Vice President, Chief Operations Officer on June 14, 2023. Prior to her promotion in June 2023, the annual base salary for Ms. Nunes was $401,200.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 97%; font-size: 8pt;">The amounts in this column represent discretionary cash bonuses earned in the indicated year, but paid in the following year. The bonus for Ms. Nunes is prorated based upon her promotion in June 2023. See the section in the Compensation Discussion and Analysis titled &#8220;Annual Cash Bonus&#8221; for additional details regarding the cash bonuses earned for 2023.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 97%; font-size: 8pt;">The amounts in this column reflect the grant date fair value computed with respect to the stock and option awards issued during the indicated year calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718ASC Topic 718. See the information appearing in Note 14 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2023 for certain assumptions made in the valuation of stock and option awards. See the section in the Compensation Discussion and Analysis titled &#8220;<i>Equity-Based Grants</i>&#8221; for additional details regarding the stock and option awards issued in 2023.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Unless otherwise noted, these amounts constitute matching contributions to our Employee Savings and Retirement Plan (401(k) Plan) and group term life insurance premiums. Matching contributions to the 401(k) Plan in the indicated year were $23,100 to each of Dr. Blanchard, Messrs. Levitz and Colleran, and Ms. Nunes.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
37
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Grants of Plan-Based Awards in 2023 </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth each grant of equity awards under the equity incentive plan made to the NEOs during the year ended December&#160;31, 2023. All such equity awards vest over a three-year period commencing on the first anniversary of the grant date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ffffff;"><b>Name</b></span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 2%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Grant Date</b></span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Approval Date</b></span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; text-align: center;"><span style="color:#ffffff;"><b>All other stock awards:</b>&#160;<b>&#160;Number of shares of stock or units (#)</b></span></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; text-align: center;"><span style="color:#ffffff;"><b>All other option awards: Number of securities underlying options (#)</b></span></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; text-align: center;"><span style="color:#ffffff;"><b>Exercise or base price of option awards ($/Sh) </b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></span></span></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; text-align: center;"><span style="color:#ffffff;"><b>Grant date fair value of stock and option awards ($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(2)(3)</sup></b></span></span></td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 19%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">60,004</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;1,614,708</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 19%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;130,998</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$29.60</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;1,509,736</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 19%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael L. Levitz</div>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,624</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;474,262</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 19%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;38,475</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$29.60</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;443,420</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 19%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David B. Colleran</div>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">16,395</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;441,189</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 19%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;35,790</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$29.60</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;412,475</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 19%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Anne M. Nunes</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9,886</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;266,032</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 19%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 15, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 14%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;10,629</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$29.60</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;122,498</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-size: 8pt;">The option awards granted to our NEOs in 2023 are premium-priced stock options with an exercise price or base price of each option award equal 110% of the grant date closing stock price, as reported on the NASDAQ stock exchange.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This column represents the full grant date fair value of stock options and restricted stock unit awards under ASC 718 granted to each of the NEOs in the fiscal year ended December 31, 2023. Generally, the full grant date fair value is the amount that we will expense in our financial statements over the award's vesting period. For time-vesting restricted stock units, fair value was calculated using the closing price of our common stock on the grant date. For stock options, the fair value was calculated using the Black-Scholes value on the grant date. See the information appearing in Note 14 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2023 for certain assumptions made in the valuation of these awards.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Except as otherwise noted, the Company typically makes value-based annual equity awards to our NEOs in which 50% of the total award value is granted as RSUs and 50% of the total award is granted as performance-based awards in the form of premium-priced stock options. The Company applies a 20-day trailing average stock price to the grant date fair value of the awards to determine the number of shares granted as RSUs and premium-priced stock options on the grant date. Depending on the actual grant date fair value versus the 20-day trailing average as applied to the grant date fair value, the actual value of the award as noted in Footnote 2 above may result in the grant date fair value of the performance-based award being more or less than 50%.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Represents annual awards granted to Ms. Nunes prior to her promotion to Senior Vice President, Chief Operations Officer on June 14, 2023. At the time of these awards, Ms. Nunes was still in her role as Vice President, Operations. The mix of time-vesting RSUs and premium-priced stock options granted to Ms. Nunes in 2023 is reflective of the standard mix granted to Vice Presidents at the time of the award. We anticipate aligning the mix of future equity award grants to Ms. Nunes in her current role as Senior Vice President, Chief Operations Officer with the mix of equity awards granted to other NEOs. Ms. Nunes did not receive additional equity in 2023 in connection with her promotion.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
38
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Outstanding Equity Awards at December</b>&#160;<b>31, 2023</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table provides information on the holdings of outstanding stock options and unvested stock awards held by the current NEOs as of December&#160;31, 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td colspan="9" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 43%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Option Awards</b></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Stock Awards</b></span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align: middle; width: 17%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Name</b></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Grant Date</b>&#160;</span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of securities underlying unexercised options (#) exercisable</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of securities underlying unexercised options (#) unexercisable</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Equity incentive plan awards: number of securities underlying unexercised unearned options (#)</b></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Option exercise price ($)</b></span></div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Option expiration date</b></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of shares or units of stock that have not vested (#)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></span></span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Market value of shares or units of stock that have not vested ($)</b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(2)</sup></b></span></span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2020</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101,644</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;33.40</div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4/26/2030</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;24,575</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;556,870</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2020</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">139,168</div>
			</td>
			<td style="vertical-align: top; width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;33.40</div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4/26/2030</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%; padding: 0pt; text-align: right;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2021</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;72,265</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;36,133</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;37.40</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2031</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;14,420</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;326,757</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 11, 2022</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;69,607</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;139,214</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;28.14</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/11/2032</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;60,119</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,362,297</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;130,998</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;29.60</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2033</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;60,004</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,359,691</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%; padding: 0pt; text-align: right;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael L. Levitz</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">August 10, 2020</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;57,145</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;34.55</div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8/10/2030</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2021</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;22,242</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;11,121</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;37.40</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2031</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;4,438</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;100,565</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 11, 2022</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;12,993</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;25,986</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;28.14</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/11/2032</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;17,776</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;402,804</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;38,475</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;29.60</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2033</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;17,624</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;399,360</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David B. Colleran</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 4, 2020</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;35,000</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;43.06</div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/4/2030</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2021</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;18,454</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;9,227</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;37.40</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2031</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;3,682</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;83,434</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 11, 2022</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;11,955</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;23,909</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;28.14</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/11/2032</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;15,325</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;347,265</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;35,790</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;29.60</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2033</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;16,395</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;371,511</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%; padding: 0pt; text-align: right;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Anne M. Nunes</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">October 1, 2021</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,760</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;2,880</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;43.27</div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10/1/2031</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;2,491</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;56,446</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">October 1, 2021</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,150</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;3,075</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;47.60</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10/1/2031</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 11, 2022</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;2,921</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;5,842</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;28.14</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/11/2032</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;5,122</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;116,065</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 17%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 9, 2023</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;10,629</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;29.60</div>
			</td>
			<td style="vertical-align: top; width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3/9/2033</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;9,886</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;224,017</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Vesting of equity awards commences on the first anniversary of the grant date and continues on each subsequent grant date anniversary until the equity award is fully vested, except as otherwise noted below. Except as otherwise noted, equity awards are subject to a three-year vesting period, in each case subject to the holder's continued employment with us. The expiration date of each option award is ten years after its grant date.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Based on the closing price of our common stock on the NASDAQ stock exchange on December 29, 2023 of $22.66 per share.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 139,168 performance-based stock options granted in 2020, which vested on December 31, 2022. The performance measurement date and vest date for this award was December 31, 2022. The Compensation Committee reviewed our Total Shareholder Return (as defined in the grant agreement) against the Comparison Group (as defined in the grant agreement), and determined and specified, at the Compensation Committee's sole discretion, that 133% of the shares granted at Target had been earned by Dr. Blanchard. See the sections in the Compensation Discussion and Analysis titled &#8220;Dr. Blanchard's Employment Agreement" for additional details regarding the option award.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Represents an exercise price of 110% of the grant date closing stock price, as reported on the NASDAQ stock exchange.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2023 Option Exercises and Stock Vested </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table provides information regarding options exercised and stock awards vested for the NEOs during the year ended December&#160;31, 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td style="vertical-align: middle; width: 40%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Option Awards</b>&#160;</span></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Stock Awards</b>&#160;</span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(53, 93, 170);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Name</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of shares acquired on exercise (#)</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Value realized on exercise ($)</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of shares acquired on vesting (#)</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Value realized on vesting ($)</b>&#160;</span></div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cheryl R. Blanchard, Ph.D.&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">69,054</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;1,819,887</div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael L. Levitz&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,186</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;423,131</div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David B. Colleran&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;13,846</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;378,089</div>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Anne M. Nunes&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;-&#160;&#160;&#160;</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;5,052</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 14%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;113,249</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
39
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Potential Payments Upon Termination or Change in Control </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our President and Chief Executive Officer, our Chief Financial Officer, and our other NEOs have certain termination or change in control benefits described in the Compensation Discussion and Analysis sections captioned &#8220;<i>Other Compensation Matters </i>&#8211; <i>Employment and Executive Retention Agreements Effective at December</i>&#160;<i>31, 2023</i>&#8221; and &#8220;<i>Other Compensation Matters </i>&#8211;<i> Dr.</i>&#160;<i>Blanchard</i>&#8217;<i>s Employment Agreement</i>.&#8221; The following table provides estimates of the potential payments and other post-termination benefits these individuals would receive assuming a change in control occurred and/or their employment was terminated as of December&#160;31, 2023:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 30.1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#ffffff;"><b>Name</b></span></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Termination<br/>
			without cause or<br/>
			for good reason</b> </span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Termination upon<br/>
			change in control<br/>
			without cause or<br/>
			for good reason</b> <span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></span></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>Change in control<br/>
			without termination<br/>
			or death or<br/>
			disability </b><span style="font-size:8pt;"><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></span></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24.9%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Salary Continuation</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,089,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,452,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional Cash Payment</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,234,200</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity Awards Vesting</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,048,744</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Health Care Benefits</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,636</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,636</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,121,636</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,767,580</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Michael L. Levitz</div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Salary Continuation</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">496,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">744,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional Cash Payment</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">502,200</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity Awards Vesting</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">902,729</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Health Care Benefits</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,757</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,636</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">517,757</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,181,565</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">David B. Colleran</div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Salary Continuation</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">469,900</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">469,900</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional Cash Payment</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">211,455</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity Awards Vesting</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">802,209</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Health Care Benefits</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,757</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,757</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">491,657</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,505,321</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anne M. Nunes</div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Salary Continuation</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">330,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional Cash Payment</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">148,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity Awards Vesting</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">396,527</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Health Care Benefits</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,879</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,318</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">230,879</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">891,345</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Termination for the purposes of this column is limited to termination without cause or termination for good reason within a period three months prior to or twelve months after a change in control. The indicated values for the accelerated vesting of stock options reflect the number of equity award shares that would vest on an accelerated basis, multiplied by the excess, if any, of the $22.66 closing price for our common stock as reported by NASDAQ on December 29, 2023, over the applicable exercise price for each option. This calculation assumes equity awards with an exercise price higher than the closing price of our common stock on December 29, 2023 will not be exercised.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CEO Pay Ratio </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As required by applicable SEC rules, we are providing the following information about the relationship of the annual total compensation of our employees and the annual total compensation of Dr.&#160;Blanchard, our year-end Chief Executive Officer, or CEO.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For 2023, our last completed fiscal year:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">The median of the annual total compensation of all our employees (other than our CEO) was $109,550; and</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">The annual total compensation of our CEO, for the purposes of this disclosure, was $4,459,800.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160; &#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
40
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on this information, for 2023 the ratio of the annual total compensation of Dr.&#160;Blanchard, our year-end Chief Executive Officer, to the median of the annual total compensation of all our employees was 41 to 1.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We took the following steps to identify the median of the annual total compensation of all our employees, as well as to determine the annual total compensation of our median employee and our CEO.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</div>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We determined that, as of December&#160;31, 2023, our employee population consisted of 354 individuals. This population consisted of our full-time employees employed with us as of the determination date, excluding our CEO. We then excluded one individual in each of two countries (South Africa and Sweden), resulting in a remaining employee population of 352 individuals.</div>
			</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 94%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</div>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To identify the &#8220;median employee&#8221;&#160;from our employee population, we aggregated for each applicable employee, other than our CEO, (a)&#160;annual base salary (or hourly rate multiplied by estimated work schedule, for hourly employees), (b) the bonus amount earned for 2023, which was paid out in early 2024, and (c)&#160;the grant date fair value of equity granted in 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 94%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</div>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Once aggregated, we conducted statistical sampling and gathered additional Summary Compensation Table pay elements for a narrow group of employees who were paid within a narrow range around our median consistently applied compensation measure. From this group, we selected an employee who was reasonably representative of the median of our global employee population.</div>
			</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 94%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">4</td>
			<td style="vertical-align: top; width: 94%;">For the annual total compensation of our median employee, we identified and calculated the elements of that employee&#8217;s compensation for 2023 in accordance with the requirements of Item 402(c)(2)(x), resulting in annual total compensation of $109,550.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median-compensated employee and calculating the pay ratio based on that employee&#8217;s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Compensation </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Board previously adopted a Director Compensation Policy and the Compensation Committee undertakes an annual review of the Director Compensation Policy with input from the Company&#8217;s compensation consultant with regard to general compensation trends for director compensation. Each non-employee director receives cash retainers and is eligible for an initial or annual equity award grant, as applicable, with a value and vesting provisions as stated in the Director Compensation Policy. In 2023, the Board revised the Director Compensation Policy with respect to grants beginning in 2024 to (1) reduce the annual equity grant made to each non-employee director from $175,000 to $150,000, and (2) eliminate a standalone initial grant of equity of $350,000 that the Company had historically granted when a new non-employee director joined the Board in favor of a pro-rated portion of the standard annual equity award in the event that the non-employee director joined the Board at a time other than at the Company&#8217;s Annual Meeting.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash Compensation </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For 2023, each of our non-employee directors was entitled to annual retainers per the following schedule, with such amounts to be prorated based on the actual number of days served if a director&#8217;s service to us commenced after January&#160;1, 2023 or ended prior to the end of 2023:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color: rgb(255, 255, 255);"><b>Compensation Element</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>2023 Cash</b><br/>
			<b>Compensation</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Board of Directors</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Board Chair Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">87,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Directors Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">50,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Audit Committee</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Committee Chair Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">20,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Committee Members Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">10,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Capital Allocation Committee</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Committee Chair Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">10,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Committee Members Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">5,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Compensation Committee</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Committee Chair Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">15,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Committee Members Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">7,500</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Governance and Nominating Committee</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Committee Chair Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">10,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Committee Members Retainer</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 22pt; text-align: right;">5,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
41
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Equity Compensation</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">For 2023, the Board of Directors approved a grant of 6,500 restricted stock units to each non-employee director, valued at $174,980 under the Plan, based on the fair market value of our common stock on June&#160;14, 2023, the date of grant for our then-current directors. These restricted stock units granted to each then-current non-employee director in 2023 vest in one installment on the earlier of the date that is immediately prior to the 2024 Annual Meeting or one year from the date of grant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Total Compensation</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the compensation earned by non-employee directors in 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color: rgb(255, 255, 255);"><b>Name</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Fees earned in cash ($)</b> </span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 2%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 2%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Stock awards</b><br/>
			<b>($)</b><b><sup style="vertical-align:top;line-height:120%;"> </sup></b></span><sup style="vertical-align:top;line-height:120%;"><span style="font-size:8pt;"><span style="color:#ffffff;">(1) (2)</span></span></sup></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 2%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color: rgb(255, 255, 255);"><b>Total ($)</b> </span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sheryl L. Conley</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,500</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">174,980</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">242,480</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gary P. Fischetti</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,027</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">524,975</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">571,002</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">John B. Henneman, III</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74,832</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">174,980</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">249,812</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Glenn R. Larsen, Ph.D.</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,500</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">174,980</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">237,480</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stephen O. Richard</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74,000</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">174,980</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">248,980</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jeffery S. Thompson</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,502</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">174,980</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">267,482</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 29%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Susan L. N. Vogt</div>
			</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74,000</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">174,980</td>
			<td style="nowrap: true; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 19%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">248,980</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 60%; margin-left: 20%; margin-right: 20%;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">Except as otherwise noted, an amount of 6,500 restricted stock units were awarded to each director on June 14, 2023, based on the closing price of $26.92 per share, which vest on the earlier of the 2024 Annual Meeting or the one year anniversary of the grant date. The amounts in this column reflect the grant date fair value computed with respect to the restricted stock units, made during 2023 in accordance with ASC Topic 718. See the information appearing in Note 14 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2023 for certain assumptions made in the valuation of these restricted stock unit awards.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">The aggregate number of shares outstanding underlying stock awards for each director as of December 31, 2023 were: 9,226 for Ms. Conley, 6,500 for each of Dr. Larsen, Messrs. Henneman, Richard and Thompson, and Ms. Vogt, and 19,358 for Mr. Fischetti. No director held outstanding option awards as of December 31, 2023.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">Mr. Fischetti's fees are prorated based on his appointment to the Board on April 13, 2023.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; vertical-align: top;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 97%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">Includes 12,858 restricted stock units awarded to Mr. Fischetti upon his appointment to the Board on April 13, 2023, based on the grant date closing price of $27.22, which vest in three equal annual installments beginning on the first anniversary of the date of grant, and 6,500 restricted stock units awarded per director on June 14, 2023, based on the closing price of $26.92 per share, which vest on the earlier of the 2024 Annual Meeting or the one year anniversary of the grant date.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director and Executive Officer Stock Retention Guidelines </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective December&#160;12, 2022, the Board of Directors adopted stock retention guidelines that generally require each of our directors and executive officers to beneficially own certain amounts of our common stock. We believe that ownership of shares of common stock by directors and executive officers helps align the financial interests of these individuals with the interests of stockholders, promotes sound corporate governance, and evidences a commitment to our Company. These stock retention guidelines supersede the director stock retention guidelines previously adopted by the Board on October&#160;6, 2015.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
42
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Generally, these guidelines require each director to beneficially own, at a minimum, a number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of our annual Board retainer for the non-lead or non-chairman directors. The minimum shareholding requirement became effective immediately, except that any director has three years from the date of their initial election to achieve compliance. Compliance by each director will be reviewed annually by the Board&#8217;s Governance and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship. A non-complying director must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price and taxes) the director subsequently acquires through exercise of equity grants, until the director complies with the guidelines. As of December&#160;31, 2023, each of our directors had met their minimum shareholding requirement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="text-align: center;"><img alt="graph3.jpg" src="graph3.jpg"/></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Generally, the stock retention guidelines require the Chief Executive Officer to beneficially own, at a minimum, a number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of his or her base salary. The guidelines require any other executive officer to beneficially own, at a minimum, the number of shares (or vested share equivalents) of common stock having a market value equal to the amount of his or her base salary. The minimum shareholding requirement became effective immediately upon adoption of the stock retention guidelines, except that any individual has five years after initial delegation to achieve compliance. Compliance by each executive officer is reviewed annually by the Governance and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship. A non-complying executive officer must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price and taxes) he or she subsequently acquires through exercise of equity grants, until he or she complies with the guidelines. As of December&#160;31, 2023, each of our executive officers has met his or her required shareholding requirement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Compensation Committee Interlocks and Insider Participation </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">As of December&#160;31, 2023, the Compensation Committee consisted of John B. Henneman, III, Sheryl L. Conley, Gary P. Fischetti, and Glenn R. Larsen, Ph.D. None of these individuals is or formerly was an officer or employee of our Company, nor have they engaged in any transactions involving our Company that would require disclosure as a transaction with a related person. There are no Compensation Committee interlocks between our Company and any other entity involving our or such entity&#8217;s executive officers or directors.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the fiscal year ended December&#160;31, 2023, none of our executive officers served as: (1)&#160;a member of the compensation committee (or other committee of the board of directors performing equivalent functions or, in the absence of any such committee, the entire board) of another entity, one of whose executive officers served on the Compensation Committee; (2)&#160;a director of another entity, one of whose executive officers served on the Compensation Committee; or (3)&#160;a member of the compensation committee (or other committee of the board of directors performing equivalent functions or, in the absence of any such committee, the entire board) of another entity, one of whose executive officers served as one of our directors.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
43
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity Compensation Plan Information </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table sets forth information concerning our equity incentive plan as of December&#160;31, 2023.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(53, 93, 170);">
			<td colspan="6" style="vertical-align:bottom;width:99%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Equity Compensation Plan Information</b></span></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="background-color: rgb(53, 93, 170);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 38%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Plan category</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of securities to be issued<br/>
			upon exercise of outstanding options,<br/>
			warrants and rights</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Weighted Average exercise price of<br/>
			outstanding options, warrants and<br/>
			rights</b><b><sup style="vertical-align:top;line-height:120%;">&#160;<span style="font-size:8pt;">(1)</span></sup></b></span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ffffff;"><b>Number of<br/>
			securities remaining<br/>
			available for future<br/>
			issuance under<br/>
			equity compensation plans</b>&#160;</span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 38%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equity compensation plans approved by security holders</div>
			</td>
			<td style="vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,417,856</div>
			</td>
			<td style="vertical-align: top; width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></div>
			</td>
			<td style="vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$33.70</div>
			</td>
			<td style="vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1,168,379</div>
			</td>
			<td style="vertical-align: top; width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></div>
			</td>
		</tr>
		<tr style="background-color: rgb(205, 229, 246);">
			<td style="vertical-align: middle; width: 38%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equity compensation plans not approved by security holders</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">109,861</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$26.58</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">125,730</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 38%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</div>
			</td>
			<td style="vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,527,717</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$33.42</div>
			</td>
			<td style="vertical-align: middle; width: 20%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1,294,109</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Excludes unvested restricted stock units.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Includes our 2017 Omnibus Incentive Plan, as amended, our 2003 Omnibus Incentive Plan, as amended, or, collectively, the Incentive Plans. Outstanding restricted stock units convert to common stock without payment consideration. As of December 31, 2023, we also had 677,822 shares to be issued upon vesting of restricted stock units.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 97%; font-size: 8pt;">The number of shares remaining available for future issuance under the Incentive Plans includes 1,044,710 shares of common stock that may be awarded pursuant to the 2017 Omnibus Incentive Plan, as amended, and 123,669 shares of common stock that may be issued pursuant to our 2021 Employee Stock Purchase Plan. The 123,669 shares available for issuance under our 2021 Employee Stock Purchase Plan includes an undetermined number of shares underlying options granted during an offering period that extends into 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Includes our 2021 Inducement Plan. Outstanding restricted stock units convert to common stock without payment consideration. As of December 31, 2023, we also had 37,166 shares to be issued upon vesting of restricted stock units granted.</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth the beneficial ownership of common stock as of April 22, 2024, by:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Each current director and director nominee;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Each of the NEOs named in the Summary Compensation Table set forth under &#8220;Executive Compensation&#8221;;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Each other person who is known by us to beneficially own 5% or more of our common stock; and</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Current directors, director nominees and executive officers as a group.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The number of shares of common stock owned by each person is determined under the rules of the SEC. Under these rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and any shares that the individual has the right to acquire by June&#160;21, 2024 (sixty days after April&#160;22, 2024) through the conversion of a security or other right. Unless otherwise indicated, each person has sole investment and voting power, or shares such power with a family member, with respect to the shares set forth in the following table. The inclusion in this table of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those shares for any other purpose. As of April&#160;22, 2024, there were 14,828,456 shares of common stock outstanding. Shares not outstanding, but deemed beneficially owned by virtue of the right of a person to acquire those shares, are treated as outstanding only for purposes of determining the number and percent of shares of common stock owned by such person or group. Unless otherwise noted below, the address of each person listed on the table is in care of Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
44
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#ffffff;"><b>Beneficial Owner</b></span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#ffffff;"><b>Amount and Nature of Beneficial Ownership</b></span></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#ffffff;"><b>Percentage of Common Stock Outstanding</b></span></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Directors and Named Executive Officers:</i></b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sheryl L. Conley</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;19,907</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gary P. Fischetti</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;13,106</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">John B. Henneman, III</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;29,936</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Glenn R. Larsen, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;30,323</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stephen O. Richard</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;27,936</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(5)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Jeffery S. Thompson</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;31,575</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(6)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Susan L. N. Vogt</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;30,278</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(7)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;695,526</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(8)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">4.60%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">David B. Colleran</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;131,515</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(9)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Michael L. Levitz</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;176,274</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(10)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1.18%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Anne M. Nunes</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;32,381</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(11)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">*&#160;</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current directors and executive officers as a group (11 persons)</div>
			</td>
			<td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,218,757</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(12)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7.79%</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>5% and Above Stockholders:</i></b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Trigran Investments, Inc.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">630 Dundee Road, Suite 230</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Northbrook, IL 60062</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;2,139,054</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(13)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">14.43%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">BlackRock, Inc.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">50 Hudson Yards</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">New York, NY 10001</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,561,112</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(14)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10.53%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Caligan Partners LP</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">515 Madison Avenue, 8th Floor</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">New York, NY 10022</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;1,426,193</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(15)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9.60%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dimensional Fund Advisors LP</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">6300 Bee Cave Road, Building One&#160;</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Austin, TX 78746</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">821,452</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(16)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5.54%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">The Vanguard Group</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">100 Vanguard Blvd.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Malvern, PA 19355</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#160;764,045</div>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(17)</sup></div>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5.15%</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">* Indicates less than 1%</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(5)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(6)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(7)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 6,500 shares subject to restricted stock units vesting within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(8)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 532,090 shares subject to stock options that are exercisable within sixty days of April 22, 2024, and 11,724 shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(9)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 98,520 shares subject to stock options that are exercisable within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(10)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 129,319 shares subject to stock options that are exercisable within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(11)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 21,295 shares subject to stock options that are exercisable within sixty days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(12)</sup></td>
			<td style="width: 97%; font-size: 8pt;">This amount includes 781,224 shares subject to stock options that are exercisable within sixty days of April 22, 2024 and 45,500 shares of restricted stock units expected to vest within 60 days of April 22, 2024.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(13)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Such information is provided based on amended Schedule 13G jointly filed with the SEC on behalf of Trigran Investments, Inc., Douglas Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon and Steven R. Monieson on February 9, 2024. Trigran Investments, Inc., Douglas Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon and Steven R. Monieson have shared voting power with respect to 2,041,727 shares and shared dispositive power with respect to 2,139,054 shares. Douglas Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon, and Steven R. Monieson are the controlling shareholders and officers of Trigran Investments,&#160;Inc. and thus may be considered the beneficial owners of shares beneficially owned by Trigran Investments,&#160;Inc.</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
45
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(14)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Such information is provided based on amended Schedule 13G filed with the SEC on behalf of BlackRock, Inc. on April 5, 2024. BlackRock, Inc. has sole voting power with respect to 1,510,317 shares and sole dispositive power with respect to 1,561,112 shares.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(15)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Such information is provided based on amended Schedule 13D/A jointly filed with the SEC on behalf of Caligan Partners LP, David Johnson, and William Jellison on March 6, 2024. Caligan Partners LP serves indirectly as the investment manager to Caligan Partners Master Fund LP (the &#8220;Caligan Fund&#8221;), and managed accounts (the "Caligan Accounts"), with respect to the shares of Common Stock held by the Caligan Fund and the Caligan Accounts. David Johnson is the Managing Partner of Caligan Partners LP and Managing Member of Caligan Partners GP LLC, the general partner of Caligan Partners LP. Caligan Partners LP and David Johnson have shared voting power with respect to 1,423,493 shares and shared dispositive power with respect to 1,423,493 shares. Mr. Jellison has sole voting power with respect to 2,700 shares and sole dispositive power with respect to 2,700 shares.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(16)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Such information is provided based on amended Schedule 13G filed with the SEC on behalf of Dimensional Fund Advisors LP on February 9, 2024. Dimensional Fund Advisors LP has sole voting power with respect to 803,968 shares and sole dispositive power with respect to 821,452 shares. Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the&#160;Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities.</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="width: 3%; vertical-align: top; font-size: 8pt;">&#160;<sup style="vertical-align:top;line-height:120%;">(17)</sup></td>
			<td style="width: 97%; font-size: 8pt;">Such information is provided based on amended Schedule 13G filed with the SEC on behalf of The Vanguard Group on February 13, 2024. The Vanguard Group has shared voting power with respect to 6,661 shares, sole dispositive power with respect to 750,045 shares, and shared dispositive power with respect to 13,048 shares.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Transactions with Related Persons and Conflict of Interest Policy </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">It is our policy that all employees and directors, as well as their family members, must avoid any activity that is, or has the appearance of, conflicting with our business interests. This policy is included in our Code of Business Conduct and Ethics, and it is supplemented by our Conflict of Interest Policy, which was implemented by the Board of Directors in October 2015 and updated in December 2022, and can be viewed on the investor relations portion of our website at <i>https://ir.anika.com/governance-documents</i>. Both the Code of Business Conduct and Ethics and the Conflict of Interest Policy are reviewed at least every three years, or more often as necessary or advisable. Among other things, this policy requires each director and officer to provide to the Chair of the Audit&#160;Committee (or to the Chief Executive Officer, if such transaction involves the Chair of the Audit&#160;Committee) written notice of any potential related party transaction, defined by our policy to mirror the definition of Item 404 of Regulation S-K under the Securities Exchange Act of 1934, or the Exchange Act. Any such notice must include all information requested by the Chair of the Audit Committee (or the Chief Executive Officer). Upon receiving all relevant information, the disinterested members of the Audit Committee may approve the transaction if they determine that the transaction is in the best interests of, and fair to, Anika, may require modifications to the transaction to make it acceptable for approval or may reject it. The Audit Committee may also establish guidelines for ongoing management of a specific related party transaction. The policy requires continuing related party transactions to be reviewed on at least an annual basis. Additionally, the policy requires all of our executives and directors to complete a director and officer questionnaire in connection with each of our annual proxy statements, which asks them to disclose family relationships and other related party transactions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">From January&#160;1, 2023 through April 22, 2024, we had no reportable related party transactions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fees Paid to Our Independent Auditor </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the fees that we paid or accrued for audit and other services provided by Deloitte&#160;&amp; Touche LLP, or Deloitte, our independent auditor, for the years ended December&#160;31, 2023 and 2022.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
46
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(53, 93, 170);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#ffffff;"><b>Fee Category</b></span></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>2023</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="color:#ffffff;"><b>2022</b></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,249,340</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,276,642</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit-related fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">188,475</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">369,600</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(205, 229, 246);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">All other fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,895</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,454,710</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,667,242</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For purposes of the preceding table:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 3%; vertical-align: top; text-align: center;">&#8226;</td>
			<td style="width: 97%;">Audit fees consist of fees for the audit of our consolidated financial statements, the review of the interim financial statements included in our Quarterly Reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements for those years. In addition, audit fees include fees for comfort letters, consents, assistance with and review of documents filed with the SEC, Section&#160;404 attest services, other attest services that generally only the principal independent auditor can provide, work done by tax professionals in connection with the audit or quarterly review, and accounting consultations billed as audit services, as well as other accounting and financial reporting consultation research work necessary to comply with the standards of the PCAOB.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center; vertical-align: top;">&#8226;</td>
			<td style="width: 97%;">Audit-related fees consist of the aggregate fees billed by Deloitte in each of the last two fiscal years for assurance and related services reasonably related to the performance of the audit or review.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; text-align: center; vertical-align: top;">&#8226;</td>
			<td style="width: 97%;">Tax fees consist of fees for tax compliance, tax advice, and tax planning services for those years.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&#160;</td>
			<td style="width: 97%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top; text-align: center;">&#8226;</td>
			<td style="width: 97%;">All other fees consist of the aggregate fees billed by Deloitte in each of the last two fiscal years for products and services other than the services reported herein.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In considering the nature of the services provided by a principal independent auditor, the Audit Committee determined that such services are compatible with the provision of independent audit services. The Audit Committee discussed these services with the independent auditor and management to determine that they are permitted under the rules and regulations concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as well as the American Institute of Certified Public Accountants. In accordance with its charter, the Audit Committee has procedures for pre-approving audit and non-audit services to be provided by the independent auditor. These procedures are designed to ensure the continued independence of the independent auditor. More specifically, the use of the independent auditor to perform either audit or non-audit services is prohibited unless specifically approved in advance by the Audit Committee. As a result of this approval process, the Audit Committee has pre-approved specific categories of services and associated fee budgets. All services outside of the specified categories and all amounts exceeding the approved fee budgets are approved by the Chair of the Audit Committee, who has been delegated the authority to review and approve audit and non-audit related services during the year. A listing of the audit and non-audit services and associated fees approved by the Chair outside the scope of the services and fees initially approved by the full Audit Committee is reported to the full Audit Committee no later than its next meeting. The Audit Committee also regularly receives updates from Deloitte and management about the services actually performed and the associated fees and expenses actually incurred.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the Audit Committee evaluates other known potential engagements of the independent auditor, including the scope of audit-related services, tax services, and other services proposed to be performed and the proposed fees, and approves or rejects each service, taking into account whether the services are permissible under applicable law and the possible impact of each non-audit service on the independent auditor&#8217;s independence from management. All such services were approved by the Audit Committee pursuant to Rule 2-01 of Regulation S-X under the Exchange Act to the extent that rule was applicable. Since May 2003, each new engagement of a principal independent auditor has been approved in advance by the Audit Committee.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
47
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">INDEX TO EXHIBITS</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 5%; padding: 0px;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit </b><br/>
			<b>Number</b></div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: bottom; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 5%; padding: 0px;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><a href="ex_659521.htm" style="-sec-extract:exhibit;">&#8224;10.10a</a></div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_659521.htm" style="-sec-extract:exhibit;">Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 5%; padding: 0px;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><a href="ex_659522.htm" style="-sec-extract:exhibit;">&#8224;10.10b</a></div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_659522.htm" style="-sec-extract:exhibit;">Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2021 Inducement Plan</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 5%; padding: 0px;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_659583.htm" style="-sec-extract:exhibit;">31.1</a></div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_659583.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 5%; padding: 0px;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_659584.htm" style="-sec-extract:exhibit;">31.2</a></div>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_659584.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8224; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Management contract or compensatory plan or arrangement.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 60%;">&#160;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ANIKA THERAPEUTICS, INC.</div>
			</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 60%;">&#160;</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 30%;">&#160;</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 60%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: April 26, 2024</div>
			</td>
			<td style="vertical-align: middle; width: 5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ CHERYL R. BLANCHARD</div>
			</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 60%;">&#160;</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 60%;">&#160;</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Chief Executive Officer</i></div>
			</td>
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
48
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ CHERYL R. BLANCHARD</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cheryl R. Blanchard, Ph.D.</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<i>Principal Executive Officer</i>)</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ MICHAEL LEVITZ</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Vice President, Chief Financial Officer and Treasurer</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Levitz</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Financial Officer)</i></div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ IAN MCLEOD</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vice President, Chief Accounting Officer</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ian McLeod</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Accounting Officer)</i></div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ JOHN B. HENNEMAN, III</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chairman of the Board</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John B. Henneman, III</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ SHERYL L. CONLEY</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sheryl L. Conley</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ GARY P. FISCHETTI</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Gary P. Fischetti</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ GLENN R. LARSEN, PH.D.</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Glenn R. Larsen, Ph.D.</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ STEPHEN O. RICHARD</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen O. Richard</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ JEFFERY S. THOMPSON</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jeffery S. Thompson</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ SUSAN L. N. VOGT</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">April 26, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Susan L.N. Vogt</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
49
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10A
<SEQUENCE>2
<FILENAME>ex_659521.htm
<DESCRIPTION>EXHIBIT 10.10(A)
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.10(a)</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b>NOTICE OF GRANT OF RESTRICTED STOCK UNITS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ANIKA THERAPEUTICS, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2017 OMNIBUS INCENTIVE PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the &#8220;<b>Plan</b>&#8221;), to the Grantee designated in this Notice of Grant of Restricted Stock Units (the &#8220;<b>Notice of Grant</b>&#8221;), the number of restricted stock units (&#8220;<b>RSUs</b>&#8221;) set forth in the Notice of Grant (the &#8220;<b>Award</b>&#8221;), subject to certain terms and conditions as outlined below in the Notice of Grant and the additional terms and conditions set forth in the attached Terms and Conditions of Restricted Stock Units, including the Appendix attached thereto (the &#8220;<b>Terms and Conditions</b>,&#8221; and together with the Notice of Grant, the &#8220;<b>Award Agreement</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 5%; margin-right: 5%;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Grantee:</b></p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid rgb(0, 0, 0); padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Grant Date:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid rgb(0, 0, 0); padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Number of RSUs Granted:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid rgb(0, 0, 0); padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Definition of RSU:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 5px 0px 5px 5px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Each RSU shall entitle the Grantee to receive one Share or, subject to application of the Cash Cap (as defined in the Terms and Conditions), a cash payment equal to the Fair Market Value of one Share at such future date or dates and subject to such terms and conditions as set forth in the Award Agreement.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid rgb(0, 0, 0); padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Vesting Schedule:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 5px 0px 5px 5px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subject to the provisions of the Terms and Conditions and other applicable sections of this Notice of Grant, the Award shall vest in substantially equal installments on the first, second, and third anniversary of the Grant Date, &nbsp;provided that Grantee remains a continuous Service Provider from the Grant Date until the date on which the Award is scheduled to vest.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">By electronically accepting the Award Agreement , the Grantee agrees that the Award is granted under and governed by the terms and conditions of the Plan and the Award Agreement, as of the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 33%;"><b>GRANTEE</b></td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;"><b>ANIKA THERAPEUTICS, INC.</b></td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33%;">Sign Name:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u></td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;">Sign Name:<u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33%;">Print Name<u>:</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;">Print Name:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 65%;">Title:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u> </u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></td>
		</tr>

</table>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Notice of Grant - Page " data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="Notice of Grant - Page " data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Notice of Grant - Page 1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>TERMS AND CONDITIONS OF RESTRICTED STOCK UNITS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Grant of RSUs</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Award granted to the Grantee and described in the Notice of Grant is subject to the terms and conditions of the Plan. The terms and conditions of the Plan are hereby incorporated herein by reference. Except as otherwise expressly set forth herein, the Award Agreement shall be construed in accordance with the terms and conditions of the Plan. Any capitalized term not otherwise defined in the Award Agreement shall have the definition set forth in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Committee has approved the grant to the Grantee of the Award, conditioned upon the Grantee&#8217;s acceptance of the terms and conditions of the Award Agreement within 60 days after the Award Agreement is presented to the Grantee for review; if the Grantee does not accept the terms and conditions of the Award Agreement within 60 days after the Award Agreement is presented to the Grantee for review, the Grantee will automatically be deemed to accept the Award and such terms and conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of the Grant Date, the Company grants to the Grantee the number of RSUs set forth in the Notice of Grant, subject to the terms and conditions of the Plan and the Award Agreement. Each RSU shall entitle the Grantee to receive one Share or, subject to application of the Cash Cap (as defined below), a cash payment with a Fair Market Value equal to one Share, at such future date or dates and subject to such terms and conditions as set forth in the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Restrictions</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Grantee shall have no rights or privileges of a Company stockholder as to the RSUs prior to settlement (to the extent settled in Shares) in accordance with Section 6 of these Terms and Conditions (&#8220;<b>Settlement</b>&#8221;), including no right to vote or receive dividends or other distributions with respect to the RSUs; in addition, the following provisions shall apply:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 68pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the Grantee shall not be entitled to delivery of a certificate or certificates for Shares in connection with the RSUs until Settlement in Shares (if at all), and upon the satisfaction of all other applicable conditions;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 68pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; none of the RSUs may be sold, transferred (other than by will or the laws of descent and distribution), assigned, pledged or otherwise encumbered or disposed of prior to Settlement in Shares; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 68pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all of the RSUs shall be forfeited and all rights of the Grantee with respect to the RSUs shall terminate in their entirety on the terms and conditions set forth in Section 5 below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any attempt to dispose of RSUs or any interest in the RSUs in a manner contrary to the restrictions set forth in the Award Agreement shall be void and of no effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding anything herein to the contrary, in the event the Company elects to settle any RSUs in the form of cash, in no event shall the amount paid in cash with respect to any RSU (calculated prior to any reduction for tax withholding or other deductions) exceed an amount equal to 3x the Fair Market Value of a Share as of the Grant Date (subject to equitable adjustment in the case of any stock split, reverse stock split or similar change in capitalization) (the &#8220;Cash Cap&#8221;); provided that, as of the final vesting date of this Award, the Grantee may receive an amount in cash that exceeds the Cash Cap (i) in the event the Fair Market Value as of the final vesting date exceeds the Fair Market Value on each prior vesting date and (ii) so long as the aggregate amount of cash paid to Grantee pursuant to this Award does not exceed the Aggregate Cash Cap.&nbsp; For purposes of this Agreement, the &#8220;Aggregate Cash Cap&#8221; shall mean an amount equal to 3x (A) the number of RSUs subject to this Award that were settled (or would be settled upon the final vesting date) in cash multiplied by (B) the Fair Market Value of a Share as of the Grant Date (subject to equitable adjustment in the case of any stock split, reverse stock split or similar change in capitalization).&nbsp; On or following a Change in Control, the Cash Cap shall not apply.</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Terms and Conditions - Page " data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Restricted Period and Vesting</u>. The &#8220;<b>Restricted Period</b>&#8221;&nbsp;is the period beginning on the Grant Date and ending on the date the RSUs, or such applicable portion of the RSUs, are deemed vested under the schedule set forth in the Notice of Grant, including any applicable accelerated vesting provisions set forth herein.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Acceleration of Vesting under Certain Circumstances</u>.&nbsp;&nbsp;The vesting of the Award shall not be accelerated under any circumstances, except as otherwise provided in the Plan or in a written agreement between the Grantee and the Company or an Affiliate; provided, however, that if, within 3 months prior to and in connection with a Change in Control, or 12 months following a Change in Control, the Grantee incurs a Separation from Service as a result of a termination initiated by the Company or an Affiliate without Cause, or by the Grantee for Good Reason, then 100% of the Shares shall immediately become vested prior to such termination (provided that if such termination occurs prior to such Change in Control, such Shares shall immediately become vested prior to such Change in Control). For this purpose, &#8220;Good Reason&#8221;&nbsp;means as such term (or word of like import) is expressly defined in a then-effective written agreement between the Grantee and the Company or such Affiliate, or in the absence of such then-effective written agreement and definition, means the occurrence of any of the following events or conditions unless consented to by the Grantee (and the Grantee shall be deemed to have consented to any such event or condition unless the Grantee provides written notice of the Grantee&#8217;s non-acquiescence within 30 days of becoming aware of such event or condition): (i) a change in the Grantee&#8217;s responsibilities or duties which represents a material and substantial diminution in the Grantee&#8217;s responsibilities or duties, as applicable; (ii) a material reduction in the Grantee&#8217;s base salary; provided that an across-the-board reduction in the salary level of substantially all other individuals in positions similar to the Grantee&#8217;s by the same percentage amount shall not constitute such a salary reduction; or (iii) requiring the Grantee to be based at any place outside a 50 mile radius from the Grantee&#8217;s job location or residence except for reasonably required travel on business.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Forfeiture</u>. If, during the Restricted Period, (i) the Grantee incurs a Separation from Service, (ii)&nbsp;there occurs a material breach of the Award Agreement by the Grantee or (iii) the Grantee fails to meet the tax withholding obligations described in Section 7 below, all rights of the Grantee to the RSUs that have not vested in accordance with Sections 3 or 4 above shall terminate immediately and be forfeited in their entirety.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Settlement of RSUs</u>. Delivery of Shares and/or a cash payment under the Award Agreement shall be subject to the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company shall deliver to the Grantee one Share for each RSU that has vested and not otherwise been forfeited within 30 days following the end of the applicable Restricted Period; provided that, in the sole discretion of the Company, in lieu of delivering one Share for each RSU, the Company may deliver a cash payment to the Grantee for each RSU in an amount equal to the Fair Market Value of one Share as of the last day of the applicable Restricted Period (subject to reduction for tax withholding pursuant to Section 7 below and subject to reduction due to application of the Cash Cap); provided further, that the Company need not treat each vesting date or each RSU the same and may settle vested RSUs in a combination of Shares and cash in its sole discretion;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any issuance of Shares pursuant to the Award Agreement may be effected on a non-certificated basis, to the extent not prohibited by applicable law or the applicable rules of any securities exchange or similar entity; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event that a certificate for Shares is delivered to the Grantee in connection with the Award, such certificate shall bear the following legend:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;">The ownership and transferability of this certificate and the shares of stock represented hereby are subject to the terms and conditions (including forfeiture) of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan and a restricted stock unit award agreement entered into between the registered owner and Anika Therapeutics, Inc. Copies of such plan and agreement are on file in the executive offices of Anika Therapeutics, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition, the stock certificate or certificates for any Shares shall be subject to such stop-transfer orders and other restrictions as the Company may deem advisable under the rules, regulations and other requirements of the SEC, any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities law, and the Company may cause a legend or legends to be placed on such certificate or certificates to make appropriate reference to such restrictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Withholding</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Committee shall determine the amount of any withholding or other tax required by law to be withheld or paid by the Company with respect to any income recognized by the Grantee with respect to the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Grantee shall be required to meet any applicable tax withholding obligation in accordance with the tax withholding provisions of Section 17.3 of the Plan.&nbsp; The ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to participation in the Plan and legally applicable to Grantee (the &#8220;<b>Tax-Related Items</b>&#8221;) is and remains Grantee&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Grantee&#8217;s employer (the &#8220;<b>Employer</b>&#8221;).&nbsp; Grantee further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including, but not limited to, the grant, vesting or distribution of this Award, the issuance of shares of Stock upon vesting and distribution of this Award, the subsequent sale of shares of Stock acquired pursuant to such vesting and distribution or the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of this Award or any aspect of this Award to reduce or eliminate Grantee&#8217;s liability for Tax-Related Items or achieve any particular tax result.&nbsp; Further, if Grantee is subject to Tax-Related Items in more than one jurisdiction, Grantee acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to any relevant taxable or tax withholding event, as applicable, Grantee agrees to make adequate arrangements satisfactory to the Company and/or Grantee&#8217;s Employer to satisfy all Tax-Related Items. To satisfy any withholding obligations of the Company and/or the Employer with respect to Tax-Related Items, Grantee authorizes the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one (or a combination) of the following:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by direct payment to the Company or the Employer in cash of the amount of Tax-Related Items;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by having withheld from the Award at the appropriate time that number of whole Shares whose Fair Market Value is equal to the amount of Tax-Related Items required to be withheld with respect to the Award; and/or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by withholding from wages or other cash compensation paid to Grantee by the Company or the Employer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the avoidance of doubt, with respect to any RSUs settled in cash, the amount of tax withholding shall be deducted and withheld from the cash payment otherwise payable to the Grantee upon settlement of such RSUs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Adjustment</u>. Upon any event described in Section&nbsp;15 of the Plan occurring after the Grant Date, the adjustment provisions as provided for under Section&nbsp;15 of the Plan shall apply to the Award.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Bound by Plan and Committee Decisions</u>. By accepting the Award, the Grantee acknowledges that the Grantee has received a copy of the Plan, has had an opportunity to review the Plan, and agrees to be bound by all of the terms and conditions of the Plan. In the event of any conflict between the provisions of the Award Agreement and the Plan, the provisions of the Plan shall control. The authority to manage and control the operation and administration of the Award Agreement and the Plan shall be vested in the Committee, and the Committee shall have all powers with respect to the Award Agreement as it has with respect to the Plan. Any interpretation of the Award Agreement or the Plan by the Committee and any decision made by the Committee with respect to the Award Agreement or the Plan shall be final and binding on all persons.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Grantee Representations</u>. The Grantee hereby represents to the Company that the Grantee has read and fully understands the provisions of the Award Agreement and the Plan and that the Grantee&#8217;s decision to participate in the Plan is completely voluntary. Further, the Grantee acknowledges that the Grantee is relying solely on his or her own advisors with respect to the tax consequences of the Award.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Regulatory Restrictions on the RSUs</u>. Notwithstanding the other provisions of the Award Agreement, the Committee may impose such conditions, restrictions and limitations on the issuance of Common Stock with respect to the Award unless and until the Committee determines that such issuance complies with (a) any applicable registration requirements under the Securities Act or the Committee has determined that an exemption therefrom is available, (b) any applicable listing requirement of any stock exchange on which the Common Stock is listed, (c) any applicable Company policy or administrative rules and (d) any other applicable provision of state, federal or foreign law, including foreign securities laws where applicable.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Miscellaneous</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Notices</u>. Any notice that either party hereto may be required or permitted to give to the other shall be in writing and may be delivered personally, by intraoffice mail, by fax, by electronic mail or other electronic means, or via a postal service, postage prepaid, to such electronic mail or postal address and directed to such person as the Company may notify the Grantee from time to time; and to the Grantee at the Grantee&#8217;s electronic mail or postal address as shown on the records of the Company from time to time, or at such other electronic mail or postal address as the Grantee, by notice to the Company, may designate in writing from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Waiver</u>. The waiver by any party hereto of a breach of any provision of the Award Agreement shall not operate or be construed as a waiver of any other or subsequent breach.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Entire Agreement</u>. The Award Agreement and the Plan constitute the entire agreement between the parties with respect to the Award. Except as otherwise stated herein, any prior agreements, commitments or negotiations concerning the Award are superseded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Binding Effect; Successors</u>. The obligations and rights of the Company under the Award Agreement shall be binding upon and inure to the benefit of the Company and any successor corporation or organization resulting from the merger, consolidation, sale, or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the assets and business of the Company. The obligations and rights of the Grantee under the Award Agreement shall be binding upon and inure to the benefit of the Grantee and the beneficiaries, executors, administrators, heirs and successors of the Grantee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Governing Law; Consent to Jurisdiction; Consent to Venue; Service of Process</u>. The Award Agreement shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts without regard to the principles of conflicts of law thereof or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the Commonwealth of Massachusetts. For purposes of resolving any dispute that arises directly or indirectly in connection with the Award Agreement, the Grantee, by virtue of receiving the Award, hereby submits and consents to the exclusive jurisdiction of the Commonwealth of Massachusetts and agrees that any related litigation shall be conducted solely in the courts of Middlesex County, Massachusetts or the United States District Court for the District of Massachusetts, where the Award Agreement is made and to be performed, and no other courts. The Grantee may be served with process in any manner permitted under Massachusetts law, or by United States registered or certified mail, return receipt requested.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Headings</u>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Amendment</u>. The Award Agreement may be amended at any time by the Committee, <i>provided</i> that no amendment may, without the consent of the Grantee, materially impair the Grantee&#8217;s rights with respect to the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Severability</u>. The invalidity or unenforceability of any provision of the Award Agreement shall not affect the validity or enforceability of any other provision of the Award Agreement, and each other provision of the Award Agreement shall be severable and enforceable to the extent permitted by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Rights to Service</u>. Nothing contained in the Award Agreement shall be construed as giving the Grantee any right to be retained, in any position, as a director, officer, employee or consultant of the Company or its Affiliates, or shall interfere with or restrict in any way the rights of the Company or its Affiliates, which are hereby expressly reserved, to remove, terminate or discharge the Grantee at any time for any reason whatsoever or for no reason, subject to the Company&#8217;s articles of incorporation, bylaws and other similar governing documents and applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 409A</u>. It is intended that the Award Agreement and the Award will be exempt from (or in the alternative will comply with) Code Section 409A, and the Award Agreement shall be administered accordingly and interpreted and construed on a basis consistent with such intent. This Section 12(j) shall not be construed as a guarantee of any particular tax effect for the Grantee&#8217;s benefits under the Award Agreement and the Company does not guarantee that any such benefits will satisfy the provisions of Code Section 409A or any other provision of the Code.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Further Assurances</u>. The Grantee agrees, upon demand of the Company or the Committee, to do all acts and execute, deliver and perform all additional documents, instruments and agreements that may be reasonably required by the Company or the Committee, as the case may be, to implement the provisions and purposes of the Award Agreement and the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Confidentiality</u>. The Grantee agrees that the terms and conditions of the Award reflected in the Award Agreement are strictly confidential and, with the exception of the Grantee&#8217;s counsel, tax advisor, immediate family, or as required by applicable law, have not and shall not be disclosed, discussed or revealed to any other persons, entities or organizations, whether within or outside Company, without prior written approval of Company. The Grantee shall take all reasonable steps necessary to ensure that confidentiality is maintained by any of the individuals or entities referenced above to whom disclosure is authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Nature of Award</u>.&nbsp; In accepting this Award, Grantee acknowledges, understands and agrees that: (i) the Plan is established voluntarily by the Company, it is discretionary in nature, and the Company may amend, modify, suspend or terminate the Plan at any time, to the extent permitted by the Plan; (ii) the grant of this Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards or benefits in lieu of Awards, even if Awards have been granted in the past; (iii) all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company; (iv) the Award Agreement does not give Grantee the right to remain retained or employed by the Company and/or Employer (or any of their Subsidiaries or Affiliates) in any capacity; (v) except as otherwise provided in a separate agreement between Grantee and the Company and/or Employer (or any of their Subsidiaries or Affiliates), the Company and/or Employer reserve the right to terminate the Grantee&#8217;s employment or other service at any time and for any reason, in accordance with applicable laws; (vi) if Grantee is not a Service Provider to the Company or any Subsidiary or Affiliate, this Award does not establish an employment or other Service Provider relationship with the Company or any Subsidiary or Affiliate; (vii) Grantee is voluntarily participating in the Plan; (viii) this Award and shares of Common Stock subject to this Award, and the income from and value of same, are not intended to replace any pension rights or compensation; (ix) this Award and shares of Common Stock subject to this Award, and the income from and value of same, are not part of normal or expected compensation for purposes of, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments; (x) the future value of the Shares subject to this Award is unknown, indeterminable, and cannot be predicted with certainty; (xi) no claim or entitlement to compensation or damages shall arise from the forfeiture of this Award resulting from a Separation from Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment or other laws in the jurisdiction where Grantee is employed or otherwise rendering services, or the terms of Grantee&#8217;s employment or service agreement, if any); (xii) unless otherwise agreed with the Company, this Award and Shares acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, any service Grantee may provide as a director for any Subsidiary or Affiliate; (xiii) unless otherwise provided in the Plan or by the Company in its discretion, this Award and the benefits evidenced by the Award Agreement do not create any entitlement to have this Award transferred to, or assumed by, another company, nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and (xiv) the following provisions shall be applicable only to employees outside the U.S.: (a) this Award and Shares subject to this Award, and the income from and value of same, are not part of normal or expected compensation for any purpose; and (b) neither the Company, the Employer, nor any other Subsidiary or Affiliate shall be liable for any foreign exchange rate fluctuation between Grantee&#8217;s local currency and the United States Dollar that may affect the value of this Award or of any amounts due to Grantee pursuant to the vesting or Settlement of this Award or the subsequent sale of Shares acquired upon Settlement of this Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Clawback</u>.&nbsp; This Award is subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in accordance with the terms of any Company clawback Policy or any applicable law related to such actions, as may be in effect from time to time. Grantee&#8217;s acceptance of this Award shall be deemed to constitute Grantee&#8217;s acknowledgement of and consent to the Company&#8217;s application, implementation and enforcement of any applicable Policy that may apply to the Grantee, whether adopted prior to or following the Grant Date, and any provision of applicable law relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and Grantee&#8217;s agreement that the Company may take such actions as may be necessary to effectuate any such policy or applicable law, without further consideration or action.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Advice Regarding Grant</u>.&nbsp; The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding participation in the Plan, or the acquisition or sale of Shares.&nbsp; Grantee should consult with Grantee&#8217;s own personal tax, legal and financial advisors regarding participation in the Plan before taking any action related to the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Data Privacy.</u>&nbsp; Grantee&#8217;s personal information will be processed in accordance with the Company&#8217;s privacy policy previously given to and acknowledged by the Grantee.&nbsp; Grantee may obtain a copy of such policy at no cost by contacting Grantee&#8217;s local human resources department.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Data Collection and Usage</u>.&nbsp;&nbsp;The Company and any Subsidiaries or Affiliates, including the Employer, may collect, process and use certain personal information about Grantee, including, but not limited to, Grantee&#8217;s name, home address and telephone number, email address, date of birth, social security, social insurance, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Company or any of its Subsidiaries or Affiliates, details of all awards or any other entitlement to Shares or equivalent benefits awarded, canceled, exercised, vested, unvested or outstanding in Grantee&#8217;s favor (&#8220;<b>Data</b>&#8221;), for the purposes of implementing, administering and managing the Plan.&nbsp;&nbsp;The legal basis, where required, for the processing of Data by the Company and the third-party service providers described below is the necessity of the data processing for the Company to perform its contractual obligations under the Award Agreement and the Company&#8217;s legitimate business interest of managing the Plan and generally administering the Awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Plan Administration Service Providers</u>.&nbsp;&nbsp;The Company transfers Data to Solium Capital LLC (&#8220;<b>Solium</b>&#8221;), an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan.&nbsp;&nbsp;Grantee acknowledges and understands that Solium will open an account for Grantee to receive and trade Shares acquired under the Plan and that Grantee will be asked to agree on separate terms and data processing practices with Solium, with such agreement being a condition to the ability to participate in the Plan.&nbsp;&nbsp;The legal basis for the transfer of Data by the Company to Solium is its necessity to perform a contract between the Company and Solium concluded in the interest of Grantee.&nbsp;&nbsp;As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Data in the United States or, as the case may be, other countries, may not be subject to substantive data processing principles or supervision by data protection authorities.&nbsp;&nbsp;In addition, Grantee may not have enforceable rights regarding the processing of Data in such countries.&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>International Data Transfers</u>.&nbsp;&nbsp;The Company and its service providers that manage and administer the Awards are based in the United States: this Award derives from the Company, incorporated in the state of Delaware, United States and the Plan, governed by the laws of the Commonwealth of Massachusetts. Therefore, in order for the Company to perform its contractual obligations under the Award Agreement, Data will be transferred to the United States. The Company&#8217;s legal basis, where required, for the transfer of Data is its necessity in order to perform its contractual obligations under the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Data Retention</u>.&nbsp;&nbsp;The Company will hold and use Data only as long as is necessary to implement, administer and manage Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Voluntariness and Consequences of Consent Denial or Withdrawal</u>.&nbsp;&nbsp;Participation in the Plan is voluntary and Grantee is providing consents, where applicable, on a purely voluntary basis.&nbsp;&nbsp;Grantee understands that Grantee may withdraw his/her consent at any time with future effect for any or no reason.&nbsp;&nbsp;If Grantee does not consent, or if Grantee later seeks to revoke consent, Grantee&#8217;s salary from or employment and career with the Employer will not be affected; the only consequence of refusing or withdrawing consent is that the Company would not be able to grant Awards or other equity awards to Grantee or administer or maintain Grantee&#8217;s participation in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Data Subject Rights</u>.&nbsp;&nbsp;Grantee may have a number of rights under data privacy laws in Grantee&#8217;s jurisdiction.&nbsp;&nbsp;Depending on where Grantee is based, such rights may include the right to (a)&nbsp;request access or copies of Data the Company processes, (b) rectification of incorrect Data, (c)&nbsp;deletion of Data, (d) restrictions on processing of Data, (e) portability of Data, (f)&nbsp;lodge complaints with competent authorities in Grantee&#8217;s jurisdiction, and/or (g) receive a list with the names and addresses of any potential recipients of Data.&nbsp;&nbsp;To receive clarification regarding these rights or to exercise these rights, Grantee can contact his/her local human resources representative.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 68pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Alternative Basis for Data Processing/Transfer</u>.&nbsp; Grantee understands that in the future, the Company may rely on a different legal basis for the processing and/or transfer of Data and/or request that Grantee provides another data privacy consent form.&nbsp; Upon request of the Company or the Employer, Grantee agrees to provide an executed data privacy consent form (or any other agreements or consents) that the Company and/or the Employer may deem necessary to obtain from Grantee for the purpose of administering Grantee&#8217;s participation in the Plan in compliance with the data privacy laws in Grantee&#8217;s country, either now or in the future.&nbsp; Grantee understands and agrees that Grantee will not be able to participate in the Plan if he/she fails to provide any such consent or agreement requested by the Company and/or the Employer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Electronic Delivery</u>.&nbsp; By accepting this Award, Grantee consents to receive documents related to this Award by electronic delivery and, if requested, agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.&nbsp; Grantee&#8217;s consent shall remain in effect throughout Grantee&#8217;s term as a Service Provider and thereafter until Grantee withdraws such consent in writing to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="8" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>APPENDIX</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>TO THE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>RESTRICTED STOCK UNIT AGREEMENT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNDER THE ANIKA THERAPEUTICS, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2017 OMNIBUS INCENTIVE PLAN</b><br>
&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">Capitalized terms used but not defined in this Appendix have the meanings set forth herein or in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Terms and Conditions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Appendix includes additional terms and conditions that govern this Award if Grantee resides and/or works in one of the countries listed herein.&nbsp; If Grantee is a citizen or resident of a country other than the one in which he/she is currently residing and/or working, transfers employment and/or residency to another country after receiving the grant of this Award, or is considered a resident of another country for local law purposes, the Company shall, in its discretion, determine to what extent the terms and conditions herein will apply to Grantee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Notifications</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">This Appendix also includes information regarding taxes and certain other issues of which Grantee should be aware with respect to participation in the Plan.&nbsp; The information is based on the securities, exchange control, income tax and other laws in effect in the respective countries as of January 2021.&nbsp; Such laws are often complex and change frequently.&nbsp; As a result, the Company strongly recommends that Grantee not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time Grantee vests in this Award, upon Settlement, or when Grantee sells Shares acquired under the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In addition, the information contained herein is general in nature and may not apply to Grantee&#8217;s particular situation, and the Company is not in a position to assure Grantee of any particular result.&nbsp; Accordingly, Grantee is advised to seek appropriate professional advice as to how the relevant laws in Grantee&#8217;s country of residence may apply to his/her personal situation.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If Grantee is a citizen or resident of a country other than the one in which Grantee is currently residing and/or working, transfers employment and/or residency to another country after the grant of this Award, or Grantee is considered a resident of another country for local law purposes, the information contained herein may not be applicable to Grantee in the same manner.&nbsp; Grantee is advised to consult his/her personal advisor to determine the extent to which the notifications apply to Grantee&#8217;s specific situation.</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="9" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ITALY</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><i>Terms and Conditions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following terms will supplement, amend or integrate for purposes of Italian laws the relevant sections of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">1.</td>
			<td style="width: 98%;">Section 7 of the Award Agreement is replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Withholding</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Committee shall determine the amount of any withholding or other tax required by Italian law to be withheld or paid by the Company with respect to any income recognized by the Grantee with respect to the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 72pt;">(b)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Irrespective of the above, the Grantee shall be required to meet any applicable tax withholding obligation in accordance with the tax withholding provisions of Section 17.3 of the Plan. The ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to participation in the Plan and legally applicable to Grantee (the &#8220;<b>Tax-Related Items</b>&#8221;) is and remains Grantee&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.&nbsp; Grantee further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including, but not limited to, the grant, vesting or distribution of this Award, the issuance of shares of Stock upon vesting and distribution of this Award, the subsequent sale of shares of Stock acquired pursuant to such exercise or the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of this Award or any aspect of this Award to reduce or eliminate Grantee&#8217;s liability for Tax-Related Items or achieve any particular tax result.&nbsp; Further, if Grantee is subject to Tax-Related Items in more than one jurisdiction, Grantee acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to any relevant taxable or tax withholding event, as applicable, Grantee agrees to make adequate arrangements satisfactory to the Company and/or Grantee&#8217;s Employer to satisfy all Tax-Related Items. To satisfy any withholding obligations of the Company and/or the Employer with respect to Tax-Related Items, Grantee authorizes the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one (or a combination) of the following:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 112pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by direct payment to the Company or the Employer of the amount of Tax-Related Items through a wire transfer bank payment;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 112pt;">(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by having withheld from the Award at the appropriate time that number of whole Shares whose Fair Market Value is equal to the amount of Tax-Related Items required to be withheld with respect to the Award; and/or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 112pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [intentionally left blank];</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;">If the Grantee is an Italian tax resident who, at any time during the fiscal year, holds foreign financial assets (including cash and shares) which may generate taxable income in Italy, the Grantee is required to report such assets on his or her annual tax return for the year during which the assets are held, or on a special form if no tax return is due. These reporting obligations also apply if the Grantee is the beneficial owner of foreign financial assets under Italian money laundering provisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">2.</td>
			<td style="width: 98%;">Section 9 of the Award Agreement is replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Bound by Plan and Committee Decisions</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">By accepting the Award, the Grantee acknowledges that the Grantee has received a copy of the Plan, the Award Agreement and the Appendix, has had an opportunity to review the Plan, the Award Agreement and the Appendix and agrees to be bound by all of the terms and conditions of the Plan, the Award Agreement and the Appendix. In the event of any conflict between the provisions of the Award Agreement and the Plan, the provisions of the Plan shall control. The authority to manage and control the operation and administration of the Award Agreement and the Plan shall be vested in the Committee, and the Committee shall have all powers with respect to the Award Agreement as it has with respect to the Plan. Any interpretation of the Award Agreement or the Plan by the Committee and any decision made by the Committee with respect to the Award Agreement or the Plan shall be final and binding on all persons.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">3.</td>
			<td style="width: 98%;">Section 10 of the Award Agreement is replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Grantee Representations</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">The Grantee hereby represents to the Company that the Grantee has read and fully understands the provisions of the Award Agreement including the Appendix and the Plan and that the Grantee&#8217;s decision to participate in the Plan is completely voluntary. Further, the Grantee acknowledges that the Grantee is relying solely on his or her own advisors with respect to the tax consequences of the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">4.</td>
			<td style="width: 98%;">Section 12, letter (c), of the Award Agreement is entirely deleted and replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Entire Agreement</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">The Award Agreement including the Appendix and the Plan constitute the entire agreement between the parties with respect to the Award. Except as otherwise stated herein, any prior agreements, commitments or negotiations concerning the Award are superseded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%; vertical-align: top;">5.</td>
			<td style="width: 98%;">Section 12, letter (e), of the Award Agreement shall be interpreted to allow any dispute arising with respect to the Award Agreement to be referred for resolution to Italian courts of competent jurisdiction pursuant to Italian rules of civil procedure. In addition, Italian mandatory labor laws shall apply and, in case of contrast, prevail over any law of the Commonwealth of Massachusetts.</td>
		</tr>
		<tr>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 98%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 2%; vertical-align: top;">6.</td>
			<td style="width: 98%;">Section 12, letter (m), numbers (ix) and (xvi), of the Award Agreement shall be construed and interpreted so as to allow the application of article 2120, para. 2, of the Italian Civil Code to assess whether any income arising from the Award Agreement takes part in the formation of the income base for computation of the severance payment due to employees under Italian law.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>UNITED KINGDOM</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><i>Terms and Conditions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Withholding.</b>&nbsp;<b> </b>The following supplements the &#8220;Withholding&#8221; section of the Award Agreement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt;">Without limitation to the &#8220;Withholding&#8221; section of the Award Agreement, Grantee agrees that Grantee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or, if different, the Employer or by His Majesty&#8217;s Revenue &amp; Customs (&#8220;<b>HMRC</b>&#8221;) (or any other tax authority or any other relevant authority).&nbsp; Grantee also agrees to indemnify and keep indemnified the Company and, if different, the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Grantee&#8217;s behalf.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt;">Notwithstanding the foregoing, if Grantee is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Grantee understands that Grantee may not be able to indemnify the Company or the Employer for the amount of any Tax-Related Items not collected from or paid by Grantee if the indemnification could be considered to be a loan.&nbsp; In this case, the Tax-Related Items not collected or paid by Grantee within 90 days of the end of the U.K. tax year in which an event giving rise to the taxable event occurs, may constitute an additional benefit to Grantee on which additional income tax and National Insurance contributions (&#8220;<b>NICs</b>&#8221;) may be payable.&nbsp; Grantee understands that Grantee will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee NICs due on this additional benefit, which may also be recovered from Grantee by any of the means referred to in the &#8220;Withholding&#8221; section of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: small-caps; text-align: justify; margin: 0pt; text-indent: 0pt;"><b>Joint Election</b><b>.</b>&nbsp;<b> </b>As a condition of participation in the Plan, Grantee agrees to accept any liability for secondary Class 1 NICs which may be payable by the Company and/or the Employer in connection with this Award, where legally permitted, and any event giving rise to Tax-Related Items related to Grantee&#8217;s participation in the Plan (the &#8220;<b>Employer NICs</b>&#8221;).&nbsp; Without prejudice to the foregoing, if requested to do so by the Employer or the Company, Grantee agrees to execute a joint election with the Company or the Employer, the form of such joint election having been approved formally by HMRC (the &#8220;<b>Joint Election</b>&#8221;), and any other required consent or election to accomplish the transfer of Employer NICs to Grantee.&nbsp; Grantee further agrees to execute such other joint elections as may be required between Grantee and any successor to the Company or the Employer.&nbsp; Grantee further agrees that the Company or the Employer may collect the Employer NICs from Grantee by any of the means set forth in the &#8220;Withholding&#8221; section of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt;">If, having been requested to enter into a Joint Election by the Employer or the Company, Grantee does not enter into the Joint Election or if approval of the Joint Election has been withdrawn by HMRC, the Company, in its sole discretion and without any liability to the Company or the Employer, may choose not to issue or deliver any Shares to Grantee upon vesting of this Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: small-caps; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>S431 Election</b><b>.</b>&nbsp;<b> </b>As a condition of participation in the Plan, the Grantee agrees to enter into, jointly with the Company and/or the Employer, a joint election within Section 431 of ITEPA in respect of computing any tax charge on the acquisition of &#8220;restricted securities&#8221; (as defined in Sections 423 and 424 of ITEPA), and that the Grantee will not revoke such election at any time (the &#8220;<u>Section 431 Election</u>&#8221;).&nbsp; The Section 431 Election will be to treat the Shares acquired pursuant to the vesting of the Award as if such Shares were not restricted securities (for U.K. tax purposes only).&nbsp; The Grantee must enter into the Section 431 Election within 14 days of such time as may be designated by the Company and/or the Employer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 12</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10B
<SEQUENCE>3
<FILENAME>ex_659522.htm
<DESCRIPTION>EXHIBIT 10.10(B)
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 10.10(b)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTICE OF GRANT OF RESTRICTED STOCK UNITS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ANIKA THERAPEUTICS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>2021 INDUCEMENT PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended from time to time (the &#8220;<b>Plan</b>&#8221;), to the Grantee designated in this Notice of Grant of Restricted Stock Units (the &#8220;<b>Notice of Grant</b>&#8221;), the number of restricted stock units (&#8220;<b>RSUs</b>&#8221;) set forth in the Notice of Grant (the &#8220;<b>Award</b>&#8221;), subject to certain terms and conditions as outlined below in the Notice of Grant and the additional terms and conditions set forth in the attached Terms and Conditions of Restricted Stock Units, including the Appendix attached thereto (the &#8220;<b>Terms and Conditions</b>,&#8221; and together with the Notice of Grant, the &#8220;<b>Award Agreement</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 5%; margin-right: 5%;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Grantee:</b></p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Grant Date:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Number of RSUs Granted:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Definition of RSU:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Each RSU shall entitle the Grantee to receive one Share or, subject to application of the Cash Cap (as defined in the Terms and Conditions), a cash payment equal to the Fair Market Value of one Share at such future date or dates and subject to such terms and conditions as set forth in the Award Agreement.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Vesting Schedule:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; padding: 5px 0px 5px 5px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subject to the provisions of the Terms and Conditions and other applicable sections of this Notice of Grant, the Award shall vest in substantially equal installments on the first, second, and third anniversary of the Grant Date, &nbsp;provided that Grantee remains a continuous Service Provider from the Grant Date until the date on which the Award is scheduled to vest.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">By electronically accepting the Award Agreement , the Grantee agrees that the Award is granted under and governed by the terms and conditions of the Plan and the Award Agreement, as of the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GRANTEE</b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ANIKA THERAPEUTICS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sign Name:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sign Name:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Print Name<u>:</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Print Name:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 2%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 65%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
		</tr>

</table>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Notice of Grant - Page " data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="Notice of Grant - Page " data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Notice of Grant - Page 1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>TERMS AND CONDITIONS OF RESTRICTED STOCK UNITS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Grant of RSUs</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Award granted to the Grantee and described in the Notice of Grant is subject to the terms and conditions of the Plan. The terms and conditions of the Plan are hereby incorporated herein by reference. Except as otherwise expressly set forth herein, the Award Agreement shall be construed in accordance with the terms and conditions of the Plan. Any capitalized term not otherwise defined in the Award Agreement shall have the definition set forth in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Committee has approved the grant to the Grantee of the Award, conditioned upon the Grantee&#8217;s acceptance of the terms and conditions of the Award Agreement within 60 days after the Award Agreement is presented to the Grantee for review; if the Grantee does not accept the terms and conditions of the Award Agreement within 60 days after the Award Agreement is presented to the Grantee for review, the Grantee will automatically be deemed to accept the Award and such terms and conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of the Grant Date, the Company grants to the Grantee the number of RSUs set forth in the Notice of Grant, subject to the terms and conditions of the Plan and the Award Agreement. Each RSU shall entitle the Grantee to receive one Share or, subject to application of the Cash Cap (as defined below), a cash payment with a Fair Market Value equal to one Share, at such future date or dates and subject to such terms and conditions as set forth in the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Restrictions</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Grantee shall have no rights or privileges of a Company stockholder as to the RSUs prior to settlement (to the extent settled in Shares) in accordance with Section 6 of these Terms and Conditions (&#8220;<b>Settlement</b>&#8221;), including no right to vote or receive dividends or other distributions with respect to the RSUs; in addition, the following provisions shall apply:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 68pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the Grantee shall not be entitled to delivery of a certificate or certificates for Shares in connection with the RSUs until Settlement in Shares (if at all), and upon the satisfaction of all other applicable conditions;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 68pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; none of the RSUs may be sold, transferred (other than by will or the laws of descent and distribution), assigned, pledged or otherwise encumbered or disposed of prior to Settlement in Shares; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 68pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all of the RSUs shall be forfeited and all rights of the Grantee with respect to the RSUs shall terminate in their entirety on the terms and conditions set forth in Section 5 below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any attempt to dispose of RSUs or any interest in the RSUs in a manner contrary to the restrictions set forth in the Award Agreement shall be void and of no effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding anything herein to the contrary, in the event the Company elects to settle any RSUs in the form of cash, in no event shall the amount paid in cash with respect to any RSU (calculated prior to any reduction for tax withholding or other deductions) exceed an amount equal to 3x the Fair Market Value of a Share as of the Grant Date (subject to equitable adjustment in the case of any stock split, reverse stock split or similar change in capitalization) (the &#8220;Cash Cap&#8221;); provided that, as of the final vesting date of this Award, the Grantee may receive an amount in cash that exceeds the Cash Cap (i) in the event the Fair Market Value as of the final vesting date exceeds the Fair Market Value on each prior vesting date and (ii) so long as the aggregate amount of cash paid to Grantee pursuant to this Award does not exceed the Aggregate Cash Cap.&nbsp; For purposes of this Agreement, the &#8220;Aggregate Cash Cap&#8221; shall mean an amount equal to 3x (A) the number of RSUs subject to this Award that were settled (or would be settled upon the final vesting date) in cash multiplied by (B) the Fair Market Value of a Share as of the Grant Date (subject to equitable adjustment in the case of any stock split, reverse stock split or similar change in capitalization).&nbsp; On or following a Change in Control, the Cash Cap shall not apply.</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Terms and Conditions - Page " data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Restricted Period and Vesting</u>. The &#8220;<b>Restricted Period</b>&#8221;&nbsp;is the period beginning on the Grant Date and ending on the date the RSUs, or such applicable portion of the RSUs, are deemed vested under the schedule set forth in the Notice of Grant, including any applicable accelerated vesting provisions set forth herein.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Acceleration of Vesting under Certain Circumstances</u>.&nbsp;&nbsp;The vesting of the Award shall not be accelerated under any circumstances, except as otherwise provided in the Plan or in a written agreement between the Grantee and the Company or an Affiliate; provided, however, that if, within 3 months prior to and in connection with a Change in Control, or 12 months following a Change in Control, the Grantee incurs a Separation from Service as a result of a termination initiated by the Company or an Affiliate without Cause, or by the Grantee for Good Reason, then 100% of the Shares shall immediately become vested prior to such termination (provided that if such termination occurs prior to such Change in Control, such Shares shall immediately become vested prior to such Change in Control). For this purpose, &#8220;Good Reason&#8221;&nbsp;means as such term (or word of like import) is expressly defined in a then-effective written agreement between the Grantee and the Company or such Affiliate, or in the absence of such then-effective written agreement and definition, means the occurrence of any of the following events or conditions unless consented to by the Grantee (and the Grantee shall be deemed to have consented to any such event or condition unless the Grantee provides written notice of the Grantee&#8217;s non-acquiescence within 30 days of becoming aware of such event or condition): (i) a change in the Grantee&#8217;s responsibilities or duties which represents a material and substantial diminution in the Grantee&#8217;s responsibilities or duties, as applicable; (ii) a material reduction in the Grantee&#8217;s base salary; provided that an across-the-board reduction in the salary level of substantially all other individuals in positions similar to the Grantee&#8217;s by the same percentage amount shall not constitute such a salary reduction; or (iii) requiring the Grantee to be based at any place outside a 50 mile radius from the Grantee&#8217;s job location or residence except for reasonably required travel on business.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Forfeiture</u>. If, during the Restricted Period, (i) the Grantee incurs a Separation from Service, (ii)&nbsp;there occurs a material breach of the Award Agreement by the Grantee or (iii) the Grantee fails to meet the tax withholding obligations described in Section 7 below, all rights of the Grantee to the RSUs that have not vested in accordance with Sections 3 or 4 above shall terminate immediately and be forfeited in their entirety.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Settlement of RSUs</u>. Delivery of Shares and/or a cash payment under the Award Agreement shall be subject to the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company shall deliver to the Grantee one Share for each RSU that has vested and not otherwise been forfeited within 30 days following the end of the applicable Restricted Period; provided that, in the sole discretion of the Company, in lieu of delivering one Share for each RSU, the Company may deliver a cash payment to the Grantee for each RSU in an amount equal to the Fair Market Value of one Share as of the last day of the applicable Restricted Period (subject to reduction for tax withholding pursuant to Section 7 below and subject to reduction due to application of the Cash Cap); provided further, that the Company need not treat each vesting date or each RSU the same and may settle vested RSUs in a combination of Shares and cash in its sole discretion;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any issuance of Shares pursuant to the Award Agreement may be effected on a non-certificated basis, to the extent not prohibited by applicable law or the applicable rules of any securities exchange or similar entity; and</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event that a certificate for Shares is delivered to the Grantee in connection with the Award, such certificate shall bear the following legend:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;">The ownership and transferability of this certificate and the shares of stock represented hereby are subject to the terms and conditions (including forfeiture) of the Anika Therapeutics, Inc. 2021 Inducement Plan and a restricted stock unit award agreement entered into between the registered owner and Anika Therapeutics, Inc. Copies of such plan and agreement are on file in the executive offices of Anika Therapeutics, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition, the stock certificate or certificates for any Shares shall be subject to such stop-transfer orders and other restrictions as the Company may deem advisable under the rules, regulations and other requirements of the SEC, any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities law, and the Company may cause a legend or legends to be placed on such certificate or certificates to make appropriate reference to such restrictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Withholding</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Committee shall determine the amount of any withholding or other tax required by law to be withheld or paid by the Company with respect to any income recognized by the Grantee with respect to the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Grantee shall be required to meet any applicable tax withholding obligation in accordance with the tax withholding provisions of Section 17.3 of the Plan.&nbsp; The ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to participation in the Plan and legally applicable to Grantee (the &#8220;<b>Tax-Related Items</b>&#8221;) is and remains Grantee&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Grantee&#8217;s employer (the &#8220;<b>Employer</b>&#8221;).&nbsp; Grantee further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including, but not limited to, the grant, vesting or distribution of this Award, the issuance of shares of Stock upon vesting and distribution of this Award, the subsequent sale of shares of Stock acquired pursuant to such vesting and distribution or the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of this Award or any aspect of this Award to reduce or eliminate Grantee&#8217;s liability for Tax-Related Items or achieve any particular tax result.&nbsp; Further, if Grantee is subject to Tax-Related Items in more than one jurisdiction, Grantee acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to any relevant taxable or tax withholding event, as applicable, Grantee agrees to make adequate arrangements satisfactory to the Company and/or Grantee&#8217;s Employer to satisfy all Tax-Related Items. To satisfy any withholding obligations of the Company and/or the Employer with respect to Tax-Related Items, Grantee authorizes the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one (or a combination) of the following:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by direct payment to the Company or the Employer in cash of the amount of Tax-Related Items;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by having withheld from the Award at the appropriate time that number of whole Shares whose Fair Market Value is equal to the amount of Tax-Related Items required to be withheld with respect to the Award; and/or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by withholding from wages or other cash compensation paid to Grantee by the Company or the Employer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the avoidance of doubt, with respect to any RSUs settled in cash, the amount of tax withholding shall be deducted and withheld from the cash payment otherwise payable to the Grantee upon settlement of such RSUs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Adjustment</u>. Upon any event described in Section&nbsp;15 of the Plan occurring after the Grant Date, the adjustment provisions as provided for under Section&nbsp;15 of the Plan shall apply to the Award.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Bound by Plan and Committee Decisions</u>. By accepting the Award, the Grantee acknowledges that the Grantee has received a copy of the Plan, has had an opportunity to review the Plan, and agrees to be bound by all of the terms and conditions of the Plan. In the event of any conflict between the provisions of the Award Agreement and the Plan, the provisions of the Plan shall control. The authority to manage and control the operation and administration of the Award Agreement and the Plan shall be vested in the Committee, and the Committee shall have all powers with respect to the Award Agreement as it has with respect to the Plan. Any interpretation of the Award Agreement or the Plan by the Committee and any decision made by the Committee with respect to the Award Agreement or the Plan shall be final and binding on all persons.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Grantee Representations</u>. The Grantee hereby represents to the Company that the Grantee has read and fully understands the provisions of the Award Agreement and the Plan and that the Grantee&#8217;s decision to participate in the Plan is completely voluntary. Further, the Grantee acknowledges that the Grantee is relying solely on his or her own advisors with respect to the tax consequences of the Award.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Regulatory Restrictions on the RSUs</u>. Notwithstanding the other provisions of the Award Agreement, the Committee may impose such conditions, restrictions and limitations on the issuance of Common Stock with respect to the Award unless and until the Committee determines that such issuance complies with (a) any applicable registration requirements under the Securities Act or the Committee has determined that an exemption therefrom is available, (b) any applicable listing requirement of any stock exchange on which the Common Stock is listed, (c) any applicable Company policy or administrative rules and (d) any other applicable provision of state, federal or foreign law, including foreign securities laws where applicable.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 97%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.</p>
			</td>
			<td style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Miscellaneous</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Notices</u>. Any notice that either party hereto may be required or permitted to give to the other shall be in writing and may be delivered personally, by intraoffice mail, by fax, by electronic mail or other electronic means, or via a postal service, postage prepaid, to such electronic mail or postal address and directed to such person as the Company may notify the Grantee from time to time; and to the Grantee at the Grantee&#8217;s electronic mail or postal address as shown on the records of the Company from time to time, or at such other electronic mail or postal address as the Grantee, by notice to the Company, may designate in writing from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Waiver</u>. The waiver by any party hereto of a breach of any provision of the Award Agreement shall not operate or be construed as a waiver of any other or subsequent breach.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Entire Agreement</u>. The Award Agreement and the Plan constitute the entire agreement between the parties with respect to the Award. Except as otherwise stated herein, any prior agreements, commitments or negotiations concerning the Award are superseded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Binding Effect; Successors</u>. The obligations and rights of the Company under the Award Agreement shall be binding upon and inure to the benefit of the Company and any successor corporation or organization resulting from the merger, consolidation, sale, or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the assets and business of the Company. The obligations and rights of the Grantee under the Award Agreement shall be binding upon and inure to the benefit of the Grantee and the beneficiaries, executors, administrators, heirs and successors of the Grantee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Governing Law; Consent to Jurisdiction; Consent to Venue; Service of Process</u>. The Award Agreement shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts without regard to the principles of conflicts of law thereof or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the Commonwealth of Massachusetts. For purposes of resolving any dispute that arises directly or indirectly in connection with the Award Agreement, the Grantee, by virtue of receiving the Award, hereby submits and consents to the exclusive jurisdiction of the Commonwealth of Massachusetts and agrees that any related litigation shall be conducted solely in the courts of Middlesex County, Massachusetts or the United States District Court for the District of Massachusetts, where the Award Agreement is made and to be performed, and no other courts. The Grantee may be served with process in any manner permitted under Massachusetts law, or by United States registered or certified mail, return receipt requested.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Headings</u>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Amendment</u>. The Award Agreement may be amended at any time by the Committee, <i>provided</i> that no amendment may, without the consent of the Grantee, materially impair the Grantee&#8217;s rights with respect to the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. The invalidity or unenforceability of any provision of the Award Agreement shall not affect the validity or enforceability of any other provision of the Award Agreement, and each other provision of the Award Agreement shall be severable and enforceable to the extent permitted by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Rights to Service</u>. Nothing contained in the Award Agreement shall be construed as giving the Grantee any right to be retained, in any position, as a director, officer, employee or consultant of the Company or its Affiliates, or shall interfere with or restrict in any way the rights of the Company or its Affiliates, which are hereby expressly reserved, to remove, terminate or discharge the Grantee at any time for any reason whatsoever or for no reason, subject to the Company&#8217;s articles of incorporation, bylaws and other similar governing documents and applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 409A</u>. It is intended that the Award Agreement and the Award will be exempt from (or in the alternative will comply with) Code Section 409A, and the Award Agreement shall be administered accordingly and interpreted and construed on a basis consistent with such intent. This Section 12(j) shall not be construed as a guarantee of any particular tax effect for the Grantee&#8217;s benefits under the Award Agreement and the Company does not guarantee that any such benefits will satisfy the provisions of Code Section 409A or any other provision of the Code.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Further Assurances</u>. The Grantee agrees, upon demand of the Company or the Committee, to do all acts and execute, deliver and perform all additional documents, instruments and agreements that may be reasonably required by the Company or the Committee, as the case may be, to implement the provisions and purposes of the Award Agreement and the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Confidentiality</u>. The Grantee agrees that the terms and conditions of the Award reflected in the Award Agreement are strictly confidential and, with the exception of the Grantee&#8217;s counsel, tax advisor, immediate family, or as required by applicable law, have not and shall not be disclosed, discussed or revealed to any other persons, entities or organizations, whether within or outside Company, without prior written approval of Company. The Grantee shall take all reasonable steps necessary to ensure that confidentiality is maintained by any of the individuals or entities referenced above to whom disclosure is authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Nature of Award</u>.&nbsp; In accepting this Award, Grantee acknowledges, understands and agrees that: (i) the Plan is established voluntarily by the Company, it is discretionary in nature, and the Company may amend, modify, suspend or terminate the Plan at any time, to the extent permitted by the Plan; (ii) the grant of this Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards or benefits in lieu of Awards, even if Awards have been granted in the past; (iii) all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company; (iv) the Award Agreement does not give Grantee the right to remain retained or employed by the Company and/or Employer (or any of their Subsidiaries or Affiliates) in any capacity; (v) except as otherwise provided in a separate agreement between Grantee and the Company and/or Employer (or any of their Subsidiaries or Affiliates), the Company and/or Employer reserve the right to terminate the Grantee&#8217;s employment or other service at any time and for any reason, in accordance with applicable laws; (vi) if Grantee is not a Service Provider to the Company or any Subsidiary or Affiliate, this Award does not establish an employment or other Service Provider relationship with the Company or any Subsidiary or Affiliate; (vii) Grantee is voluntarily participating in the Plan; (viii) this Award and shares of Common Stock subject to this Award, and the income from and value of same, are not intended to replace any pension rights or compensation; (ix) this Award and shares of Common Stock subject to this Award, and the income from and value of same, are not part of normal or expected compensation for purposes of, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments; (x) the future value of the Shares subject to this Award is unknown, indeterminable, and cannot be predicted with certainty; (xi) no claim or entitlement to compensation or damages shall arise from the forfeiture of this Award resulting from a Separation from Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment or other laws in the jurisdiction where Grantee is employed or otherwise rendering services, or the terms of Grantee&#8217;s employment or service agreement, if any); (xii) unless otherwise agreed with the Company, this Award and Shares acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, any service Grantee may provide as a director for any Subsidiary or Affiliate; (xiii) unless otherwise provided in the Plan or by the Company in its discretion, this Award and the benefits evidenced by the Award Agreement do not create any entitlement to have this Award transferred to, or assumed by, another company, nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and (xiv) the following provisions shall be applicable only to employees outside the U.S.: (a) this Award and Shares subject to this Award, and the income from and value of same, are not part of normal or expected compensation for any purpose; and (b) neither the Company, the Employer, nor any other Subsidiary or Affiliate shall be liable for any foreign exchange rate fluctuation between Grantee&#8217;s local currency and the United States Dollar that may affect the value of this Award or of any amounts due to Grantee pursuant to the vesting or Settlement of this Award or the subsequent sale of Shares acquired upon Settlement of this Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Clawback</u>.&nbsp; This Award is subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in accordance with the terms of any Company clawback Policy or any applicable law related to such actions, as may be in effect from time to time. Grantee&#8217;s acceptance of this Award shall be deemed to constitute Grantee&#8217;s acknowledgement of and consent to the Company&#8217;s application, implementation and enforcement of any applicable Policy that may apply to the Grantee, whether adopted prior to or following the Grant Date, and any provision of applicable law relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and Grantee&#8217;s agreement that the Company may take such actions as may be necessary to effectuate any such policy or applicable law, without further consideration or action.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Advice Regarding Grant</u>.&nbsp; The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding participation in the Plan, or the acquisition or sale of Shares.&nbsp; Grantee should consult with Grantee&#8217;s own personal tax, legal and financial advisors regarding participation in the Plan before taking any action related to the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Data Privacy.</u>&nbsp; Grantee&#8217;s personal information will be processed in accordance with the Company&#8217;s privacy policy previously given to and acknowledged by the Grantee.&nbsp; Grantee may obtain a copy of such policy at no cost by contacting Grantee&#8217;s local human resources department.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Data Collection and Usage</u>.&nbsp;&nbsp;The Company and any Subsidiaries or Affiliates, including the Employer, may collect, process and use certain personal information about Grantee, including, but not limited to, Grantee&#8217;s name, home address and telephone number, email address, date of birth, social security, social insurance, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Company or any of its Subsidiaries or Affiliates, details of all awards or any other entitlement to Shares or equivalent benefits awarded, canceled, exercised, vested, unvested or outstanding in Grantee&#8217;s favor (&#8220;<b>Data</b>&#8221;), for the purposes of implementing, administering and managing the Plan.&nbsp;&nbsp;The legal basis, where required, for the processing of Data by the Company and the third-party service providers described below is the necessity of the data processing for the Company to perform its contractual obligations under the Award Agreement and the Company&#8217;s legitimate business interest of managing the Plan and generally administering the Awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Plan Administration Service Providers</u>.&nbsp;&nbsp;The Company transfers Data to Solium Capital LLC (&#8220;<b>Solium</b>&#8221;), an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan.&nbsp;&nbsp;Grantee acknowledges and understands that Solium will open an account for Grantee to receive and trade Shares acquired under the Plan and that Grantee will be asked to agree on separate terms and data processing practices with Solium, with such agreement being a condition to the ability to participate in the Plan.&nbsp;&nbsp;The legal basis for the transfer of Data by the Company to Solium is its necessity to perform a contract between the Company and Solium concluded in the interest of Grantee.&nbsp;&nbsp;As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Data in the United States or, as the case may be, other countries, may not be subject to substantive data processing principles or supervision by data protection authorities.&nbsp;&nbsp;In addition, Grantee may not have enforceable rights regarding the processing of Data in such countries.&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>International Data Transfers</u>.&nbsp;&nbsp;The Company and its service providers that manage and administer the Awards are based in the United States: this Award derives from the Company, incorporated in the state of Delaware, United States and the Plan, governed by the laws of the Commonwealth of Massachusetts. Therefore, in order for the Company to perform its contractual obligations under the Award Agreement, Data will be transferred to the United States. The Company&#8217;s legal basis, where required, for the transfer of Data is its necessity in order to perform its contractual obligations under the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Data Retention</u>.&nbsp;&nbsp;The Company will hold and use Data only as long as is necessary to implement, administer and manage Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Voluntariness and Consequences of Consent Denial or Withdrawal</u>.&nbsp;&nbsp;Participation in the Plan is voluntary and Grantee is providing consents, where applicable, on a purely voluntary basis.&nbsp;&nbsp;Grantee understands that Grantee may withdraw his/her consent at any time with future effect for any or no reason.&nbsp;&nbsp;If Grantee does not consent, or if Grantee later seeks to revoke consent, Grantee&#8217;s salary from or employment and career with the Employer will not be affected; the only consequence of refusing or withdrawing consent is that the Company would not be able to grant Awards or other equity awards to Grantee or administer or maintain Grantee&#8217;s participation in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 68pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Data Subject Rights</u>.&nbsp;&nbsp;Grantee may have a number of rights under data privacy laws in Grantee&#8217;s jurisdiction.&nbsp;&nbsp;Depending on where Grantee is based, such rights may include the right to (a)&nbsp;request access or copies of Data the Company processes, (b) rectification of incorrect Data, (c)&nbsp;deletion of Data, (d) restrictions on processing of Data, (e) portability of Data, (f)&nbsp;lodge complaints with competent authorities in Grantee&#8217;s jurisdiction, and/or (g) receive a list with the names and addresses of any potential recipients of Data.&nbsp;&nbsp;To receive clarification regarding these rights or to exercise these rights, Grantee can contact his/her local human resources representative.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 68pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Alternative Basis for Data Processing/Transfer</u>.&nbsp; Grantee understands that in the future, the Company may rely on a different legal basis for the processing and/or transfer of Data and/or request that Grantee provides another data privacy consent form.&nbsp; Upon request of the Company or the Employer, Grantee agrees to provide an executed data privacy consent form (or any other agreements or consents) that the Company and/or the Employer may deem necessary to obtain from Grantee for the purpose of administering Grantee&#8217;s participation in the Plan in compliance with the data privacy laws in Grantee&#8217;s country, either now or in the future.&nbsp; Grantee understands and agrees that Grantee will not be able to participate in the Plan if he/she fails to provide any such consent or agreement requested by the Company and/or the Employer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Electronic Delivery</u>.&nbsp; By accepting this Award, Grantee consents to receive documents related to this Award by electronic delivery and, if requested, agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.&nbsp; Grantee&#8217;s consent shall remain in effect throughout Grantee&#8217;s term as a Service Provider and thereafter until Grantee withdraws such consent in writing to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="8" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>APPENDIX</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>TO THE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>RESTRICTED STOCK UNIT AGREEMENT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNDER THE ANIKA THERAPEUTICS, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021 INDUCEMENT PLAN</b><br>
&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Capitalized terms used but not defined in this Appendix have the meanings set forth herein or in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Terms and Conditions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Appendix includes additional terms and conditions that govern this Award if Grantee resides and/or works in one of the countries listed herein.&nbsp; If Grantee is a citizen or resident of a country other than the one in which he/she is currently residing and/or working, transfers employment and/or residency to another country after receiving the grant of this Award, or is considered a resident of another country for local law purposes, the Company shall, in its discretion, determine to what extent the terms and conditions herein will apply to Grantee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Notifications</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">This Appendix also includes information regarding taxes and certain other issues of which Grantee should be aware with respect to participation in the Plan.&nbsp; The information is based on the securities, exchange control, income tax and other laws in effect in the respective countries as of January 2021.&nbsp; Such laws are often complex and change frequently.&nbsp; As a result, the Company strongly recommends that Grantee not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time Grantee vests in this Award, upon Settlement, or when Grantee sells Shares acquired under the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In addition, the information contained herein is general in nature and may not apply to Grantee&#8217;s particular situation, and the Company is not in a position to assure Grantee of any particular result.&nbsp; Accordingly, Grantee is advised to seek appropriate professional advice as to how the relevant laws in Grantee&#8217;s country of residence may apply to his/her personal situation.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If Grantee is a citizen or resident of a country other than the one in which Grantee is currently residing and/or working, transfers employment and/or residency to another country after the grant of this Award, or Grantee is considered a resident of another country for local law purposes, the information contained herein may not be applicable to Grantee in the same manner.&nbsp; Grantee is advised to consult his/her personal advisor to determine the extent to which the notifications apply to Grantee&#8217;s specific situation.</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="9" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ITALY</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><i>Terms and Conditions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The following terms will supplement, amend or integrate for purposes of Italian laws the relevant sections of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">1.</td>
			<td style="width: 98%;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Section 7 of the Award Agreement is replaced by the following wording:</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Withholding</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Committee shall determine the amount of any withholding or other tax required by Italian law to be withheld or paid by the Company with respect to any income recognized by the Grantee with respect to the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 72pt;">(b)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Irrespective of the above, the Grantee shall be required to meet any applicable tax withholding obligation in accordance with the tax withholding provisions of Section 17.3 of the Plan. The ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to participation in the Plan and legally applicable to Grantee (the &#8220;<b>Tax-Related Items</b>&#8221;) is and remains Grantee&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.&nbsp; Grantee further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including, but not limited to, the grant, vesting or distribution of this Award, the issuance of shares of Stock upon vesting and distribution of this Award, the subsequent sale of shares of Stock acquired pursuant to such exercise or the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of this Award or any aspect of this Award to reduce or eliminate Grantee&#8217;s liability for Tax-Related Items or achieve any particular tax result.&nbsp; Further, if Grantee is subject to Tax-Related Items in more than one jurisdiction, Grantee acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to any relevant taxable or tax withholding event, as applicable, Grantee agrees to make adequate arrangements satisfactory to the Company and/or Grantee&#8217;s Employer to satisfy all Tax-Related Items. To satisfy any withholding obligations of the Company and/or the Employer with respect to Tax-Related Items, Grantee authorizes the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one (or a combination) of the following:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 112pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by direct payment to the Company or the Employer of the amount of Tax-Related Items through a wire transfer bank payment;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 112pt;">(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by having withheld from the Award at the appropriate time that number of whole Shares whose Fair Market Value is equal to the amount of Tax-Related Items required to be withheld with respect to the Award; and/or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 112pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [intentionally left blank];</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;">If the Grantee is an Italian tax resident who, at any time during the fiscal year, holds foreign financial assets (including cash and shares) which may generate taxable income in Italy, the Grantee is required to report such assets on his or her annual tax return for the year during which the assets are held, or on a special form if no tax return is due. These reporting obligations also apply if the Grantee is the beneficial owner of foreign financial assets under Italian money laundering provisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">2.</td>
			<td style="width: 98%;">Section 9 of the Award Agreement is replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Bound by Plan and Committee Decisions</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">By accepting the Award, the Grantee acknowledges that the Grantee has received a copy of the Plan, the Award Agreement and the Appendix, has had an opportunity to review the Plan, the Award Agreement and the Appendix and agrees to be bound by all of the terms and conditions of the Plan, the Award Agreement and the Appendix. In the event of any conflict between the provisions of the Award Agreement and the Plan, the provisions of the Plan shall control. The authority to manage and control the operation and administration of the Award Agreement and the Plan shall be vested in the Committee, and the Committee shall have all powers with respect to the Award Agreement as it has with respect to the Plan. Any interpretation of the Award Agreement or the Plan by the Committee and any decision made by the Committee with respect to the Award Agreement or the Plan shall be final and binding on all persons.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">3.</td>
			<td style="width: 98%;">Section 10 of the Award Agreement is replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Grantee Representations</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">The Grantee hereby represents to the Company that the Grantee has read and fully understands the provisions of the Award Agreement including the Appendix and the Plan and that the Grantee&#8217;s decision to participate in the Plan is completely voluntary. Further, the Grantee acknowledges that the Grantee is relying solely on his or her own advisors with respect to the tax consequences of the Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%;">4.</td>
			<td style="width: 98%;">Section 12, letter (c), of the Award Agreement is entirely deleted and replaced by the following wording:</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 22pt;text-indent:-15pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> </b><u>Entire Agreement</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:72pt;">The Award Agreement including the Appendix and the Plan constitute the entire agreement between the parties with respect to the Award. Except as otherwise stated herein, any prior agreements, commitments or negotiations concerning the Award are superseded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 2%; vertical-align: top;">5.</td>
			<td style="width: 98%;">Section 12, letter (e), of the Award Agreement shall be interpreted to allow any dispute arising with respect to the Award Agreement to be referred for resolution to Italian courts of competent jurisdiction pursuant to Italian rules of civil procedure. In addition, Italian mandatory labor laws shall apply and, in case of contrast, prevail over any law of the Commonwealth of Massachusetts.</td>
		</tr>
		<tr>
			<td style="width: 2%;">&nbsp;</td>
			<td style="width: 98%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 2%; vertical-align: top;">6.</td>
			<td style="width: 98%;">Section 12, letter (m), numbers (ix) and (xvi), of the Award Agreement shall be construed and interpreted so as to allow the application of article 2120, para. 2, of the Italian Civil Code to assess whether any income arising from the Award Agreement takes part in the formation of the income base for computation of the severance payment due to employees under Italian law.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED KINGDOM</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><i>Terms and Conditions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Withholding.</b>&nbsp;<b> </b>The following supplements the &#8220;Withholding&#8221; section of the Award Agreement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Without limitation to the &#8220;Withholding&#8221; section of the Award Agreement, Grantee agrees that Grantee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or, if different, the Employer or by His Majesty&#8217;s Revenue &amp; Customs (&#8220;<b>HMRC</b>&#8221;) (or any other tax authority or any other relevant authority).&nbsp; Grantee also agrees to indemnify and keep indemnified the Company and, if different, the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Grantee&#8217;s behalf.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Notwithstanding the foregoing, if Grantee is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Grantee understands that Grantee may not be able to indemnify the Company or the Employer for the amount of any Tax-Related Items not collected from or paid by Grantee if the indemnification could be considered to be a loan.&nbsp; In this case, the Tax-Related Items not collected or paid by Grantee within 90 days of the end of the U.K. tax year in which an event giving rise to the taxable event occurs, may constitute an additional benefit to Grantee on which additional income tax and National Insurance contributions (&#8220;<b>NICs</b>&#8221;) may be payable.&nbsp; Grantee understands that Grantee will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee NICs due on this additional benefit, which may also be recovered from Grantee by any of the means referred to in the &#8220;Withholding&#8221; section of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: small-caps; text-align: justify; margin: 0pt;"><b>Joint Election</b><b>.</b>&nbsp;<b> </b>As a condition of participation in the Plan, Grantee agrees to accept any liability for secondary Class 1 NICs which may be payable by the Company and/or the Employer in connection with this Award, where legally permitted, and any event giving rise to Tax-Related Items related to Grantee&#8217;s participation in the Plan (the &#8220;<b>Employer NICs</b>&#8221;).&nbsp; Without prejudice to the foregoing, if requested to do so by the Employer or the Company, Grantee agrees to execute a joint election with the Company or the Employer, the form of such joint election having been approved formally by HMRC (the &#8220;<b>Joint Election</b>&#8221;), and any other required consent or election to accomplish the transfer of Employer NICs to Grantee.&nbsp; Grantee further agrees to execute such other joint elections as may be required between Grantee and any successor to the Company or the Employer.&nbsp; Grantee further agrees that the Company or the Employer may collect the Employer NICs from Grantee by any of the means set forth in the &#8220;Withholding&#8221; section of the Award Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If, having been requested to enter into a Joint Election by the Employer or the Company, Grantee does not enter into the Joint Election or if approval of the Joint Election has been withdrawn by HMRC, the Company, in its sole discretion and without any liability to the Company or the Employer, may choose not to issue or deliver any Shares to Grantee upon vesting of this Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: small-caps; margin: 0pt; text-align: justify;"><b>S431 Election</b><b>.</b>&nbsp;<b> </b>As a condition of participation in the Plan, the Grantee agrees to enter into, jointly with the Company and/or the Employer, a joint election within Section 431 of ITEPA in respect of computing any tax charge on the acquisition of &#8220;restricted securities&#8221; (as defined in Sections 423 and 424 of ITEPA), and that the Grantee will not revoke such election at any time (the &#8220;<u>Section 431 Election</u>&#8221;).&nbsp; The Section 431 Election will be to treat the Shares acquired pursuant to the vesting of the Award as if such Shares were not restricted securities (for U.K. tax purposes only).&nbsp; The Grantee must enter into the Section 431 Election within 14 days of such time as may be designated by the Company and/or the Employer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="Terms and Conditions - Page " data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Terms and Conditions - Page 12</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_659583.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.1 </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">I, Cheryl R. Blanchard, Ph.D., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Amendment No. 1 on Form 10-K/A for the period ended December 31, 2023 of Anika Therapeutics, Inc.; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: April 26, 2024</p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Cheryl R. Blanchard</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cheryl R. Blanchard, Ph.D.</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>President and Chief Executive Officer</i></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Principal Executive Officer)</i>&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_659584.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.2 </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">I, Michael Levitz, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Amendment No. 1 on Form 10-K/A for the period ended December 31, 2023 of Anika Therapeutics, Inc.; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: April 26, 2024</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Michael Levitz</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Michael Levitz</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Executive Vice President, Chief Financial Officer and Treasurer</i></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Principal Financial Officer)</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>anik-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/26/2024 11:00:12 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:anik="http://www.anik.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anik.com/20231231">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.anik.com/20231231/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="anik_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>anik-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/26/2024 11:00:12 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.anik.com/20231231/role/statement-document-and-entity-information" xlink:href="anik-20231231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.anik.com/20231231/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
<link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
<link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
<link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
<link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
<link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
<link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
<link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
<link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
<link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
<link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>anik-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/26/2024 11:00:12 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Fiscal Period Focus</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Fiscal Year Focus</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Annual Report</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Transition Report</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
<link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Well-known Seasoned Issuer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
<link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Voluntary Filers</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Current Reporting Status</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
<link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Interactive Data, Current</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Filer Category</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Small Business</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
<link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Financial Statement Error Correction Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Shell Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
<link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Public Float</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Common Stock Shares, Outstanding</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>anik-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/26/2024 11:00:12 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.anik.com/20231231/role/statement-document-and-entity-information" xlink:href="anik-20231231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.anik.com/20231231/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
<link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
<link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
<link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
<link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
<link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
<link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
<link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
<link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
<link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
<link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>blanchard.jpg
<TEXT>
begin 644 blanchard.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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MX5!+QDXSBM;&9B:Q+EP@8# YS3;6YV)'''G/KC]:JZC,6O9#@<8S5H0%(HW
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1\AJ%R?4U$>M>6JLCMY4?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>conley.jpg
<TEXT>
begin 644 conley.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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MI:#"[,#+"3')]>U:K\UYSX$U%HM=:V9CY=TN<=L@5Z&_!Y]:V1S-6&T444P
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$UL?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>fischetti.jpg
<TEXT>
begin 644 fischetti.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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MXS_"X[AAP16??LA ,8SN/ ]*P2/9<G;1F?>WDLCG<>?:H((F9\!=[L0,>I/
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J^)!GG]VW6@";4)!/=2R>6 "YP,^]9Q(W'Y5ZU>O2?.D^IK-/4_6@1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>graph1.jpg
<TEXT>
begin 644 graph1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $- E@# 2(  A$! Q$!_\0
M'  !  (" P$               8'! 4! @,(_\0 2!   00! @,%!00&" 4#
M!0$  0 " P0%!A$2(3$'$T%1810B<8&1%3*AL2,S0E)RP0@6-#=B=++1)(*2
MX? 70U,E-F-SHM+_Q  : 0$  P$! 0               @,$ 04&_\0 ,1$
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MV/PV6_[6],4ZN'RV?NY:_P"VEP-6/OMF,)( 8UOU4N KI7W\"/%=F[;%MEP
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M<)7*@_J-EKS>T&": 5QD[+)J4CGM(DX7O<.A) YCKYKKI'3W=6\7#=T$Z"W
M]O?7G6&\#2W]L#?F=P#LKA12_42::^;6.<"-[D"T3@LECM=:KOW:QBJ7)&F"
M0O:>,#?P!W'S6W[2<;:RVB,K1QT)FM31@1Q@@<1X@>IY>"DR*MU&Y*?2WL34
M$HN)5>O-$9#*Z/PLF-BX<YCH61E@< 7L+=G-WWVZ^OFM9EM)Z@;H72-:MC#/
M>QUCOIH!*P<(WW W)V^FZN=%..(DDET(.A%W97UAF>UAALIA\WI_[(BFKGNK
M!L,D'> @M&PY]5I</?UWA-.QX%FFN_MP1F&&ZVPSN^']EQY^ ^'16VBXJUE;
M*K?D[PN=]2)=F.EG:3TRRE8>V2W+(9YW-.XXR -AZ  *6HBKE)S;DRR,5%60
M1-T43H1$0!$1 $1$ 1$0$5[2M3NTGI>;(1,;)9<\0P-=TXSOS/H "?DM-@<#
MK-AHY"[J;O)GN:^Q3?".[##MNT$="!^*]^V?3]O4.CG0XZ-TMJM,VPV-HYO
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MAO#(9&DA_$.@Y[].2 W*(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MOF-=FN<QX<PEKFG<$'8@K+7PL*RUWZEM.M*GML?<2*F.R'M.=>?!@]0R;V2
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M5=Y&Y+>M/GE/,]&^#1Y+9ZKR)M6_9XW?H8CL?5RT2VT*>59GN4SE=V"(BT$
MB(@"(B [P_K6?Q!:/^DO_9L%_'+^06\A_6L_B"T?])?^S8+^.7\@N4_OP_)&
MI]N11*(B]D\\(B( B(@.6D@@M)!',$>"^D>Q;7IU!1^R,I*#E:S-V//6>,>/
M\0Y;_7S7S:L["Y"WBLK6NXY[F6H7AT?#XGR]0>FRSXF@J\,KWY%E*JZ<KGVL
MBU^ OOR>'IW9:TM62>,/=#*TM<PD<P05L%\VU9V9ZZ=]0B(N (B( B(@"(B
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M'&/)K1R6H4U0<]:K_"V_/4XZBCW/4MWL:UC<L:DL8_+VY+!O R1OD.^TC1S
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M.8]O5KAL1\E]A2J1J1O%W/"G!Q>JL=$1%:0"(B *VOZ/+C]L9ENYX3 P[?\
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M[-%BG%[,V:C^M<XS"8>1[7#VJ4%D+=^>_G\EK<WK_&4HW-H$W)_#AY,'Q/\
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M)5'T;DD#_P!D\CYCP*Q5Z2=U=&<+M&QTDC6,:7/<=@!U*]*M:6U,V*!A>\^
M_-3?#XB#%Q&65S73[>](3R:/15U*B@O$E&-S$P6 ;6X;%T!TW5K.H;_N5J=9
MZUCQW'3Q;FRW.CI.K8O]RM5K37)E$E'"O(9S;)8'CZ-_W5=D[\SS*MP^$<WQ
M*WH0J55'Z8'>>:2Q,^6=[I)7G=SG'<DKHB+TS,$1$ 1$0!$1 $1$ 7:*1\4@
M?$]S'CHYIV(75$!*<+K/.5I8X6RMMAS@UK)QN23ZCFKFA+C&TR !^PX@.FZI
M_LSPYR&<%N0?H*GO_%_@/Y_)7&O%QV13RQ7F;*%VKL(B+"7A$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!0KM4QOM6#9;C;O)5?N?X#R/X[*:KQN5H[=66O,.
M*.5I8X>A"LI3X<U+H1G',FCYS19>6H2XS)3TY_OQ.X=_,>!^BQ%]&FFKH\YJ
MP1$70$1$ 1$0!$1 3#0$L5V/)X"X=Z^0A<UH/@[8CE\OR5/9.G+CLA9IV!M+
M!(Z-P]0=E.L7<?C\C6MQ'WX9 \>NQYA>G;5C&1YNKFJH_P"&R<0>2.G& !^(
MV4*+X=>W*7[K_A&JLU._0KA$1>@9 B(@/>G:L4K#9Z<\D$S>CXW%I'S"GF([
M4LG%7]DSM:MEZ1&SA,T!Y'QZ'YA5XBJJ4:=7OJY.%24.ZRS),%V?ZN.^+N2X
M').Z0R?JW'X'E]"/@K@T)I]FF-,5,8U[97Q@NDD:-@]Q.Y*^?NS/3[M0ZKJP
MO;O5@/?SG_".@^9V'U7U T;#8= O"[17#:I*3:WU/1POUIS:L<HB+S#8$1$
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MEH]H!LZ&%W5_B"[T]%:(&P '0)LB\*M6E6EFD;804%9!$15$PB(@"(B (B(
MB(@"(B (B( B(@"(B (B% 1J?5?<:B;AY<3?;/-'*^K(>[X+!C&[@/>W'H7
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M0RECXWL86 M(Z>Z2#Y[H#5S=I&&@ST6(GCM167&-C^(-'=/>WB#7#BXM]NI
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MGM<^-FP'+[WJ>2M-$!5V4T1>CS]BS4QM&[B!98YF,EE#(WL%9L0)&Q +7 [
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MOK!L\SY!+(]X8QHX#PAS1NT[C<CQ'56$B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
4B (B( B(@"(B (B( B(@"(B _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>graph2.jpg
<TEXT>
begin 644 graph2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1$'17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C0Z,#0Z
M,C4@,34Z,#DZ-3$      Z !  ,    !  $  * "  0    !   "6* #  0
M   !   !6          & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   _1
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 7 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M_.)*>D5?->]E&YA+3(U"RQF_6[8Y_P"S<8O(!97]I@ SJUS_ $G[_;^?[/\
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MM]R.DDI22222E))))*?_V?_M%;)0:&]T;W-H;W @,RXP #A"24T$!
M!QP"   "  ( .$))300E       01@SRB2:X5MJPG &AL*>0=SA"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24T$"@       0  .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             5@   )8    !@!G '( 80!P &@ ,@    $
M             0             "6    5@                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   5@     4F=H=&QO;F<   )8
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   %8     %)G:'1L;VYG   "6     -U<FQ415A4     0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M]O;86;C9V,W*Q7^I0\N#'@$ [7.K<6[H]NYB.L?ZL=0MS\*VRU['EESF U@
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MDI22222G_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %
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M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9$
M   !_]L A  " @(" @(" @(" P(" @,$ P(" P0%! 0$! 0%!@4%!04%!08&
M!P<(!P<&"0D*"@D)# P,# P,# P,# P,# P, 0,# P4$!0D&!@D-"@D*#0\.
M#@X.#P\,# P,# \/# P,# P,#PP,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" %8 E@# 1$  A$! Q$!_]T ! !+_\0!H@    <! 0$! 0
M    ! 4# @8!  <("0H+ 0 " @,! 0$! 0         !  (#! 4&!P@)"@L0
M  (! P,"! (&!P,$ @8"<P$" Q$$  4A$C%!408382)Q@10RD:$'%;%"(\%2
MT>$S%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&
MI+16TU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<X2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^A$
M @(! @,%!00%!@0( P-M 0 "$0,$(1(Q0051$V$B!G&!D3*AL? 4P='A(T(5
M4F)R\3,D-$."%I)3):)CLL('<](UXD2#%U23" D*&!DF-D4:)V1T53?RH[/#
M*"G3X_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:FML;6YO9'5V=WAY>GM\?7
MY_<X2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
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ME1;_ )6>8].72-/BC2WM[**P6\M!&%2&D4(*Q!.(;<LPVQ56/_."?EX>2_\
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M\J>9-5\OZ=_SC#I=SI7DKRV([>XCO8[]72^EOIG0.TDX<DE.(#58#>F*HO\
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M78J[%78JE&O32V^C:E/!(T4T4#M'(IH5('4'%7BW^(==_P"KM<_\'_9BKO\
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M%%$4/=I7><K5N&*O1/R@_)"X\@_E=YU\AZ]KS:E=_F#KOFO7M7EM"WU?3_\
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MY]?E#8?F3:VK6]VMCY>\W6/F]KJYG*:I;>G)=->M,J!0[3(P#J$H.*KSV/\
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MQ)H_J32$<T>W+H@4,Q=05D+E5X?Y,_YQK_-_2S_S@-9_F#^6M_YJM/RUT_\
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M5=2\B77E'R1YXUCRGJOY<M-:QVUG<P6US!#/+;0H:1L'(K55)V.^*H_\T?R
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M\PJSG:OQ<JXJ_53_ )QCT37_ "S_ ,X[_DIY;\UZ;=Z/YF\O^3-'TW7M*O\
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M_<,59[Y>_/#R%KWEG6_,DNI-H;^586D\W:#J:&#4--=/M1S0'XB2WPJ5J&)
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M).:KZ/D\Q:+%Y=/FR:_6#R^M@-4?4)%8 6AB]82%*<OL&M*5[4KBKX]\Z?\
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MNIBKY&_YRY_+JU_-#RGH7E;4?R^UCS-;)-<:EHOGGRQ(JZ[Y4UVT]%M-U"Q
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MS]_VQ;G_ (CFQ[(_QS%_6#BZ[^XG[GY,9ZH\<WBKL5=BKAU&!7UY_P XA?\
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M\[$YS^'Z7W$,XMW[L5=BKL5=BKL5=BKL5=BKL5=BKS+\YO\ R57G[_MBW/\
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ML5>J6]S;7<23VMQ'<PN 4FB<.I!Z$,I(.*L?T;S?Y;UW5M>T+2M6@N]9\KW
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M_(R7'P!WKXY[G?\ *X]8_P"K)8_\C)<? '>OCGN=_P KCUC_ *LEC_R,EQ\
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M2_F<7\X?-W^*/+'_ %,>F?\ 27#_ ,U8_D-3_J<_D?U+^9Q?SA\W?XH\L?\
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M>_\ ^31S:=B?X[B_K!P^T?\ %LG]4OYW1TSV%X!O%+L5=BKL5?I]_P ^V/\
M>[\WO^,&B?\ $KW.']M?IP^^7Z'I/9WGD^'Z7ZJ#IG!/3-XJ[%78J[%78J[%
M78J[%78J[%7A?_.37_K/_P";O_@,WW_$,VO8?^/8?ZP<+M+_ !;)_5+^>#/8
M'@G8J[%78JX=<4/T=_Y]O?\ *;_FA_VPM/\ ^HF7.,]M/[G%_6/W!Z'V?_O)
M^X?>_74=,\]>J;Q5V*NQ5V*NQ5V*O__2^_F*NQ5V*NQ5V*NQ5V*O$/\ G(P
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MI?@_Z2'_ .:,? \U\8]SO^5RW?\ U+\'_20__-&/@>:^,>YW_*Y;O_J7X/\
MI(?_ )HQ\#S7QSW/TW_YP*\V2^;/*'Y@W$MBE@;/7;>)420R<@;1&J20*9P7
MMA#@S8_ZI^\O3=@SXH3]_P"A]Z9Q[OG8J[%78J[%78J[%78J[%78J[%7AO\
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M_P#+IW'_ '"4_P"RG'_1,?\ 4_M_8O\ )X_G?8[_ *$,M/\ RZ=Q_P!PE/\
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MMIWFZ30M:U+3#<6R-+^XM)(]-'JF-RR23CB2J#DJQ_\ ,/\ -C\ZO-/Y4_\
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M @0W#&OJ( Q 5J@ FG4XJQ[_ )4?^3S)Y1CD_+'RQ.GD$U\DB;2[:4Z3\?J
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M^<J/R;'DS0O)]MY4TGS+YH\I:];75[J&KWUY<+;7>F6C1O&L*1.>,;?$\K$
M<?VE7K?YT?G_ /FMY \Y_P#.).B67EO1=$TG\]O-.F:)YTM=0:>XU73WF@2X
MNK6)5"0KPJ8S(68U&RCKBK[9J>YQ5BGG9_.2^5]7'Y>Q:7)YSEB$6@/K;2C3
MHII&5/7N1!^\=(E)<HA!:G$$5J%7YE6__.8'Y]_EUY,_/;1?S3LO+OF7SO\
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M]G9Q 3->02P2+)(75R).2AMEW5>K?\XU?D-I?_..?Y86GY?:=J0UFZN-2O\
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MT/R]Y=\F00W$>L>8X=8LK&[^KVG&:4F\K>E(@D3(WIDN%7DR<\[5DWGK\_\
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M?+%E9:AI_G3R=KMN\MKK$-U'$L!Y('"&%HV)Y(P8,5H*US%G+BD3WN5CAPQ
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M-KR?Y:\XKYEU3\R;%[:VN]5M?J<%K(UI+:@N('E9EI+R--]J9+MGMD]I2@3
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MZQI]_<>?])T6TUQ_,/KO-%J.AV\EG#>JUN )5EA9?4C(3XTJ'',T5>=^8_\
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M><_^<?\ \RO,MQ^=%U:ZUY9M9/S0\U^1?,FG)*;UEM$\IC3C<03%4!<SM8?
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M5U,5=3%74&*MTQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\
M_]'[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
-8J[%78J[%78J_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>graph3.jpg
<TEXT>
begin 644 graph3.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1SP17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C0Z,#0Z
M,C4@,34Z,#8Z,C$      Z !  ,    !  $  * "  0    !   !D* #  0
M   !   !!P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !NZ
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ :0"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M#&65[6M^@]E-+7L_X*O]Q!+R!?\ 5*RYE=F7E"US?3.YC6[1:_\ 9F11E.]
M-I978RNC)JR_T?\ 1_3]2RRE$O?]6,S$IS<K*R[J<XW-JLOJ8S<64V,L_2VX
MU3&?:,/?31^D_6J[/T?\W9Z75-Z7TUA868E#36&!D5L&T5?S 9[?;Z.W]%_H
MT_[,Z;Z3:?LE/I5[ME?IMVMWSZNUNW:WU=WZ3]])3Q7J?5+(=<;<C*?]K8&M
M=#;7Y%?HX>2T/K]!U_J9&^BES+F^IF_8?UGUO2K79=,ZKB=4JLMQ"XBE_I6A
M[2QS; UK[*7M?'Z2GU/3N_T=WJ5?SE:F.G=/#@X8M(<T!K7>FV0!$-'M^C[6
MJ>-B8^(QU>.P5M?99<\"=;+7NON>9_?ML>Y)294L_P#I73O_  P[_P!M\I75
M2SOZ5T[_ ,,._P#;?*1CO]#^2#M]0__2]"<[(Z=FWV&I]^%EN%KGU O?58&M
MI>'4,_2646MKK>ST&66,M]7U/T7T#?M;%_<R?_87(_\ 2"MV65U5NMM<&5L!
M<][C#6M&KG.<?HM:J[NHX[<)^>X.^SL!<' 27-[6,:/S7_F)VXLCPM;L:!\6
M'[6Q?W,G_P!A<C_T@E^UL7]S)_\ 87(_]((3OK%T<,;8S(%C'.VN<P$AFI;O
MN=_@:W;7/K?9_/5_I*/4K2N^L?1J,CT+<EK#J#8=*PX/;2:76_0];=9N?5_@
MJOTUOIU(>GL?M3KW'V)?VMB_N9/_ +"Y'_I!+]K8O[F3_P"PN1_Z043USI0K
MKM]<.9:'.KVM<XN#7>C[6L:YWZ2YS::/^Y%KZZL?U'V(9^LG0]SVC,8XUB3M
MEP(+FUM]-S&N]7=8_P!-GI?G_P#%V)>GL?M5KW'V)OVMB_N9/_L+D?\ I!+]
MK8O[F3_["Y'_ *003]9>ABOU?M;37&X. <1]+TP/:WZ;G?0K_G/3_2_S2);U
MWI55OI.OW/X]C7V $L^TL:Y]3'L:ZRGW5?Z7?6RK]);6EZ>Q^U6O<?8N[J]
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M +"Y'_I!!M^LG0Z3:UV8QSZ XV,9-CQL;9>^*Z@][]M6/<_V)S]8>D>J*69
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M*?_5]2N;8^I[*W^E8YI#+(#MI(]K]KO:[:JM^%>>FVXF-=LR+6EIR7[IW/\
M;;?^C=6_U-NY]36/K_,K_1UJZDCK7@C2_%YZKH/5Q7<VW/)=8<8,L8^P$#'?
M5ZED6.LVV9%-'Z1GZ1C[;/TWJUH#?J]UW[.]EF4Q]UAJ<]_JW-&X8S<5SF[-
MMS6XN8U^=C5>M^F?9_VENV7KJ$D$N'^R^O3CV?;P;L8WC<[BUEEM+Z6Y+&,K
MJ=MQ:K6?H:Z/2M?^A_EQHZ=]:6G$%W4V/94:CE!K&AUD3]H8'FIWL]E.SV5V
M/]7*_25_J_I[R22GG;.B==)NIJS@W&OMLO+MSO5:]U[[JF,LV[VU5XSJJ_YW
MV>CZ?I>DH4_5_KV/;6:.I>G6W8PC5Q-;#Q^F%E6_:VOU7>GZF3[_ --5ZOK+
MI4DE/.MZ#UM]-8NZ@\6&ZQ]SJ[7#VO=0]KF?HVLW5_9[/1I]*NJC[1_A?2_3
MDJZ5]8_7KLR>I->UMC38&,:V:P*C957^B_1^J^M[+??]#WT_95O))*<1^!]9
MC=8^OJ-;&.O+@QS \>C)<UK?8STG^GZ=.S]-_-?:/5_6?3I@.E?67>P.ZJ33
M_A(8P/.XTFSW>CM[9/H;?2?1^B_26K>224\[;TGZR 9%U>>'VN!%=9@@^F^R
M[%=[ZVU5Y'O]*U];*J/WZ4YQ/K6V_%:W):YE=5AM)<S8;#9ZE--SO1;;:S[-
M^J^O717_ -R_3_P%W0I)*>;?T;ZSDL>WJ3&V-83N:-HWO+/6_1>DZMSK&M?Z
M619ZGV7_ +B6?34_V/\ 62MM@HZFUA.\MW-#@7/#_?9N87[_ %/1]/8_TZ/]
M#Z?Z%="DDIH],QNHX_K#.R/M(<YAI<8W "MC+6N].NBK^?;8]FVI7DDDE*22
M224__]G_[2'24&AO=&]S:&]P(#,N,  X0DE-!"4      !
M        .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))300*       !   X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      .-    !@             !!P   9     L &$ ;@!I &L 80 @
M #( ,  R #0 ( !P '( ;P!X 'D ( !G '( 80!P &@ :0!C ', ( !' $X
M5P @ %8 90!R ', :0!O &X 7P!0 &$ 9P!E %\ ,P    $
M             0             !D    0<                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   0<     4F=H=&QO;F<   &0
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $'     %)G:'1L;VYG   !D     -U<FQ415A4     0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MO4RSTO\ NU^D]EBWZW58[KA=C/-=#+/TH+??94VBQU;:@7.8U_VNOWN=^_\
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MG'Z+6JN[J..W"?GN#OL[ 7!P$ES>UC&C\U_YB=N+(\+6[&@?%A^UL7]S)_\
M87(_]()?M;%_<R?_ &%R/_2"$[ZQ='#&V,R!8QSMKG,!(9J6[[G?X&MVUSZW
MV?SU?Z2CU*TKOK'T:C(]"W):PZ@V'2L.#VTFEUOT/6W6;GU?X*K]-;Z=2'I[
M'[4Z]Q]B7]K8O[F3_P"PN1_Z02_:V+^YD_\ L+D?^D%$]<Z4*Z[?7#F6ASJ]
MK7.+@UWH^UK&N=^DN<VFC_N1:^NK']1]B&?K)T/<]HS&.-8D[9<""YM;?3<Q
MKO5W6/\ 39Z7Y_\ Q=B7I['[5:]Q]B;]K8O[F3_["Y'_ *02_:V+^YD_^PN1
M_P"D$$_67H8K]7[6TUQN#@'$?2],#VM^FYWT*_YST_TO\TB6]=Z55;Z3K]S^
M/8U]@!+/M+&N?4Q[&NLI]U7^EWULJ_26UI>GL?M5KW'V+NZO0&^RG*L?^:P8
MUS23^[ONKJI9_6MLKK3]-HR&-NR<L!F3EO\ 4?6T[A6T-;553O\ S]E=?Z5W
M^F]79^C0ZNO=*NR:<:F\/?D;_1(!VN=6*WV5L=^?8QEV][6?S6RWU?3V)V]?
MZ*YNX9E<<B3!(@OW-#OI,?6WUJW_ .$H].ZO]%;6E8J@%5K9+//IR!;1FXK?
M5NQMS7TR&FRJS;ZM=;W^QEV^NFZK?^C?Z7HOLI]7UZF'5\8B35DM/=IQ;S!\
M);2YG^8Y5[OK5T&JE]OVMKRRIUWI,!-I8W=OV41ZF]OIOW,_,_G+/T:M6=7Z
M;5D/QK,AC+:_IM=I$-]9WN^C^CJ_26_Z)CZO4_G:DK%:C95=EOVMB_N9/_L+
MD?\ I!+]K8O[F3_["Y'_ *00&_67HSFM?ZY:QS0Z7L>PC=Z6QAKL:RWU',R*
MK-GI^RI_JV?H]BEB_6'I66TNJL=+:3D6--;QL8TP_P!1VS8VW_@=WJOK_2U_
MH?TB7I['[5:]Q]B7]K8O[F3_ .PN1_Z02_:V+^YD_P#L+D?^D$%WUDZ-'Z/)
M%Q+JF!M0+R?6V^BYNT>ZO](WU+?YNK_"(EO7.DTV"NW*8UY+Q!G_  9=79NT
M]NVQCJ_^,_1I>GL?M5KW'V,OVMB_N9/_ +"Y'_I!+]K8O[F3_P"PN1_Z00;?
MK)T.DVM=F,<^@.-C&38\;&V7OBNH/>_;5CW/]B<_6'I'JBEF0+;C<W'-3 7.
M:]Q:W],V/T+6.?Z=C[/H7?J_](_1)>GL?M5KW'V)?VMB_N9/_L+D?^D$.KU\
M_,JRG5OHQ,7<:6VC;998X>EZ_I'WTTU4NL8SUOTUK[OYFGT:_M&BDE8&P51Z
ME__3]4(!!!$@Z$%5.K7XV-TW(NR:3D8];)LI:&DN;^Z!:ZNO_/>KBKY^17C8
M=M]M9MJ8/TC -WL)VV$M_<8P[[/Y"2GGK.K?5.MSS?B@"MKF6.%1=4?38/T9
MT:VUU=.VNK>S]'O_ $?^%4[<GZHX==5KL4UN#*[*6^B\6:.:UFUA L];UW8]
M.0__ $F1BU9'\[6BM^L5+S6W]EW"K(>RNM[FL:W;8T[[+C86MI8UK=GO_GO\
M&HCZQTW,%8Z/DN8*A^B?6T.#'-LNLI^SN/J?S>+Z?IM9Z;\MGV1)2*_J?U:W
MFAV(\MI-@<=I:[?:^[(LJ]+=]J^U79.+]L9ZU=7T\?+]7U/23V=7^KS,._+Q
M,#U1@NQV[15M&ZY_JL95M:]WJ4.N]9];*_S_ -RS>B.^L5-;S/3C:=S36^D,
M<QWJFKU'UY#ME7I[[/Z3=]FKOLV>EZGIY'H0Q.LXU8R,UO3'5OR<QM!#1[W!
ME5>0UUP<W;]IKMMNI^S,_P"UGZ+U/6]5)2.KJ'U?]5P=TYK+:W,K%8V/=M=;
M374_TZB_U'N9D59=?H>O^J^G^D]_HJS9D_5FUF%D.QB]W46LJQ"QA<XL;675
MACJB[TJJ&9+_ ,_939OM_P %ZK*U/UCQGUU7T],:,8M;;58-I;^F;?ZMN]C/
M2IQJFUU?;LW?9Z?K65^E_A++6+U7$LR*L7]DV8]>3<-KK*VCW.KN_2V5-W/;
M;^JOH_X.GTO4LKK?6DI!1U;ZJ,=C9>-0T4/=NJRMNUM;G556@UL=^DJ];&LQ
M?6]E?\Y^G_PWICJZG]43<VBO WBL.?C%E!L<6QON=56QK[JJZ_1IQV[_ $_\
M&RJO[-6IGZRXUV/;D?LFPUO8X.LM8&M<19:QC;M[/4;C>Q]]ESZ_T/J_S7JH
MUG7J&-#;.EV69+JVY-U;:P![ZZ_5MFP?Z.V_&]WZ6S[/;CI*19>9]3]A]7'9
M;]IJ9::ZV[O4K?\ IFV?HG>G:S;E/W6[OYJRZK^;3Y?5/JC;?:^^DWW0;KG"
ME[MIQA#G6^W;4YFWT[=_\AF3^C])%M^L.-7:Z>EW3559NM+&- ;0_P!*VMF]
MV^ZNJW?_ $=MO^!^SU7?:*U7R_K,&XV0^SI)=?37:YNZ#47%]M+:W/>QF1^G
M^SM99LQOZ1^I_P YZ7J)2'.ZE]5G8M@^RVLLQR_):VD;7;J['4LVY=+S15]I
M_9^_&_3_ ,U13_-6TU>G:R.H?52F^W"MQV^IZ3*\BNNO<T4W5M?^EV?X.K'Q
M*]_^$KK]+T_YQ/U#J635FY-1Z;3;B5W-QVV.$V6NLKKS-E- :Y^2U^19^F>S
M^C>G]I_6?3O^SVNF]8ISL[TOLNWUJS8S)#9:X5MH:]CG%@?NKNR;J??[/T7Z
M+U+/7]%*:3.H?50XXR+<048^/:6T/].?YAK,MKFMIW?X&QV7Z'\YZ./;=97^
M@]C'K'U6Q['W_8G,?=.1<XU!KP7>E<Q[ZK7,O=]HR/3;593790_)KM_2?H[K
M%TC:*& -96UH#B\ -  <Z=[_ .L[>Y1^QXFW9Z%>R(V[&Q ;Z41'^B=Z7_%I
M*<;IK/J[U"_(PL;!:*<9M#B'LVL<6B_"J;]ELAS'8K<1^/\ IJF?S?\ P-2T
MF]%Z4U['MQF!U5AN88XL.W=9_6>ZMEK_ /A_T_\ /?I%:954QSG,8UKGQO<T
M %T#:W='TMK?:II*4DDDDI__U/4KG6-J>ZI@LL:TEC"=H<X#VLWP[9N_>5/*
M=U.OI-]E(;9U UN=56![0\CV5C]YM?\ I'?\9L_P2OJKU)N:[!N;@G;DEOZ,
MZ \^\,<\.K;:YF[TGV-]/U?YQ&]*5U<JOJOUCA]3^F2]@96+@^)L=6Y]F1Z>
MU]?V:NYCJOYZR[^;_1?I4]76?K [8']'<W?::S^E$L:"RMMMWZ-K';K+F6?J
M_K?JU659_.U>A:G?\ZBXLQA752T-],WAMC]H8=+'5W#?:ZWVY+OS/^T_VCWW
MI ?6YSAZAQPQQ8"UH(+=?TE@L]1V_P"AO]/T_P##>G^8@ICB]8^L-US'7]-.
M/4*+K7U-E[BYL>A3ZC_0J9;NWU>G_AOYZJS[.E5UCZROK8]W20PO#26%YD16
M+KVGV?2LL=Z&-_X,A5_\]JZ8FJY_IN<3<VL.]3TZ8K;Z#ZZV_I?M&Q_Z3?;^
MBL]'']*]=!C>O]GJ^T[?7V-];8-K=\?I-C=UNUN__A;/ZZ2G"MZO]8'-;3C=
M+?3 (-A +6FO[/N:QDU[VN<[+IK_ )%=615[%,=6Z\ZC&>W"FX9#L;)9KL=M
M9M=<RQH=Z%/VO_"N98STV+?224X-O5>NWT8F3@X88W(K?:^JUKBX;;:/28^Q
MO\UZ^$_(L_FOYQ*[J?U@?A66C!.*]F0ZO:V;K/1:QSF6MK#-CGW9'HT_H?M+
M*J[O6_P%BWDDE."[K77FUVO'1WO<W?L9O (+6^IZ;]"Q^YK?;;C^K2^ZVO'_
M #+;4YZK]8FL%CNFM+=MA+*W.<X;6CT=K;&4;_5MW^UWI/\ 2_X9;J22G ;U
MGZPEK7OZ26[VAS*P\N<'>F]_V>QVUC*W6Y#/19D?S%/J>ID*1ZO]8"W$:SI@
M]7(I+[GESA54_>RNL/EC;OYHNNMJ]'?_ "[/>MU))3@,ZE]8[ADO;@^@YAQ?
M1H?K]*U_VUKK_:Q_ZKZ3O4K]F-ZO^$MJNJ4*.K_6>RBO_)@%NVOU#:75P7-'
MJ#8WUO=N=ZOZ)]E=7]&]7[16NB224\\_K/UBJILN'27V;6%S*@X&PO+]*M&M
M;Z?I>WU??9^?Z2:SK'UAQFW6VX MJH%KK'"6:,LL92VECM^_]#Z5UMCK/3?_
M (+_ (/HDDE-;IN3;E=/Q\FYH9;=6U[VMW  D2[;Z@8_:K*222G_U?4KFV/J
M>RM_I6.:0RR [:2/:_:[VNVJK?A7GIMN)C7;,BUI:<E^Z=S_ &VW_HW5O]3;
MN?4UCZ_S*_T=:NI(ZUX(TOQ>>JZ#U<5W-MSR76'&#+&/L! QWU>I9%CK-MF1
M31^D9^D8^VS]-ZM: WZO==^SO99E,?=8:G/?ZMS1N&,W%<YNS;<UN+F-?G8U
M7K?IGV?]I;MEZZA)!+A_LOKTX]GV\&[&-XW.XM99;2^EN2QC*ZG;<6JUGZ&N
MCTK7_H?Y<:.G?6EIQ!=U-CV5&HY0:QH=9$_:&!YJ=[/93L]E=C_5ROTE?ZOZ
M>\DDIYVSHG72;J:LX-QK[;+R[<[U6O=>^ZIC+-N]M5>,ZJO^=]GH^GZ7I*%/
MU?Z]CVUFCJ7IUMV,(U<36P\?IA95OVMK]5WI^ID^_P#35>KZRZ5))3SK>@];
M?36+NH/%ANL?<ZNUP]KW4/:YGZ-K-U?V>ST:?2KJH^T?X7TOTY*NE?6/UZ[,
MGJ37M;8TV!C&MFL"HV55_HOT?JOK>RWW_0]]/V5;R22G$?@?68W6/KZC6QCK
MRX,<P/'HR7-:WV,])_I^G3L_3?S7VCU?UGTZ8#I7UEWL#NJDT_X2&,#SN-)L
M]WH[>V3Z&WTGT?HOTEJWDDE/.V])^L@&1=7GA]K@1768(/IOLNQ7>^MM5>1[
M_2M?6RJC]^E.<3ZUMOQ6MR6N9758;27,V&PV>I33<[T6VVL^S?JOKUT5_P#<
MOT_\!=T*22GFW]&^LY+'MZDQMC6$[FC:-[RSUOT7I.K<ZQK7^ED6>I]E_P"X
MEGTU/]C_ %DK;8*.IM83O+=S0X%SP_WV;F%^_P!3T?3V/].C_0^G^A70I)*:
M/3,;J./ZPSLC[2'.8:7&-P K8RUKO3KHJ_GVV/9MJ5Y)))2DDDDE/__9.$))
M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M9BQKRXJJ"@)S=0F=!H83QC]YD/-U4HC5ZJ49_1#HG_Y4ZE_SA#KOYM>1+O\
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M>_S>$>6?R$N/RJDUWRE^87_.)5S^>,T.H32^4OS T2[4+<63D"&*Z!E3TN-
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M?]#7?D__ ,M/F/\ \)G6O^R/'^2<_P#1_P!-']:_RK@_I?Z67ZG?]#7?D_\
M\M/F/_PF=:_[(\?Y)S_T?]-']:_RK@_I?Z67ZG?]#7?D_P#\M/F/_P )G6O^
MR/'^2<_]'_31_6O\JX/Z7^EE^IW_ $-=^3__ "T^8_\ PF=:_P"R/'^2<_\
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M?]#7?D__ ,M/F/\ \)G6O^R/'^2<_P#1_P!-']:_RK@_I?Z67ZG?]#7?D_\
M\M/F/_PF=:_[(\?Y)S_T?]-']:_RK@_I?Z67ZG?]#7?D_P#\M/F/_P )G6O^
MR/'^2<_]'_31_6O\JX/Z7^EE^IW_ $-=^3__ "T^8_\ PF=:_P"R/'^2<_\
M1_TT?UK_ "K@_I?Z67ZG?]#7?D__ ,M/F/\ \)G6O^R/'^2<_P#1_P!-']:_
MRK@_I?Z67ZG+_P Y9?D@CHNH>8M1T.%]EO-4T35+."NVWJS6JK7?QQ_DC4]
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M_A,ZU_V1X_R3G_H_Z:/ZU_E7!_2_TLOU._Z&N_)__EI\Q_\ A,ZU_P!D>/\
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M]+_2R_4[_H:[\G_^6GS'_P"$SK7_ &1X_P DY_Z/^FC^M?Y5P?TO]++]3O\
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M8@8J_1?%78J[%78J[%78J[%78J[%7S?Y'_\ 6F/SW_\  >\H_P#)N]S9Y_\
M$\7]:7Z'78/\;R^Z/Z7TAFL=B[%7S=Y+_P#6G/SP_P# 8\I?JO<V>?\ Q/%_
M6E^AUV'_ !O)_5C^E](YK'8NQ5V*NQ5V*NQ5^1WGWRO^9P_-G\R?S%_*7\KO
M^<@_R?UK\Q>%A^8$OE7_  9=Z9K9TX-;6NHPPZG=R/;S&*I$B<7H:_"W*JK&
M+K\L=:T[R%^4GDS\N_\ G'3\_ORYU7\F_,=UYK\N^?+:;R?J>J7FJZA%+#?7
M6HB_OI(9Y)Q,:G@ -@!04Q5-_,_DWS+YI\E_\Y">2KO_ )QJ_/"WM/\ G(GS
M59>;/,>HQ'RF9K"YLFL76*U!U/@R.;%:EQ7XC3MBJSS'Y8_,Z\_,KSO^8_DC
M\E_SW_+5_P R[JQO_//EZQT_\OM6M[F\LH5MOK-M-K%Q=RVCRPH%?TB!7XJ=
ML5>S?E]YS\]_EWY[_.3S[IW_ #B=^<>HW_YSZQI^M:U8W,OEA8;.73["/3T2
MW*:H&*LD88\N_3%6.:K<:_K_ .8_YK?F!Y@_YQ _-_68?S?\D6?D/S1Y3G?R
MQ]2&GVK7!+QN-4]3G(+A@:G:@(WQ5\TZ-_SCQKGEG\H/)'Y2^6?R/_YR!T<?
ME_\ F,?S-\N^<>'DN>^CU98!!$C12Z@T#1QA0WQ*:MUVVQ5ZSYQT+\VOS"T;
MR'<^<?RH_P"<A-1_-G\KM<N]<_+W\[+.#R'I^K:>;U$BFLC:6UTMG-;.B .C
MQU;]HTVQ57\H:)^9_EC4_P RO/5]^3?_ #D+YK_.K\RM(BT*7\XM3_P3]=T>
MPMW]2&VTS3H[M;&*+G1G0Q%7/4#>JKZ+_P"<+?)&H^1Y_P VI-6_+?SSY/UG
MSUK-OYBU[7?-MKY>TVTO;EH?JPAT_3_+LSP0"-(@SDH"[-R))Q5]V8J[%78J
M[%78J[%7S;_SBO\ ^2UUC_P-O-7_ '5[C-GVM_?#^I'[@ZWLO^Z/]:7WE__2
M^M7YW_\ DQO^<:?_  .+G_NDW>;/0?W6?^I^D.MUW][A_K?H+Z2S6.R=BKL5
M=BKL5?,7_.1_YR_FQ^3FAZCYG\B?DYI_Y@^6/+.@WOF#S?Y@U;S/:^7X+>*S
MJ3:6T;P74LT[("XY*D=**'+GCBKR:_\ ^<Z= \KW/Y+>9OS!\G2>1OR<_/#R
M)<>:/+OY@WUX?6LM8M+7Z]-HM[:>@J*TD&\$@F_>M153P5>Q_EU^=7F_SO\
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M8FO;ZX^MV[+;,)!$%X_&@&*OLSR/_P X]W<O_.0'_.5_G3\P/*.GW/E#\W-
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M=G#/CF+C($>]-/T[HG_5XL?^DB/_ )JR/AR[BSXX]X=^G=$_ZO%C_P!)$?\
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M?]7BQ_Z2(_\ FK'PY=Q7CCWAWZ=T3_J\6/\ TD1_\U8^'+N*\<>\._3NB?\
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M^J%?Y+TO^IAW_0K7_./7_EIM!_Y%/_S7C_*VK_U0K_)>E_U,._Z%:_YQZ_\
M+3:#_P BG_YKQ_E;5_ZH5_DO2_ZF'?\ 0K7_ #CU_P"6FT'_ )%/_P UX_RM
MJ_\ 5"O\EZ7_ %,._P"A6O\ G'K_ ,M-H/\ R*?_ )KQ_E;5_P"J%?Y+TO\
MJ8=_T*U_SCU_Y:;0?^13_P#->/\ *VK_ -4*_P EZ7_4P[_H5K_G'K_RTV@_
M\BG_ .:\?Y6U?^J%?Y+TO^IAW_0K7_./7_EIM!_Y%/\ \UX_RMJ_]4*_R7I?
M]3#O^A6O^<>O_+3:#_R*?_FO'^5M7_JA7^2]+_J8=_T*U_SCU_Y:;0?^13_\
MUX_RMJ_]4*_R7I?]3#O^A6O^<>O_ "TV@_\ (I_^:\?Y6U?^J%?Y+TO^IAW_
M $*U_P X]?\ EIM!_P"13_\ ->/\K:O_ %0K_)>E_P!3#O\ H5K_ )QZ_P#+
M3:#_ ,BG_P":\?Y6U?\ JA7^2]+_ *F'?]"M?\X]?^6FT'_D4_\ S7C_ "MJ
M_P#5"O\ )>E_U,(FS_YQE_(&PNH;RV_*?R\)[=N41DM1*H/B4D+*?I&1EVIJ
MI"CDE\TQ[,TT38QCY/:+#3[#2[2"PTVR@T^QME"6]G;1K%%&HZ!40!0/D,P9
M2,C9-ES1$1%#9&8$NQ5V*NQ5)]<\O:#YFL)-+\Q:+8Z[ILO]Y87]O'<1'_82
M*PR<,DL9N)(/DPGCC,5( CS>-M_SBW_SCVS,Y_*;0 7)8A8&45)KL P ^0S-
M_E;5?ZH7#_DO2_ZF&O\ H5K_ )QZ_P#+3:#_ ,BG_P":\/\ *VK_ -4*_P E
MZ7_4P[_H5K_G'K_RTV@_\BG_ .:\?Y6U?^J%?Y+TO^IAW_0K7_./7_EIM!_Y
M%/\ \UX_RMJ_]4*_R7I?]3#O^A6O^<>O_+3:#_R*?_FO'^5M7_JA7^2]+_J8
M=_T*U_SCU_Y:;0?^13_\UX_RMJ_]4*_R7I?]3#O^A6O^<>O_ "TV@_\ (I_^
M:\?Y6U?^J%?Y+TO^IAW_ $*U_P X]?\ EIM!_P"13_\ ->/\K:O_ %0K_)>E
M_P!3#O\ H5K_ )QZ_P#+3:#_ ,BG_P":\?Y6U?\ JA7^2]+_ *F'?]"M?\X]
M?^6FT'_D4_\ S7C_ "MJ_P#5"O\ )>E_U,._Z%:_YQZ_\M-H/_(I_P#FO'^5
MM7_JA7^2]+_J8=_T*U_SCU_Y:;0?^13_ /->/\K:O_5"O\EZ7_4P[_H5K_G'
MK_RTV@_\BG_YKQ_E;5_ZH5_DO2_ZF'?]"M?\X]?^6FT'_D4__->/\K:O_5"O
M\EZ7_4P[_H5K_G'K_P M-H/_ "*?_FO'^5M7_JA7^2]+_J8=_P!"M?\ ./7_
M ):;0?\ D4__ #7C_*VK_P!4*_R7I?\ 4P[_ *%:_P"<>O\ RTV@_P#(I_\
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MF?\ ,U8H5U#4-8U+G#J[>A%Z<4,5W9RR6OIQT5(ROVBI+*ILO_.(GEB#5/\
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M(/F9?,WD35?/GF#4=74275I)I6H6KWEZ]U-%!)9W$C<$'$R*O2I.*O'?./\
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MX6E\]_E?^<.JZ'J5YI=OY]U;RK;::--L[2PDMK[2+."2WOHHQ:)+ P^,?W9
M 5L59R/R,_-<?G'Y[O\ RO;:?^6WY7^>+/S.//EK;:_=:I8>9;[5[3T-/U*/
M0IK6---O8Y.+W4L4U)0O&CEN2JO+/^A:/SMD\J?\XUZI?Z'"GFO\@O+6I>1-
M5\L>7//6HZ!)J>G7-M80Q:K8ZU96<4D3F2R!:VE7B8VW?FH&*LNT[_G'G\S/
MRSU/R3YD_*7R%Y:=)ORQU?\ +[7_ "%KWF:\N8-&N=3U>36EOQJ<ME+-?QM/
M/(+A/31F^'@:;XJ^H/\ G&SR!K_Y5_D'^47Y<>:OJP\Q^2?*^GZ1K7U.4S6_
MUBUB"/Z4A52RU&QH,5>W8J[%78J[%78J[%78J[%7_];[^8J[%78J[%5-Y8HV
MC6214:5N,2L0"QI6BCN:"NV*J+7UDJEFNX54%U+&10*Q@EQUZJ!4^&*KY+JU
MB@^M2W,4=MQ#?6'<+'Q;H>1-*&NV*M_6(.;1^LGJ*@D9.0J$/[1'AMUQ5;];
MM>5NGUF+G=J6M4YK650*DH*_$ #7;%7+=VK2B!;F)ISR A#KS^"G+X:UVJ*^
M&*L<U?S9#IEYY8M;71]1\PQ>9=3;3&U#2EAFM]/*PRS&XO7>:,I$#%PJ@=N;
M*.-*D*LDCNK:9IEAN(Y6MVX7"HX8QL-^+@'8^QQ5:+VS:V-XMW"UF%+&[#J8
MJ T)YUI0'WQ5@GY??F9Y?_,B7SY%H%O>P/\ EYYLO_)NNF]B2(/J&G1PR2O!
MP=^41$Z\6/$G?X1BK/5N;9IY+5;B-KF)0\MN'!D53T)6M0#BJQ;ZR=BJ7<+,
ML7K,HD4D1?SG?[.W7IBKS31OSA\I>;-(\H>8?(JWOGOR_P"<-9FT:'6M&B1H
M;%[=KB.:XO1<20/'"DMLT9*JS%BM%*GEBKTY;JV>66W2XC:>  SP!P70,*@L
MM:BOOBK45W:W!*P7,4Y"JY$;JQ"O]EMB=C38XJW#=6UQZGU>XCG]%S'-Z;!^
M#CJK4)H1X'%7+<VS23Q+<1M+; &YC#@M&&%07%:K4;[XJZ*ZMIRRP7$4S(%+
MK&X8@.*J30FE1N/'%7GMS^:?EJV_-'0?RDX7<_F7S#Y?U'S)8W<*1O9+:Z7<
MV]I<1R2B3DLOJ7*44(12M2.F*O0GNK:/UO4N(D^K@-<<G ],'H7J=J^^*M&[
MM5D$37,0E9Q&L1=>1<KR"@5K7CO3PQ5WUJU].24W,0BA<QRR<UXJX-"K&M :
MFE#BJX7-NTSVRSQM<1J'DMPP+JK="5Z@'%6(^<_S$\E?E]H%[YH\X>8K71="
MTZ\L["]OY"9!%<W]S':6T3+$'8,\TR+TVK4T )Q5E?UVSI;GZW#2[/&T/-:2
MFE:)O\6WABK OS5_-#RU^3WD7S#^8'FE;JXTCRU;QW5_9:<D<UX\4D\5L&BB
MDDC#4>5:U84&*H3\V/S;\M_D[Y?TGS#YEL=7U2+7M<L/+FBZ5H=F;Z^NM2U-
MV2UACA#)7FRTJ3BKS%?^<M_RJGTO39M.L_-&K^;-3US4/+D?Y6V6B7,OFB'4
M])B2?4(+C3J#TA;0R)(\C.(^+H5=N:@JO3-!_.#RCYB\[:;^7UBNIV_F;5/)
ML/GJ&RO[">S,>E3W9LE$ZW"H\4XF!#1.H8=\51_D+\T/*7YC:'K'F+R_=RQZ
M5H>O:IY<U">_C^J\;[1[M[*Z YG=?5C(5OVABKT,$, RFH.X(Z$8JWBKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_7^_F*NQ5V*NQ5\C?\Y0V^M:=Y
MF_YQK_,.S\N:WYC\N?EM^8<NI>=8_+UA<:K?6UC>Z'J6G)<"QM%DGF1)[F/G
MZ:,5!Y4VQ5\:^2_RFUK\R=6_)"+\P?RE\QQ^3]4_YR!_-'S/YF\L^8M-N(!;
M:9>Z;J$VF/JD6Z+#--Z2A78QR$^G\88@JI!>?EE^95E^7_Y+Z'K?EK64_)SR
M3Y]_-&QU_P HZEY0U#SI;6MI+JTJ^5)[CRY'+#/<V4-L)5@<<UBYQNJ4XNBJ
M<^=?RF_,"#\MORCT+\M+;SQYQU/RCY1URX_,_P QWFE7OEF]UO\ +F[U;UI/
M)D%O<BXG6\DC'&RB,OK111&K(9Q55;^87Y6^8O-/YP^;WUI_,7D[3-<OO*%Y
M_P X[^:=*_+;5-?O=#T:ULK(Q6>F:I:SVZ:"\%RLHNH)HD!#%I#(IXJJS+7_
M ,C?,]WY=_YSD\]^6O(.J)^;NN>?;FW\FZY%'-;:Q>^5C#I+:E:Z'<2-&4%[
M;+=1!H&7U)* MR12JK(KORIY(U74?^<?+O\ (?\ )7S?^7?E+2_S/2[\VVP\
MN:AY== /*>J6WUM;6[2)HVC:2.%[AD57FX_O)#\6*O%-&_+O\R]-_)3\ZOR[
M_*?R#JZ:5I[^3I+C\SYO*%[Y<\V>:]/AU1GUW2=5TZXD@EU>\M[4R&2Y@DC6
MZ61H@P8[JIG!^5BZ=Y>TS6X-*\R^=_R+NOS:T76/S6_*'3_RVU?RKIT%A!H]
MU;>K8^5IS<3W=K]>DM9KN.&,QLR<O3<AL5?6?_.#GEB7RQY-_.F&V\BZ[^7/
ME_6/S;\QZGY*\M^8K.>RNTTFX@LA:R"*Y+.(VXGA\1H!QVXT"KYJ_)S\OO,L
M?G'\AD@_++S3H?\ SD5Y0\[ZUJ'_ #DM^<.JZ7=VUGJND2QWL=VK:U.!#J4-
M^TEL;.&%I!$%!X0<#BKS_P#YQ2\FZ5YHM?\ G%Z?RA^5FOV7F>QU;S>WYX_F
M#JNE7(TG5_*5W#JEJ+*35)^=O>V]Q.UNL%JK-Z3(S&.*A9E65?E)^5FI^6?(
M/_..'E+RU^4>K>2O.7D7\\]1F_,RY'EVXL82/0\P#3[^6Z$"QW=K'!-;HLZL
M\:@K'R!^'%4T_(S\OM<@\T_D"^D?E;YJ\K?G-Y/7S"?^<M/S*UK2KRSBUQ;G
M3KN&6*35KH>GJYN]2:">U]%I!%&E085 0JI7^1'Y"W_D/0?^<1-0T_\ +_S9
MY/UKS)^57GG3OSWU;2(+RWUIIYM/MI;&&]DF_N[E)R_U-9J>FXXQ\5%,5?2G
M_.#V@WGE+3OS!\J6_P"7IT3RKH3:-!Y?_,VY\K7?D[5/-#K;2K<?I;2[[]Y-
M>6955EO% CN"]5W5L5?*GY<^6?S(O?SF@\QQ?E)J'Y>R:EY3_,W3?S(T72?*
M&J:9!'>SA7TFVU#S#=W%P-?EF,;2PRH/30MQB-&X*JF_Y=?D1YV\A^7_ ,DE
M_*SR/K/DCSOYO_YQI\Y:;Y[UA(KJUDD\VO;:7)HZ:Q/+0)<QW$L_H>J0R ,J
M41.*JLL_YQC\E:)I_P#SD/\ E1KWDC\DO-_Y:Z3I7Y*7NB_F+KFMZ#?Z/:7/
MF47FFF:-VNU437=8Y&DG /K[,))>-550?_.55CYYTG4/^<W_ "_I_P"6'GCS
M=<_GOY#\JVOY:WOEK1KK5+.>73+:ZM+]9[FW#1V[P-*KE)"'=?[L.WPXJ@OS
MN_(W5/,&J?\ .:GYB6_Y<ZUJGYA:9_RKRX_)3S#;VEX]Y%<V&F:>;F?1/3']
M['*K)*\(Y4!C<\:KBKV+S1^6WG?_ *&!O?RGT_RWJ=Q^3/YK^<M$_.'S-YDC
M@8Z38R:%#74](GF/PB6_U.QT^=8ZU97G/1<5>)_D?^4_G:/\V/+VI?F'J?FC
M0/S?\O\ F7S=>^<=3TWR!J$4WF"QN_KZQQ7/G?ZV;&YLY(&A>TC91Z3K$B1Q
MLM<58#/^35W??D-^=GY>:/\ D=>>=-#\J3^2-:T'\Q-2\E76A^:]>FT_7%FU
M:TU*PO%,FJ7]I8FXYWMNM+A96C )-"JRW\Z/RPNO-WG[6R^D:]Y*_*;S#Y&\
MM6O_ #C[/I?Y8:MY@NO++0B<W<.F06,MG+Y>OTG].7E)"I9> +@1E,52K_G)
M7\M-6U%_^<E-*\V_E-YT_-/\V-?O?*%Q^2/Y@:5H5]?11:%96>G172I?VP]&
MT6.ZBNGNK7D#*T@;TY11E5?<_P#SF)Y4\X>;_*'Y0:;Y(%_!K=I^;ODZ^.M6
M&G_I-M*@M[IVDU"6V8%&B@J&<R40#[1Q5Y+^:/Y+>0/RZT.TDUZ^_-C6?S:U
MK7=6\[Z;_P Y!>1M#GU#6+7S)/:P6;PM!H]M)%#;SV\<<*VLT/U9XH^+OR'+
M%4-Y8UG\V_(7YF?E'^>WY[^1-=O;KS5^2$'D_P ]W/E#1KK69M,\RP:K^E/3
MO--TM+F>);B&2G.-&C6560E1QJJ\D\Q?E)Y@B_YQ_P#+&M><O)^NP^8;C\QO
M/'Y@^7?RNOO*EUYRTB[&OW-[/IVF>:M&TXF1'DBG4QR!J6TQJS<EIBK]0_RR
MEU*?\N?(<NL>4U\B:J_E_3OTAY*243+I,OU:,/8K(NS" _ #[8JSC%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%7__T/OYBKL56221PQO+*ZQQQJ7DD<A5
M55%223L !B!:DTE&@Z]8>9+ :KI1DETV9V6ROG0I'<QBE)H:[M&W[+4HW454
M@FW-AEBEPRY]1W>1\VK%ECECQ1Y??YCR07FSSKY-\AZ8FM>>?-NC>3-'>=;9
M-6UR_M].MFF<$I$)KEXT+,%)"UJ:'*FU,M$US0_,VE6.N^7-8L?,&AZG'ZNF
MZQIUQ'=VMQ'4CG%-"S(XJ"*J3BJ:;8JD*>:/+DGF:?R9'K5H_FNUTZ/5[GR^
M)5^MI82RM!'<M%7D(VD1E#=*BF*I]BKML5=BJ12>:/+D/F6T\G2ZU9Q^:K[3
MYM5LO+[2J+N6Q@D2&6X2*O(QI)(JEN@) Q5/L5:V\<5=MBK'/*7E'RSY$\O:
M;Y3\GZ/;Z!Y<TA9%TS2+4$0PB61YG"@DGXG=F._4XJG\TT-O#+<3R+#! C23
M2L:*J**LQ/8 #%6&^7OS)\@>;+K2;'RSYPTG7;S7M"3S/HMM974<SW6C22B!
M+^)5)Y0-(0H<;5VQ5FQ(4$GMN<52/RUYF\O><M"TSS/Y5UFT\P>7=:A^L:3K
M5A*L]M<Q$D<XI%)#"H(J,53S;%4@\P^:?+7E31=:\Q>9-;L=$T+RW;M=^8-6
MO)DB@LH$7FTD[L:(H7>I[8JGD4L4\4<T3K)%*H>)U-0RL*@CV(Q54Q5A'FG\
MR_RW\BW>G:?YU_,#RWY/OM6_XY-EK>JV>GRW.X7]RES+&S[FGP@[XJS1)(Y4
M22-UDCD4-'(I!5E(J""-B",57[8J[%6ML5;Q5K8XJWMBKL5=BK0IVQ59++'#
M')-*X2*)2\CL:!545))\ ,58UIWG?R?JWE&W\_Z?YGTNY\CW5A^E8/-PNHAI
MS6/'G]9^LLPC$845+$TIBJK;^<?*-W%Y:GM?-6CW,'G2I\G317UNZ:M2%KD_
M4&5R+BD*-)^[Y? "W05Q5DE1XXJZN*I!+YI\N0^9;3R=+K5G'YJO]/FU:R\O
MM*HNY;&WD2&6X2+J41Y%4MT!(Q5/ZXJI33PV\;33S)!"E.<LC!5%305)H!BJ
M2Q>:?+L_F6\\G0ZU9R>:M.L(=5OO+ZRJ;N*RN)'BAN'BZA'>-E![D'%4_P 5
M=BKL5=BKL5=BK__1^_F*NQ5\S:UH7YJ^=/S%U;R#YG6.3\FEN(==E\P6Z"VD
MO[1DX+Y<E56)=/74R3./MQ4C;[9S>XLVEP:<9L?]_P#37/A/^J#X; =#OT=)
MDQ:G/G.')_<WQ7RL?ZG\]R>HVZOI:*..&..&*-8HHE"11( JJJB@"@;  =!F
MC)O<NZ I\3?\YL6^KW=M_P XT6N@)I4FN3_G=Y=72H]<CDFTXS?4]1XBYCB*
MNR>RFM:8$OD6S\^^?ORN_+FQ\G>777RKYL\^?\Y >:-)_/6/2+RP\O6F@ZA-
M:3:A;:?H5]J:7%M9VVHI#;O;RS(7D$C!:2O\*KU^R_.C\X/R=\H?EM^;/YS>
M:K?5O(FEZSYO\I^<8[/4]-U8RVLL+W7E:ZO[O3HHK=KY+BT.GRF)45FF4LH;
M%7G7GO\ .C_G(+\I].\RF^\R2:CYWT_\D/)_F'S!]>BM(TTK5/,OFZ2UU6]Y
MR1<8TTZTN"J>L3%&L0>0,H:JK-M+_,+\]?)OD3SM^8'F+SM+>>0ORL\W^3_,
M/IOYBT7S3K4OEBZD>V\S6VI76D6\$/U>.&1;V M&) $8!BH Q59^5WY[?FYY
MT\]>5?RVU#S->1ZW^8/FU?S>T$QP1QR)^5EQ97-Y;:71D?X6NX(;5FKSI+6O
M@J\S_+7_ )R!_P"<HM;\M3_F]!JEKJ5Q>>4_.FJ></(6H>8-#NXK?4],L+N?
M3[/1_+]K;1ZG:S6-U D,\4\KLZ<S)\="%7HGY!:I%JO_ #EA^5-\?SQN?SIU
M#6?^<?KG6M8FO)=.FETZ[U+4M-FE5&T^&$1PSM5HX9 6C"[,0<57?\Y%_P#.
M1'F[RG^=\]EY%\X:_!_@GSQY#\L>8M"OM1T*RT$CS'-9FXMH-(E@;5=2,MK=
M-(TZRHL3CX"1')BJ$NOS&_.33O,7GC\QT_.37)M,\M_\Y067Y9:5^7$EOIQT
M7_#]_<V%K<P3GZM]9D?_ $HM$XF4QE:"O)L55K#\Q/SBL?-LWGV;\XM<OM,_
MZ&NN/RFM_P O9X-/.C)Y9N;PVCPN!;"Y::.H>*3UAPIQXD$U51&G?\Y%>:2W
MY?\ E6Z_-!?\>:E_SE;JODS5?+;RVPU)O*UK>7X%E+:\!(D*P_5_B*@T*?%\
M0JJQ_P C?\Y#>;_-7Y\:%I&E><O,.M_E[^9UC^8\%SIWF74= E=AY<CD$$EG
MHNF0)=Z6D$T3Q*;F1FF3XG7GN%7E/Y6S^>;/0?R@UG\LK][/SMY7_P"<.]%\
MPZ/%$$8WJZ1YFM+VXTYE9)/AO8(9+<T%1SJI!&*OTG_YQ[_,;4/SG;\S/S:T
M_6IK_P#*OS#JEOI?Y0V;*JPMIVDVBQWVH)0<B;F_DG0U8_#"H &]57YY?\XL
M>:?-$/Y?_P#.)GE#R'^?5YK=W^;.B^;_ "MYH\D6ATV6+RI#I^FWUS9ZE;V\
M4!GAGT^\2%)'G=A-ZHY#=!BK[$_YQJ_-OS[^<_FRQ_2VIRVUG^3_ )+B\M?F
MYI<:HL5U^8DUXT%_&YX D6<-AZJA>(I=*:':BKY'_./1;;29?^?IK7/G_6;S
M49/+%I/:>3;^^MC!<P7GEBTE-T+40I,PM"/1B=6XJGPMR;?%7HOGK\VOSK_(
MJW_YR"T/1O/]]^8USY=_*CRCYVT"\UZVL4.C7NKZI+I>J7%LMM##&EI!;H;E
M8YN:Q^GNQ3E55]$?\XIZW^;.HZS^8EIYU\QQ^8_)"6VCWODIK_S-HGF?6[>>
MY6X%Z)[K0[>UB^K3"..2 /'RKZ@5BM JKY[A\S:7Y8'_ #F/K?F6+\OC^?.B
M^<M7U+5]/_,^,E;WR%:V8;0XK .Z2-:26Z<(N!,8E,O,<SBK&]6_.KS3J_E7
MSGJJ?FL?^<;K/\K/R6\G^<?R@_+G11IUO:ZM>ZOI4EX0\>I032WELES$FG1V
M\/'C7<^HR45>E^8?SB_."Q\RC\K-3U74/+/GC_G)*S\AZQ^4]NJ(9_+JWL<<
M/G:UMA)&6_W%QVSW(]0,5:8<OA&*L5\A_F]_SD/YY_.R>]MM<@T?3]#_ #<U
M+RAYE\DZGYDT.WTZ+RS97$UJENFA26XU0ZA)"L=U%,)_WA;9/2(7%4AT+S=^
M=\W_ #BU^4'YD/\ \Y ^:9//'YU_F7Y:\O3ZS+;Z6\&D:;<:[=V+Q65K]4".
MSP@"1IB_,@&BTIBK*M4_.#SIY.\O_FU^6^N?F7YQU^^\O?G98>0/R^\S6MSH
M6G:Y=V^HZ#;ZR+'4=8O[9;&VB1I)!]8]'U2H5%JS8JQG\M_S8_./\X](_P"<
M5?+,_P";FL>5#YU\[_F;Y>\W^9=#DTN[U#4M+\KQW36*&]%J]J\H6%0;F"$!
MOMJOQ5Q5-O)7YU?F%YVTK_G'7R%Y^_.6\\@Z1YLO/S,L?,OYK6AT[3=5UJZ\
MCZX^EZ5IXNKF"2U@EGMU:YG,<0:3TR$XJ6Q5)OS'_.'\_-2_,'S;Y0_+;\RX
M+Q/RZ\J^5=2_+;SC<^8_+6A:7YC_ $C;-<7&MZO;WEJ_Z1M9Y4-N?J311Q\&
MXTD=2JKZP_YRG_,;4?*>A_E;Y>M]?\P>7/,_Y@ZM/;6\/EK4]&T2*=K'3IKV
MZCNM;UR&>&TAC5"X*(99"H1=BV*OES\L?S*_./\ /B'_ )Q$T>\_.77?)2?F
M'^7?Y@ZKYYUGRTFF?6M3N?+VJ66GZ?-ZTMI- C@2>HSQ1A7^(*JJ_P *J \L
M?GO^8/YE^7/R3M_S$_/&7\G]*U?\C=6\]:EYYLDTNS77/,5AJ(T]EG%]!+"\
M5O !/+;Q<>9D[*%HJ]%\K,%_Y]0V[;#C^0UT=Z4VTJ3%7BWE@ZC^6OYW?\XC
M?DP]I)/HVFZUJ_Y@?DQ"M1$^AZQY&U5KS2HV^( V.J<U45J(IXJ"@H%7HWY/
M_G1Y^UG6?^<:O-#?G1>^?/-/YZQ>8C^;WY1_[CC8^6(K/3KJ[]6UM+>W%U8_
MHN[ABLW-Q*WJ,]'_ 'A%%6)?E%K7Y\><],_YQ AU?_G)?SE7_G)/R3YBU;SY
M-%::*LMHVAV]M=V@TES8DVTA^L>G-(WJ&0"M%8@JJB?+G_.0OYL:_P"0_(WF
MN^\W,NN:C_SBCYV\Y7UY;V]O&9=?TBX@AM=1'[LE7 !8JIX$D_#THJR/1OS>
M_,'\J$U>;S[^<WFOSEH&K?\ .-%O^:VM:O)8:5<:EIFMK=0VDDVCP);0PJCI
M<5$4_- ZAV:G*JKPSSYY^\]?F#^0G_.9WDGS5YXUY])_+"+R'KFD33^8-$US
M4(EU>9WO+6^U31[6.U>#]RDWIA:Q'_=G"@Q5[-^>?YG_ )@^1[W\VM!_+G\W
M]1NK;R_^6?Y<7'E/SS*VGZE=_7-9\['3+J_>=(%CN&D@;@RTX$"@ .^*HO\
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MMO.VO:/<265_-8Z-H]SJ0TNWO(F22W-[)$%=XV$G!6"$5)"J%\V7^J?\X_\
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M27DTA@N]<CO(KUIBQ_>AEOYN(;9:BG08JUY6_P"<=ORO\G7OD._T33+N.?\
M+>/S3#Y6$UY-,D:><;Q;_5Q*KDB3U)E!7E]@;+MBK%K#_G$K\IM)\N>3_+&E
M3^:M-L/R[UZ77_R]N;;S'J:7>AM/ UK+8Z?<"?U(;-X'>(P \.+$8JRG2?\
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M'4/*2V\OGOS#?:?Y8_+ZWNE]2%];UNZCL;-Y(P072!I3/(H/V(VRIM?-D_\
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MK+O.?_.0_P":6F>?O->BZ)YE'Z%T_P U?DAIFD+<6%H)OJ7G1[D:P)**P#7
M1>Y],_8(Q5]":+_SEO\ EMKGG;1O*MOI^L0:#YHU[4?*OE+\R)A9#1=2UO2O
M6^M6<02Z:\05MI5CFEMTBD9&".?AY*O,+#_G*[4?S$_.3_G&G1/(OEWS-Y=_
M+;\T;[S3,?,>M:;:II_F72],T>YFM;BPG2:>:$?68ED595B>2.CA2AQ5Z?YC
M_/?SCHW_ #E'Y9_(FR_+:^U?RKKODV;S%=^<+>2S#VTJ7T5J9R);Z,_580])
M0(C*7*^FK+4XJ\K_ .<8/^<N3YU\F?D]I7YJZ;K]AYJ\_P"@:OJ%I^9-_I]M
M8:!J]UH1EFU**W,<HDC,%NO/F\"1R*KF-VXXJRN+_G,;R#YITG7(=-L_,_E!
M=:\C>8/./Y:>;[BTT^==9T[1;8R7-YI]J+N5UEB5TFCAOHX#(A!I3E15//RT
M_P"<F=.\X>9?*/Y::-Y0\Z^<]9?R=Y5\S>://IL=.M-/M;/S'8M/;75_QO (
MI9&C;E# CT)/ ,B,P591^:'_ #DAY?\ RW\PZGY5LO)/FO\ ,C7?+.@CS3YX
MLO*=K;7'Z#T9FD2*ZO&N[JU4M-Z,IBAB+S.L;D)0;JL>\S?\Y@_E5Y7\J_F%
MYSN8-8O] \@:/Y6\PK=65O'(VL:5YP &FW6F(95:5>8D20.$93&VU*$JHCS_
M /\ .67D'R#>ZU9OY=\S>;6T77/*GESGY=M;>]-WJ?G""6YL;:T0W,;2.D*1
MR2"@HLT17E4\55&W_P"<M_(;^5+S6KSRSYDTCS99>=#^79_*Z^BLHM;D\R^B
MMT+-'^N&QX&V;U_7-R(A'5F<=,52+_H=#R5=KY,L- _+WSMYH\X^<M=\P>5T
M\AZ9:Z?)J.GZSY9CAFU"VOI'OTM441SK(LR3O$5WY[C%53S3_P Y-G6O+7_.
M0<'Y=^5/,,%W^46A>:;:X_,6YBT[]%67F30M-:Z:TDMY+MKLE'90':V]&0JP
M5V7<JL+\O?\ .6]KK?Y2:[%YBL/.7D/SYHGY,Q?F2OFJYT:QY:I8+9HEWJVD
MVDMQZ3&.Z.T%TL)(*'CP:N*LLUC_ )S"\K>4CK.DR^1_/GG>7R!Y/T'SA^8'
MF;2M,L3;V6C:Q;/.+^X!O(AS187=X(5:2@8Q(ZHQ"KVG\P?SGT'R-I'DB_T[
M1=6_,#4_S+OH[#R!Y<\MK;R76IN]I+J#2QR7D]K;I$EK"\K/)*HXC:I(&*L&
M_+O_ )RA\K?F')^45O'Y.\R^6;S\YG\T)Y:LM7CL1);_ .$RJ7WUSZM=SB,L
MY*(%+&JGEQVJJQ/3_P#G*+R=YCU_\J/,D.N:]Y7\H>9_+WYC:M?Z+>:=8O:R
M0>2+RWL[V[OKH323P&!E=X5A#"17/J<2JC%6#Z5_SEQ=Z_\ G5Y'6]T3S)^6
M7Y/W7Y4>9OS"UJ3S9IMK"M]86,VG/8ZG!/;373JJ6\LK/"Q21>2<X_B7%4O_
M #7_ .<SXKC\I?S,NO(6F:W^7OYB:3Y1L/.GD23S#;:=,-1T2[U*ULS?01V]
MS>(A7UP'AN1',G-28_!5Z'KG_.3^B?EYYL_,S3]7B\X^?I[3\S?+_P"7N@^4
MM)TC3S)::EK/E^#5((+)UN8WN8'J7DEGXLCL5IZ2\L53^#_G+KR%<>4K+6U\
MM>8X?-^H><+_ ,@6WY57,5E;ZY_B/3(VGO;-GENUL52&!?6:<W7I>G0\ZD+B
MJ 7_ )S(\AZC8^2(_*OD_P U>;O./GB^\PZ;:_EY81Z=#J=G=^5&B368+F2\
MOK>SYV[3QA5BN',H=6B#K5@J^MH)?7@AF,3P&5%<PR@!TY"O%@"0".AWQ55Q
M5V*NQ5V*NQ5V*NQ5V*O_UOOYBKL58I#Y)\KP><+SS]%HUNOF^_TZ+2;K7:$S
M-90N9%A%30#D:F@J:"O09>=5E.(8>+T W7GWM TN,93FX?615^7<RO*&]X-^
M<?Y#Z'^=^N_EL?.UXU[Y%\B7M_K%_P"2U,\(U+5);86VGW#W-O/$\8LQ),Z@
M;EV4U''=5XU%_P X8Z1H7F"!O)'FD^6O(-G^9_E;\TM/\D/#/>"WU31+6>TU
M)$N9[EG(U$-"[,U2CHQ^+G\*KUKR#^1DGDG\H_/_ .5[>9!J+^=]4\XZB-9%
MMZ8M_P#%=[>783TO4;E]7^M<:\ARXUVKBKR&]_YPQM9]0_YQ5UJS\\/I^L?\
MXZV^B:?YBF2SK%YGL="AI9Q2Q^L/1:&9I'B:K\1)(M#4$*L]_*O\E/S+_+/S
M)YRM!Y\\M:W^5GG?SAYB\V:KY9GT"Y75PVON\IMEU :D8.$<A7<VIY+4=P0J
MP(?\XF^=AY"?\@A^<RI_SCDSFV7RPFBA?,JZ$;CUOT -:^M^E]5X_N#)]4];
MT?@YU^+%6=VG_..NJ+_SD%I'YU7/FK1[*S\MPW]KI>F:%H*:5JNH6-Y;?5H-
M,US48[EDOK2Q%)+=3 K*X4EOAW51OGK_ )QXD\Y>;?SO\SCS4+!?SA_*Z+\N
M%LC:>I]0,1U$_72_JKZE?K_V*+]G[6^RKY^_,3_G F?SU>VTK?F!I'H?X;\G
MZ*][J_EJ+5=3TV7R@8V0Z%>272?HZ&^,8:Y549V/1Q7%7OVL?\XU:9K7_.0,
M7YSW'F.9?+\NF\]8_+E8%%O>>88K&XT>WUF2X#!@\>FW4EOQ"_R-RJBXJP[\
M@?\ G$R'\B=<T?ZB_D#5/+OE6RNK'RYK5MY)M=/\XO%-\$2W^O1W3^L8HB49
MU@1I10N>M57I7F;\A+/S9^9OY@>>M4UZ1-*_,'\KS^6FH:'!$$FAADN;J:6[
MCN"Q'(K=%0O#8BM3TQ5X%H__ #AKY[^KW]KYP_.FU\QV\/Y*ZI^2OE:"U\O)
MIZV>GWBQ1P7\Q%Y*TTX2%?5%51B!P";U59?YC_YQ'FU[3_/=B//2VQ\Z?DCI
MOY/B7ZAR^KMI_P!8_P!R5/6'(/Z_]UM2GVL5:UO_ )Q'FU?S+J_F$>>5@_2F
MM_E?JXM38<N'_*N3*3'R]<5^N>KUI^[I^UBJA^6O_.'FF_EGYY?4]-C\@:IY
M-36M8UNQFO?)5LWG*W_2\MQ.;-?,BW0<QPR7!X2&#U> $?*F^*J'Y<?\XG>=
M/)'FK\B+C4?S>M]=_+__ )QS.M6GY>^4(]"6UNI=/U2PGL(!J&H?6I/5GMHI
M5162)%95JR<VY8J]G\V?E!KFJ_GCY$_.GRUYOM]$GT#0+SRGYKT"]T[ZZFH:
M1>7<-Z1:RK/ ;:<2P <V$B\2?@J,5>7>4?\ G$BWT#R[_P XX>6=4\W#6=._
M(G3/-&EZH@M&@_3,'F73Y["0 K,3;^FLY.Q:OMBK%/R\_P"<+/\  /E?S#Y)
M@U'\OWTFY\E:OY.\O><-/\B6FF^;/3U*V:TBGU+5H;HBX:*-J/PBC,Q')S7%
M7LOY(?D#)^3WF'7==;S.->76?)'D7R>+46OU?TSY,LKJS-SR]1Z_6?K/+C3X
M*4JU<523\S?^<?/./F3SYYO\[_EK^9UO^7DWYH>4[7R;^9=O>:,NL--9V+W1
MM+S3F>Y@6WNHH[V:,<UDC(8,T9*XJDVL_P#.'/DZ^\W_ )':GI^M7-GY)_*/
MRR/*>M>1KE/K,?F#3[&WDCT=;J8LG%K.:>66H0\RU/A&*I)Y0_YP[N/+'Y;_
M )>>2KS\R9_,6M^3?S1T?\Q=6\W7=@JS:C%H7&WL=/,:2_ (K&""W#\F^Q7C
MO0*M>=O^<,[+SDGG>ZN?,VF7.K:W^:R?FGY8BUK0H=7TJWG72H=)ET[4-.GF
M5+R":%'Y'DC*6#)1EJ567>2_^<:9_+?FC\F_-<U_Y2T6X_*ZY\U75[H'DKRQ
M'Y=TF];S)9P6:^G;1W,Y1H5@!9W9VDZ?" ,58YYW_P"<3]:\]_F)YV\\:AY]
MTG2!YC\J>9_*UF^B>7UT_4[VU\Q6+V4,/F&]CNRFIPZ=R]2W4PQL& )?Q51/
MF+_G$R77M/\ J/\ CA;?_D =S^27J?4>7Q7!@/Z4IZPV'H_W7O\ ;Q5Y)=_\
MXV?F_K_YH_GMY9T?SJ?(GY<^<_RS\B^1=8\P7.B1Z@-:MK2SU*TU"337:ZB-
MM=6\;\ 762.D]2C,JD*LX_YRX_*34-<\B?DKY0\K^5M9UCRAY"UF-[Z31[)=
M<NK&WLM*GL;$MI37EA)<@F6ADBG#Q$!^+ FBJAY/_)'\TO-'D[\CO,UK=Z3^
M1_GS\E+O7].\E:>/+T+V-QY9U:(62F]T2&_*65V\,<<P2.Z<(XH]>3(JJ.\I
M_P#.%D.CZ%^5WEOS)^8$WF?3_(OE3\RO*OF&Y6Q6SN-7B_,6]2ZGN 4E9('@
M56% K!B:CB!3%4/HW_.'GFW4K_2$_-3\WH/.GEG0ORKUO\I-.T/3-"72)/T3
MJR6D7UV2X^MW!:Z].T4.0JQDA2B+\7)5*;/_ )PCNT_+#SQ^6=QK/Y=Z5_B/
MR[9>7=-\Y^5_(-KH6LRI:7=O<&XU6X@O7%R\@M@&2,1H6)<CH,5>E:K_ ,XM
M2ZE^8VK^?AYS6%=4_-_R[^:8TSZE4HN@^75T$V'J>MN9N/J^I3X?L\3UQ5B/
MFG_G"NR\Q6FMW,GF31]0\PR?FYKGYI^7%\Q:!%K6BK^G+)+"XTK4=,GG5;F,
MQK42!T=6XLE"NZJ8>=?^<3]7\X?E%I'Y60:I^7/EJV]:_GUL:3Y#AM;&UN;Q
MU,&I:#!#?QR:??6:K2.<RR<B>3KL!BK['T/36T;1=(T=]0N]7?2K*WLWU6_?
MU;JZ,$:QF>=P!RDDX\G--R3BJ:8J[%78J[%78J[%78J[%7__U_OYBKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>henneman.jpg
<TEXT>
begin 644 henneman.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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M7RV)8A5]6XI4NX["P5WY9N$7N361)/+-<>9)AYI#\BGH@^E5&FY Y)&G]KC
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MC%F))/<TY%J,=*L)78CG' 8'2G.J;2S<$#@U*OW:BN.B_P"\*8"1JY09)/<
M^E2# %2#J?K3#]X4#+^CZE-H^J07UN2)(FR1ZCN*^B-*U"+4["&\AX250Q!_
MA)KYL3[U>X_#UF_X0^S.3G+#K[U,@1+XTMXY;)9>/M 8",]ZB\/ZIY5X;.7!
MF@4;O]L$<U>\8?ZZS';BL)@%\7Q8&,@9Q]*J.Q$MSD/'X,'CR1 Y,1B!C7/"
M@^E8RG'%;_Q,_P"1YM?^O85@KVIK8H<Q&:!T(H/6E!/-.X&;99^R$'^\QJSY
5@IEOQ'Q_>-+@9Z5RXB*;1K3>A__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>larsen.jpg
<TEXT>
begin 644 larsen.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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M7^5/8UVH<;1SVJ$:,L0YWK]17HVDR?Z.GTKS^% "#7;:3)BW2LJ,@JQ.FCE
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MF.W3[[?X"O-=:\8ZMK1,;3&UM.BV\)P,>Y[FL.YNKB^N7NKN9YYW.7=SD_\
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<C#?_ /78TY;$]3.;K24-VH[5 "&C-%,[T@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>richard.jpg
<TEXT>
begin 644 richard.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#F]G%0N3%S
MBK.[C%5IS\IKS3H$BO<R;>*T5/F)FN?7_CYS7068S&/I38%:564__6H5FQ_]
M:K=Q'G'!SZ5/!8*%#SMM'91UJ+-EI7*:B5ONHQ^@JY;?:4;/EO\ E6A&V$VP
MH /7%.5IHVW$_I34#3D9MZ1<2 J&./8BNLA8O'RPKCK*ZB<@N-K#N*Z6WE#Q
M91LU7*T*R(=4P$89'Y5Y_JS*)2%(SFNTU>XVPL#U(XKAY8FEF9CZUC*0W$S3
MN]/TJ%BW^16H;4^AJ!K4^E2IBY2O:E@]:>_GK5%$\LY-.,XR>:T3"Q2;.:KS
M$[35QN>U5IAP:=S)HI0C=.,UT=J (U]*YU#B?BNALSF('VIR$BV,*2[#)'W:
M;&&DDY).32L,E1FI[=H4DS*X1<]357LCJI1ZLWK#26:$2;2?6GW%@N>5Q6QI
M*F2T#0S*R8Z"I);?S5DW#:14R74UC)7.1>,PN<=*UM/NBK*-W!XQ5>]MXU&3
M,H]14%JIC<,Q^4]"*UINZL854KW1IZI&&')K#,"]16S>[C&I)X(K(D<*,5Q5
M%:5@6Q$T:U \0/:GRR$"HTER>:BP[F?=)M4X%9+.VX_6NDGB$B'BLIK;YCP.
MM;0V%<B88JO,.*M-C%5)SA:M&+*'2>N@LB/)7/ QR:YT F>NGTM5;RU;H2,U
M3%%79*H;SAD8QTSWJ1HK*.[\S4(Y9@HR$0< 5=U&%H+R%C@AONXKI(K$/;+-
M''NR,,,9%-RL=?+=:'-Z9JUI//G3!-!@X",>#6WJ5_+;V\,@E/F3?*0>@H:W
MM(P3!$@DSV[5#K-NYLX9"A(!!Q4R>NA<8V6I0NK;1[>)?MES,TTQX(/&?:DT
MF%8V:&.9I8B>-W5:WXH+6_LX%>W4[?NL?X34O]GQV,P=0"6ZD5I&:ND93@[&
M;>7L7GBS/$H7OWK-D0[JAE?[3XE=7&&B.1]*OL.2:YZWQDVT10FBW+50*5:M
M20C&*HOC<*S6PF2@9B-5&0;CQWJX#^[-4V;YC]:U@B691&1569:MU"ZYJB#-
M*XD!K>L&Q&I';FLV2#C-7[ XCY[50EH;5_=17(@:$L'7@@]JMQZM=C3G@63R
MT/\ K&]%[UBL0CH_OS5NX@-Y"T$3[1*,$BA*YU0EH3RZM;W"6]K;)*1U\Q1R
MU5M=NM1C,"AY$A'M6OX:TRRL0ME>-(9\Y211QBMS6M(LVAW&[R0.%(K500^8
MYW0M66#(\_S-XY1OZ5?FUT^8(V7@]..E<I9Z1=W&JB<LJ1J_R*.#C/>M4XEO
M6<D=<*!4N"6H2F[$\5HL5U)=OS*_3Z4]Y*69CD#/05"037'-WE<SOH,?)7-9
MTC8?\:U'^Y61.X#4XK03+0E B-9K3_.W/>IC+^Z-9+2'>WUK:.Q++7:D5?FI
MQ'%-R11J0.=>,41GRUQ3&DJ(LQ/%%A%EI=XVU/IUW]GN4AER!NX:J*KF:*,G
M!D8*/Q-=+K?AJ73)5@F#!PH9),<-6\8.Q4)I.QTD$!F@# 98#*N*RKJUOIIF
M:8D(#U!ZU2TG7;S3-T$B;XL8R:34/%D(C*E@,'(%)I]#J4E;46>86B/)T9AM
M1:J:%B6[D=V&0.!6!=:M+>38B4R32<*J@G%>L>#_  6NG>&KF>]5C>31EP&'
MW<+Q6GLW*.AS3J*YS$Q^>D4\53M;Y+PRC</.C<HRY]*LDG%>?*$H.TAQ=Q)?
MN5@W+?O,5N,?D.:Y^=LRFJB-L4M\E4&(W'ZU<?A*SF/S'ZUHB2ZSXZ4W+-QC
M-,EN;:W&9) 3CH*RY]>)RENF/1B*Z(4)2,7-(UF"(,RR*H]S5:?5[6 'R_WA
M%<_-//<-^\<MGMFAD"1A17;3P26YE*L^AT7ACS=7\8:>LI^7S00OXU],:EI-
MKJEN8;A <#"MW%?/'PQ@2X\;60;@(<U]*]_K6E6*CHB8M[GEVJ^&)-*G+2)Y
MEJ?X_2N;N_#T&JW:V^GV_F.3R5[5V_C;Q2L,S:-'&Q9\ OCC/UKG]%U.Y\-W
MH/E"5I?E91SUJ%@VUSHU>+M[K.G\+?#O3]"*W=R@FO, \GA3777'%K.3_P \
MV_E4L;>;"DF,;AG![53U:X2TTB[GD.%6)OY&E%6T1FVWJ?+EQ=RVOB"]:-BA
M\TFM"W\4W*OMF59%]A6'?[I+Z>X!R)')JN'(^;T]:WG0A->\B54:.]37+.YB
M^]L;'0UG,X>7(.1[5SR$.-P&*L)<O&>#7-+ *WNFJQ#ZFY+]RLX_>/UIR:B7
M7#KGWIADC))R:Y)8:<7L:JK%G-MEVR6)]S4JJ *=L&<4K  <5[:BD<5V0.6#
M?)UJ0L77D8(I\8&"<<U')UJ@.O\ AH[+XWT_8<9;!KZ7GD\J*1\<@<?6OEWP
M!+Y/C#3G]9 *^I)$#L-W;H*Y:^Y<-CF]5TZS'AV[GNXE+L-^XCY@<\<UYO;>
M:3:W[N3$DFSGL/\ (KMO'&IJUQ!I&=J/@R$5RFKQ&PM!Y?,)XQZUU4(ODL^I
MA4:YO0]=@8/;1,#D,H((KE_B+<_9?!]P2<;@5JSX+U$7FAPQELM&H'X5RGQG
MOC#H=G:*?FE<D_2N11:J69LI7C<\5'IV-1R68D8'/RCJ!4G3MFE60J<$=:Z[
M$7'HJJ,#H*4KS42?O+AB#A4'YU8[TT(C*X%0D')Y-6&8569AN/UJ6,A)P33#
M3NXH/WJL CY4BHY!UJ1"<FF-UI :GA>86_B+3Y/29?YU]9_>P1T/-?(.D$_V
MO9\_\ME_F*^NXB?)3D]*Y:^Z+@>=>)HEN_$,HZ2H!CWJC,%FM#:W PIZ'T-7
M=;9O^$EE.3^=4]7)\I>3793V2.>75DO@&2>QUN33Y"3'CY:Y_P",][YWB*RM
M ?EBA)(]#DUT_A4G^VH#GG;UK@?BJ2?&TV2>(Q6%36J:4_@..7FE=@B%V["A
M/NBH[XG[,>>XK48^U7$ 8CECDU([[1FE3_4K_NBH92=M B&64A3S46XGG%-N
+2=HYIXZ"H;'8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>thompson.jpg
<TEXT>
begin 644 thompson.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ 'L# 2(  A$! Q$!_\0
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M5>/I5F#1TB&4) ]*Z8M]3!E/6KI[5X;M!NRNUL5SQU>&[N#<W[^3''\J;SM
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MS6;S4IR2]S*6^@[#\J0&8Z?+D#BDX"U)STIK*"<GD?RI#$0@K3L4#  Q2]J
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>$OX?R%)_:5W_ ,]?_'1_A4$LKS2&20Y8]3B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>vogt.jpg
<TEXT>
begin 644 vogt.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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M1?7"EHX[:/>54=S79^'M2EU/2C.[.Q7H[IM+?A47A;3[9= LI/)C\V6(,\A
MS^=:T\T,,$H+JBJ,9)Q6:V-V[Z'%WB:G)/)?_9YKULGRH-V(^.E-MGU6_LVD
MU+26TZ96PJQMN1Q73Z3>QR0K'<>6I891=V<CUJSJ$L<:,_8"I>Q:O>QY!\0;
M+'DW,#Y>(@$"GZ3,DMS8W*C"W4161?4CBI?$Q^T2W*#E&&1[5FZ6CV&DV[RG
M)AF.PX[&G"5XV)G&TKG;> M1:"1[4L3$[%5)KJ]5F C<9ZBO,_"D_P#Q,/*7
M.XW.0/;K7=ZO<#YL&M:$[HY<1!<QXOXV/_$W4^QJ#1IMICY[TGB^3?JH(Z8-
M4],DPR\]#6C8HK0]8TVX!B3FM5IQN//>N2TNX)A7FM8W1R>>]3S!R$*.-RUV
MNC$>2O-<0MO(''!-=CHP81J#6-%6+JF].@>UE 8H=I^8#I7AGC**YOM:@@EW
M?O4XR,$CL?I7O$>-O(R",$&O'_'D)L?'-OG/E;59"?3TK:HM+DTGJ=-X5UQ_
M^$#M6Y+VP:WD..05.*TKW2=.O[&&2?4#$S1X.^7&<^U<3X*UZ/2/$FJ:%>E5
MBNY?/M=_0D]0*]$DTS3KBX6Z:QB>8C&\C/Z5BU9G5&5T<Y!)X:\/LY2_1Y -
MO4M5Z%KS4K-KE25L\90N,,1]*T;K3XT7>+.%6'3" 51U'4/L^GLLCA9&X ST
M%1*VQI?JC@O$D@M[=GS\^":YZ#4GGT./SGS),[-@<#CTK0UZ1KQ9GW?NPI ]
MZYI2J01(3_JTP/;UJH1T,ZDG<Z#PMJWV'6[>9B A?:Q(X_&O4]3(>+?C&1G
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MH\A#'KZ^U>:?PTL2]4@I"@Y);\!1FF]A]**Y34"<TT=32TB]Z '$]A24M)0
EAX!KU:POW_LZVR?^62_R%>3DFN\LV/V*WY/^K7^59U%<T@S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>xbullet.jpg
<TEXT>
begin 644 xbullet.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  .  X# 2(  A$! Q$!_\0
M%@ ! 0$                 ! 4'_\0 (A   @(!! ,  P           0(#
M! 8%$1(3 "$B!R,Q_\0 % $!                     /_$ !P1  $#!0
M               ! O 1(3%AL?_:  P# 0 "$0,1 #\ U3/LROT=<OJ;\^CX
MOH_5'J6H4TCDLI+*O)"$D1U,0!4'92V[#;T#Y9_&F0:S>LW-+R10UF."*_4F
M/#LDJRM(J=P0!!*.L[\/GZ&W\/B,DP@W\GKY#I-R"IJ<:A7CN5FM5I" 0LAB
M$B?L4,RA^7H$C;Q.!896Q*&XRV#9N6V#2R!3''&@+%8H8]SUQ*68A-SMR/OP
)W"UDY8.T?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139755372368496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 22, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">Anika Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document, Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document, Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document, Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document, Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-14027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">04-3145961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">32 Wiggins Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Bedford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">01730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANIK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity, Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity, Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity, Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity, Interactive Data, Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity, Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity, Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document, Financial Statement Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity, Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity, Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,427,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity, Common Stock Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,828,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No. 1 on Form 10-K/A, or the Amendment, amends the Annual Report on Form 10-K of Anika Therapeutics, Inc., a Delaware corporation, or we, our, us, Anika, or the Company, for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission, or the SEC, on March 15, 2024, or the Original Filing. This Amendment is being filed to amend Part III of the Original Filing to include the information required by and not included in Part III of the Original Filing. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 4 and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.

&#160;

Except for the matters described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing other than as expressly indicated in this Amendment. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company&#8217;s other filings made with the SEC on or subsequent to March 15, 2024.

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000898437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M> &+A?X?;?*V0Z^#@DQ(EA3&T(.$IOE?_%00L6,P=AH,O,+ >V'@#AH,_,+
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M0]V1->/2Q)4=2/+,Q/#4:G4H4RV!U9ARG2J_<_;DJHA1MLC^%M8V_VI,P.P
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M>;-C-O'6JA!H"ZW.6R4$O/V$@%Z2: KB:<6X.?>P TV"@  $ (0YF)&Z5J5
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MD&\OWE3T-R;W=H!&G=1J^:<MM#I+5?G'WZ_\,P6B.+C>#!Z@3^@+,>?W;[P
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  +1II8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    (  M&FEA-433[[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  M&FEB97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M"T::6-S"A/W@"0  S34  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  M&FEBR]\)O[@(  (D.   -
M          "  2,2  !X;"]S='EL97,N>&UL4$L! A0#%     @ "T::6)>*
MNQS     $P(   L              ( !/!4  %]R96QS+RYR96QS4$L! A0#
M%     @ "T::6#JJHN=  0  / (   \              ( !)18  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    (  M&FE@D'INBK0   /@!   :
M      "  9(7  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   (  M&FEAED'F2&0$  ,\#   3              "  7<8  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  ,$9      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>35</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="anik20231231_10ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anik.com/20231231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>anik-20231231.xsd</File>
    <File>anik-20231231_def.xml</File>
    <File>anik-20231231_lab.xml</File>
    <File>anik-20231231_pre.xml</File>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" original="anik20231231_10ka.htm">anik20231231_10ka.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>blanchard.jpg</File>
    <File>conley.jpg</File>
    <File>fischetti.jpg</File>
    <File>graph1.jpg</File>
    <File>graph2.jpg</File>
    <File>graph3.jpg</File>
    <File>henneman.jpg</File>
    <File>larsen.jpg</File>
    <File>richard.jpg</File>
    <File>thompson.jpg</File>
    <File>vogt.jpg</File>
    <File>xbullet.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>30
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "anik20231231_10ka.htm": {
   "nsprefix": "anik",
   "nsuri": "http://www.anik.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "anik-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "anik-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "anik-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anik-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "anik20231231_10ka.htm"
     ]
    }
   },
   "keyStandard": 35,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 39,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 35
   },
   "report": {
    "R1": {
     "role": "http://www.anik.com/20231231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d202410KA",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anik20231231_10ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d202410KA",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anik20231231_10ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Financial Statement Error Correction Flag",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r7"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Common Stock Shares, Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Interactive Data, Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.anik.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>31
<FILENAME>0001171843-24-002274-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-24-002274-xbrl.zip
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M42:["[BLLK49T059]U^<_@102P,$%     @ #$::6-P!&!L6!@  3$   !4
M  !A;FEK+3(P,C,Q,C,Q7V1E9BYX;6S-6UM/XS@8?5]I_T,V^QQ""\PN:#JC
M;H%1-<R :&=O+RLW<5L+)ZX<!\J_W\_IA3*-G8].75E"T"8G]CF^GN2$]Q_G
M&0\>J2R8R#MAZ^@X#&B>B)3EDT[X;1!U![U^/PP*1?*4<)'33IB+\..'GW]Z
M_TL4?:(YE431-!@]!\-IF:=47HJ,!G="*L*#*#B-V^_B]G'[-&BU+HZ/+UKM
MH/LEBO3UG.4/%_K7B!0T !YY47WMA%.E9A=Q_/3T=#0?27XDY 3*.#Z)5^AP
M"==G4[6^8!-\%B].KJ%;13^=5-C6^?EY7)U=0PM6!X1"6_'?7VX&R91F)&*Y
M;I1$<RG815$=O!$)455+-DH(C C]+5K!(GTH:K6CD];1O$C#=<,1F4C!Z3T=
M!\N/W^[[VRW!<A6G+(N7F)AP#H2K$J:2CHU$5\VGZS_3-?^Z<:5ZGL$X*%@V
MXS2,?Y12*C+"\BBCV8C*'<G5EK%GFBRCN9XFT:*R79D:BMDOV2F4)I-R1*-U
M?3ORM93DK'WIF)1<_7@#OR['0'?%]7NBNB:2LX>C1&1Z!3MIP4]<486)KRC4
MHJ /D[+Z ,MC!'^9>H:%82QD5JT#KR7HTJ)52177-Q=DT !*6<XT\ :^+K&:
MJA,U"Q)TKBBL]QM+$A?)5I<5JRXO:'(T$8]Q2EE5O_Y0-<:BTRC[[ZJJ\/+5
MK.!D1'DG-)U>,.%ZU15RHST.QZ1^D.V=T>6R9_HOO3$D(TYKV#5!#\<0QB+M
MP] J<"RWX(Z8WM )X8L^[,Y9'3D#PA&?7BDEM,0U*Q+"_Z%$7N7I)4S)&F)-
M4,=]NZCWCDHFTFLX9NM8(_8@''7;X!AN(1WS&T+Q%E*;IQTSZ>9Y2?@]G8%7
MMS"J@SEFMA@UYFE@Q;GN/TG 7>CUJK'E3%"GN]8UX_1KN6F#MW:N;8A31O=T
MP@H%;:&^DJRN.VTPI\SZ<*<KH6>J[6>@;5!/E+F2SSV1FHFBKG+*>TCF_53[
MLS%;W&\V='@#WBG7;II*6A3+/WJ/;QEY6K"'X-B#C[=R*)[,IL^(/ 2_:JS=
MRCLI'MGBP8.5I %^"*9W FXJ^+]L9IU(-K KKZ6KE908>-6==N5"A;9'4Y&;
M5VL3Q!&C 4U*"0W0:H^&3-7>6Y@@CAC!!JH?1 Z>LY'@-71JSSMNG:MY,B7Y
MA!KV,AO,Z<S[BW+^.8<5:4!) 4,F[1=%:=D3&O!.N?XI.&R81%9.1-9Y="O.
M*;?E+=;"L>G!!:MH[6T$!N[8O2@J2:+8(P7_2Y9,++;%!G?N264/=J.)D,]6
M6[J%<LIKD!'._R@+,!J%N8MK44YY76543F P?9+B24U[(IN1W-QN5K0CGOUD
M++MERJ#0KE)4/T($6WG-R:2&9C/8^3,!\.F9NI)2R)Z <9]8V.(O<CLVI[!
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MN*D)=\DX\,US6=+$2_GBC[UD2$^9*X6US])83E:N_:LMN)Y/:]5]G6UG:LY
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M ?[BBRR28X4!O*F*EBR23J=#G]O9W6^^:K=7D-_W)KU<*T:2^L=_O^QV]M_
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M ]GJW.CSC^]_L186JPB"[";A&DZ<'EVPG/ GS'HOO.O#Y85]F4/10BL%POE
MZ=GIN!FKZ^4?T184YQ]/?STIS:+XK_]Z.XW-A\]['P^;[R\.>[\T>Q\N#R]>
M P-<PU:_T3:GSLH6A=E.)<^J.__\!C,&L SGO]OT?_"<YW^:Q"J+1LWB)2H>
M*:S 3P?5*X#+^,7SOSSK'V.%YDTK<!L1B24JNC6+O9 ;7Y[,DY&%*") .LR"
M%*O%2/>+583*<;@0$A3EA3A"ZO1\\FX>>*G'B0$E49F_ _YV]1LP\[*0 QR#
MYJ5XCNNR_Z:[W6U9!0C.69";<PSH/K:TY&%:(2B3%U\JXIQ5P471$J\@XEZN
MM8A;1VHD/3J$YZ7P?&!N7<2(.X5*=%3Y*PJL9N6%!$8(_ZE/1J0D7\WF7K1H
MX#$.KX.C#\<Z$2"_KM.IN=R"0UW2V$AIIXPC<OBCR[7;?K-JA'2Y\\;<=NL-
MJ\=G;L237-^\8JSF3F-6=+K#9M?H)JY"TJI=F4_,E7E<368EJ;')/@Z2M#1I
ME"$3%2^JPIID"/7U#04)_.K9NUYY^6XQCY[$<IY62;RG2!>#51+P"T/@*].7
MF5+H<^^S)(AD4C!'=MM/(W/YEN4\K#XC'F<QS<<^TK?Z_*G"HMXG'?S'<BR.
M;] ^&G"6W]%#A=H[Z>P@ ]!5!1INEK#F B/@ H^*I&E0?O!;X0(_?AW IY%(
M(IBA0E:\"A*2*9$7^8$7X@F$F71X,U9)C[QXE C,,PE&U1%5T=E^[KVH5$(V
M0.7]2FM+>YVTR,-X&"IY'MA.F+^#JP<+&:0)O"CR)N2<T9%^4(Z3! 07E4GJ
MQ97CL20C)-(Y*0%*A0AV#9D\5J' HFYG,W-)2Z@@=LMVVCM.^'O@Q4,/7MD\
M^QS*!?FSGG=VQ:^M 1;D[G?W,%;^ B>=SU#'UX<A2!B'9,9!/&/;# RZN8<W
M 9618WQ$\_2R49#J<=W5&KNSJ#KRQW$//Z#B7K[$93B/W>YM579/D5#O((62
MW'D).W-+HH0H9TBLE%0N^>>D1_EI[&Q4R\YVRE?A^ @_IEV48XI'X4^^ AO;
M9L.B (UC=%HJI*RK0&5)N#"$5?75!R>NO%P_&J2S]!"'T[>#7"*R[=N.PXTD
MLILI! \>(@8%YQ;O9[[-AB@=PB%!8CTZ*$4)M6(!+_+"11)H&8C*$0C%)J*$
MC>BPDU'"TA6]2G")_/KVZRXI6FDK;5*?HJ2^.''=4S$<O%=(N78(^GAU.4=[
MNW;:K4[[H-D!]MF$$_ 1G#[)%%VY1E]]7A$O7>G8>,%1M<<Q&'!85:KMSDI>
MMGZ]C8ZX7<(F>),);"/N\XRR!72>"FS1E3*V'&:R))C)(F EB>?(6S=&\0Y/
M5IT$'OWX<Q9)L=WFBN &W1-B9&KDW<2R,Y400P+[PUE 2JY$Y1BV6D4C4_[\
MGXS*AQKD'OZ;)IP/Y,V%X592#B(V%:J@HVPV4NE(^@$LUS+AG),>]"%47OI,
M(#0/O0ZA@@0.09*_2S^=T!\.<>T^>[>]WV[L=/<;N]N[AL#, -_1O#*-[F:!
MN5#<T"D9J@07?P[$2)M1V 7\#W1^8Q%W"VO$W)4?*<DA[ZD'0H]L M@LO9GZ
M^2PE&P!^^?8.Q57!FS)]+P=K"E\2^E.%J(VA\D)<Y]F[7BIZL)*AZ':)%'>(
M%.%4NL9_W(ET$ #K/J3#^5^4_D5H4,E9ON8.+3%2U!VH:>_9N\Y.XV7W96-G
M=V^9F!A5Z@:>*M+/]][_.C);1V:_163V9GS*.PJ8E2/1A$6)ZH=_G!_W3GN7
M9Q?_%J=GEX??)>W\2X$Q#V3BQ\$<14DN=+I41_2ME!&Z"H8HC.9U=T=K)Z!4
MEB"E\.C[ .\3#(5%(4"R8\UM#>'A?R;\*^'QB OKI+&/HJ2LJ+#&@HL6!AU-
M9:EPBC7I8]<2_I6!UI'!W?0&.X:^\?R-5^*T&,0485!2\.$ UH B]>Q4(E=>
M*2<)G4M66\ZK^^VG!X?]!L[OQ(M!+>CLFE-.7S[3WQ ,/HPJ0V%I \PP8C=/
MR"%V6D1Q#AJ6.#HZ,N=*Z3WDXV*+GRX'D<7+SJT[,M#8L>EZ!VYY=4N\E[Z'
M;M!(53L?2+NAO*BBTZ$P,?QRZ2>K'B%[> &5X/)L454:P9:!ZI6A;H#[ (?J
M7.=<'<&7$U!F]^FMV^V72XD1OU"BMS<!>IHF8H?NL^FA/L883)FH.WS%*1>L
MQVD:,EF+@:W_*3U>[:_=;>/7^IR&(?:V\2^NH^B\-./X%50/6"LJ'TRHHD@\
MAZO:*8CO>('*^ZIE1YYP:453J[O$:Z-2?@LA!5PIYZEE^1FZ@-'%0!)UB-Z-
MH;H"F0'KJ<AN9B9V"6#FC:S>7\&IRVR'E!M$&;P$DV'FTONDS2U*=J#J\TJF
M:FA^R,ELZC&=9?,1A2#I!98%$L,C?"66 ;FUC3</7R"OB"JNJ1A$^02XC7YP
M$*$TD"0;)B ))%.JXQ)<(5&4]BU@E@CZ;N98I8D.0>V,J&#RENCY(*612\)%
MH\SNR51E:+*B4NS1TS"G/[.(6<;*VO(X2@MEU6@>'\\AX9W+Y?5A7W!)?W'6
M1:&<<T?9??B=N:7^S@_XG=H0^[$,L8?/5O@NA<)L<YWW+BY1AWSBJ,+E:1U=
M'IX <;3$P='%81\LRD%#'/YQV/_U\NBW0W'VX<-1__""49C[9Q?G9Q>]RT/Q
M\>RWPXO3WFG_^UB>C[<:!P'&D52<//%YW<47/U9AJ*[)LJ*LRT1R20>FE2"H
M>Q 5;"Q0+3,=5.7$9=#=]&*A?@5FJM%?@);L%=3@3;H)JZVQE$TR4H')9F#6
M@LXR5: T<<!,8 I 2)_QV)Z>29EJ'8[\B7@S*KVH^2#(EW,+C#@,9$:WHL>Z
M] :=ZXW6%RN$ 0^"+%?[W8!2Q7W0!,OC1S7M/_!"QA4K/0,S"K$IP4AZZ12F
M!:HDK#X;4 U.DIFI*R_<7'OEV;LSH('WRHMI?2T-T.SIYP9:FN@;MFG_,Z R
MI#3:'B H;&<F::')&$TPDCHC)T8R#>:L_<*@* L)]'5093&.T4 [![W3\'?"
MKA5\!=V0!I3=Y*4ZM,.9,##0H<[I$^B[3N4$R/8LHH1QIIJAEP0)1Y&6YT0I
M3_(ZT?PP([,<QII\"N#L!$XR+,&/ZBFP"X/M?<DV&3Y/#R7YD&E.>,=0 DEA
M6"5VBB?&RBXR-7\#%8(>G>"?:$-;@\S877CU6G+RSD3IF'/@Z[> @06T.F4/
M1F[;M,2>F<-+A],YS -L$^$LX(80EY!,J%WR/24-QX] P5?W<3;FO?E<8=*1
MS=R@,!V)!GX'; 5\=Y13$%ID5\$H(\\5)3]A!!CUHWE#S!7E.&$];0 F4LR@
M >/J==7Y +BD4UB[<)%'Y>&=UQHQ%,4>S=TFV,$;\$4%RH$Y*,J!2\'<2WD%
MX;_XDR/8N5#!\("YLC$0)RP8TV7H@44XI0?GL1IE?EJ>, U/TR5L%%B9T2>D
M'Z)_'#9-R$^U?P9) @<&<R1Y#=.L>J&7IEG$?(>+SJ%7XK49NBP-Z3 7!BG:
MP53JB.D1?#3,$FNKCB1\9T2B'R:!$ /51*D*E#FG&!+LPMJ(P<>,!!9/69W^
MF)0\EQ./.(XVT-DO6MEB'/'UEY=):.5^'$27^&BU]54]\2]HW^)ZKF I/B]7
M4:S(A88II:F:/6#CF&4S*IX,G[<;<!E6M;.[_<)D7.<)V@_V<;VZN[M_OR6M
M^ZN^<GL<"51;!&PV7^:%^.\Q_5]1[R4T5=9]\8E;,MD?:@J5T.H69;ISHWG_
M8,NXY'OXYEM6-;W2-@YOW<G>I+A_*WMLU.O[1>MK.*5ZD9_BC :8^UC3S".N
M\"48F0P9MQ$$<_AY'E!7N;N0S",?%0[DU[?2*1Y-7_C>.@)"Y[YSL.\8XQ!^
M.Q*.7RSXCKO].-^ &;[-.SL0BN>[^HN/^<7OP+4K+(%N>P>,J^V7\(_=W4>T
M!;XG;]O_[S#2Z6 JXT4HCENBKZ)0+F[F96,B_OTA)>AJMC:?ZS[@]RKBBI69
M=7O;ZS8B,/L[:SBFG:HQ1>HZ]N:O!3:YSL..CSK -= &5LF5W5T2*3^47$GE
M?"HC<=82%P%ZY$>U9#&291VYN+V&8ZHE2ZVQ+$N6G[%F/5Z( :8HJMD\00CV
M6K00T^R^7+<1==N==11WM6BIE9;;'!T;[>E844[TC3T#]2AJ+\DZ"H:RSM%G
M+\E%2[P/O8C,F88XG[8.6K7J852/5^LV(E ]UE =ZN[6JD>M>BQ)F(^AC"(4
M,,=>G,BHEBY%OME?0_]$IY*3:^FR+M)E(^7&+29+;;/4UD)MG_QP]LE'+UZ(
M\Y;X$"3^5*9I4"L.ZQS&7<<Q[=6*0VV6+ =;U#02[UOB)[!.L,BCP56OM7!A
MX=)=MQ&M:22W%BZUUE*1(Y(E7H2I9Z<M\9N:5+0+_4'EREIZ.];1E[KF<N7'
MZ$91K&P<!HI@R%"&:C"J.5>F8B7T:DB!,N@9 T*50 5TY3C#<JOB"\99' 7)
ME&M:LP3AWR2V#C<OJ?%&79B7G1K 9MV01->_WYGYXKT*:6V=6/?9*AUK%HQ&
M88F@'KSW4<ZI5@_ISN]2#WM3\/>&XEA'MRR?4.7Y8]LG,_E]=^KOW@:S"7!?
M"FMNOMWZ<SZ!E8S]\F];]^LU5?CJJ^VO*4M^"&60,5$9-V @XZO EZ_O4!?W
M582P)+*_Q_QWNE8ZF#+YIEX3:LZX]X;'>-]_VC+N!&LZ12^;P.$M6)%[.%H5
M6D!Q;?^]C)MOP=K#=^<7AX.C@\/32\2@>#N,M^CC_9^.#C\L8UO='B_Y2B8J
M3^XA&&<"S^Z^^C(BN=]D2W*:I/0&*[Y+J&^Q&DN"/P;5]C!'Y_DN^&#KKRW<
M0DUYK\-V:W>9DN[SY$TL]Q +3U+X"QLY[G9;.X^JS<"[SQ%@;&1@I_O30(Z!
M/DWWH3/N/I0#C^L#@?%DVMTV(Q%11^I@=OOCXUC-Q <YC#.,.N$+$*Y)99.I
M\\ZU[-!8\TS-,SG/ !<$<^Q/F>:*/5;!)EF8$F;U\7$?$?DU5A-Q0.('V!H,
M. )1_0B!7<4+9J E$#D$?-8O0Q,155J"?9O)D?:.X$\:5LR [0,'72%^-4*\
MI?"*$#\(-B9Q'6AO77Q#S6$UAST!#KOCJ702^+'RI\$\$>\#E4I_FK?#0)3W
M+,9.?/XG[.G UR.P+28+V^]-P^MQP\>)C+"M-:-% J,!3S(&7YQ-X,XPX&9[
M&FPO9ZP=#>&)\':)%Q(P_H$7_^._N]O;6EN&T9$ 0)1)'"""XIVJ*VZL :]X
M5?-DS9-KS9._P365)1I@MX#/.9!1H&+Q&QY)EG4;FF\']MPSC,MG'C-;J)L-
M$S?_OV V0P3( 'F4\%?MCSE;5QZ!"S!^_4R[]F=9XF>A2C[)4*9PYQ+#MMM\
M$G:Z:\EUCV>&GE$GB+X&7N9.@1;?M>! JRW36MY\7WESVP'Z_+0W..C]SVMQ
MT+LX?(&2 13>B(:;I"!1\,"?@V(^\WQJE.7E35X+V-&$$3ZZ0EQ9T]X\B")U
MQ7J D1T8?A37"NZP;56FT@O3J18JA;-<T#T=/7)L!P,O7DM14S-<S7#V@ \F
MH,.>RBQ>Q6F_'7T\7L%I%:HU 61?(TO-^: !E?=G+S*NGVZCR(? JF@"FR;7
M<W7-2L$,5?Q)&'C"]*O*8;+A<H3C';FJ^RA(I)=(<]S;]G7D;GHRG/EX2@#V
M$X3EN*!>Q;424,ND-99))(TBF?>YS(71X/+HA(610@/!]/R;2&LA5,@DQTHH
MG.SS9.%/ R_%%J0@/XCVC !Q_-5PM(.DH@;AM1^M9I^U9Y^!] 9S]&+]I,(1
M=?_KYZUA'58Z/V4->A*J(76ZN0L#)1E\"6]+5)CE'2263NAD3DT*RVREN:BS
M6SR33[S%^OK#'N]0/@19Q+M2G[FUT/B^SG?,3R,7W4EK0([J$P_CNUZ8L#//
M9Z_X803/2+B ?761HW6G7M/V!?OXRL]>TNQAZF\%TMH:,'1-]S7=FQ&^U]3>
M!T,2C,YE^NZ%8^R<E9/X6I+T.J>.[]:IX^N6.OYX*LV%:8@VX 9JM6)3"_CO
M*N"!)D^T97- P<-DZ[P8(#AT>D'VK5LA^(LT\RULBOZ)>X >FIZ0#7'R#V\V
M?]/;>F]R> XXI8#,'_<^V[_/OD!_Z8+><+!UI,,.8 04+MMD(?=U-N^.FX-Z
MX=9'-M[L./)W(.>9U%W'U/)\W0L2&^L)C SZ7@P''AZ"<P4''-ETU)S1&^G6
MF5XJ9IB7- _=["/3?S$82Z%]Q]AK$?0^S'"ZAE?#[W##Q NP<R#()!E14TZG
M426\PZ9!C?(E;+@I&CAIW]D7W0]/1W?S@/0P"\C>Y7,[\<'@Q3ZNU/.P"4?"
M=3H5?P..%4!7(<RR.0^S9$4"B!W4]30(L?NAC4CC:.Z;-)*_Y9[+N):Z1BU=
M:^GJ9KD78PD?;</.+>-VDB#-DCF(E6 8A&@D6HFV0D:I8<HRP^0)HYARI 8E
M1V+;2Y >&+I(N/6HT_'5R 0.0H4+>$,XJG)Q42+FBIAQ@'VJ:@:L&7"-&? @
M;NE4"9N2[(6)$L.8/+_ GS]E\%[1]^8!ID6=4.)544W)N5!G1E \<"U)_YM4
M]=5?J;^R05]Y(+_0WI-TW%1Y8>J3^D<OT5_N8O?M"O-]^J)3E>_\4)?DUR7Y
MJTORS^"_=4Y;9Q.GV]>9@3*Y"]D\VO3V]AYG>CTP2=--G!B:_C)*R"7Y0V%%
M')T>')X?GB):Q)-%@MC;KI$@'CTJ5B-!U.ZCM70?%6MN674[X<QYQ&_P?7E\
M=/J'4X=7JK+C<I@\7.+!$R%&1E2L,_Y.O-B?8G+?/A7(.GGYZUF'5W-'S1WW
MKD@_B].I^EW%GW-.P8AE%@7IHLGHDP'\=\ 10ZZ14?$G"_V ,PP7.M(9AMY0
M<7 1?B.<2W3*(A*FFF,$PXFR$HL-Y#RU=6B$]Z#S:?=K#JLY;*TY["/H\W-1
MQ6=YVH7AL^?.X='>S<F\_?(%/7>E:]5G>8@C5B'"I*0/7T].B>R=5R^WW7&L
M);L]GE;+A>5U+5DM8-97P-REENQNE2]P4D<)PD=37@$<SRA@,-$GR<_HH4Q2
M+D[5BC%RB#=WTGS@V ]'6H;D_KRZ>KSFKJ?(78,LGM!W;:W9$I-=?.S=O\J,
MDHA34Q6>I'"\XZD"FC8F*R)4^R@.KLQU>:5KT3@-:$*)#EBH)JV*S"=TMU-D
M,]<:W5Y+9GN\P[NN/:NER)I(D9/6^U:OQ8SZ'@QA,4@Q:7#-2VYJ"JXIN%Q%
MQB!F"VW&REF 7IJG1MAU<5#-MS\(WWYM<=!7U0:MJ@#BJQ\"3*)'?),S$A9
M+EL]WU<(.EK\WM>7"@G. '8T8UVS,^*ZI9F*R6L=B>U=L9!>;,U9QRE=<JGA
M]]D()I5=NZR#(H8D^H]@:A$"1:)<D-:Y[E0?.8G_<19%5.&3A>21&P=I$S[4
M#!7,)\=3EI,9@R!KHV,8XVAROV #H^*\<0W";H5;M7^O6(4$4V/8C(07%&9=
MLF/T;)VGENJ5;LZ+J%686A2NBRA<+E:\H4A'DSQ(B:4:N;SVC\INV MO&[8Y
MA4 (':.,>$/K/2\&!/,^H5)$BI:QR)#$Q,X8#:?7W%5SU[ISU]?4R2T?T)4E
M<KY]42)]4B@Z>QJZ.5Z.A<%Q?OKOP:$!:M1N.#R>!1(I/8\0C5]:>Y=?OK4*
MS];;-:A:&)^N^*0'P^>W"G_J!3&=M)[^;_B,)R(U"R)V'!+:M%UCBSHI:U%1
MBXJU%A4G2<NDU6)=P$.5\Q4$A2U#)RXAC1:X$UC.,Q7Z%7HX"9"U9)\'K'+:
MKZN<-E!Z_9A53A\1O_2\)3X$B3^5:1I\RS*GL?FH4^E4_*TN=JJ+G587.]G6
M<-N;.-D-+W4RZDDO#)7O^K\V:Y9UW5-=]U37/=5U3[61_=2,[,$<368;S?)2
M\;.:1HF*! 7ES%]<\H0=.740S;K8R#F&GFGM!D]*$2&,*!4BB3J"1"T^L1,'
MT-DG,-W12:5&Y#<KPN^!$A1++^$>A:Y7T'6Q66<BI='WT1&&WH&"I_ 48W2B
M!]_$&)LHQ3O=]+@.)=7GW5HZ+QMW^L*!/,\68K"(TBENBOL]G2R?OW+'Z:70
MV;W/^ZG&9NY1K'&I14/'J7K9Y97^'3-M@:*<[G2XKGJP!)!O.L/MZLYPG;7U
M;M0)_+6D_C$E=5]%E'2?Y#G%_0\G@WLD[G.?-XI9Y-D*)H&?DA-(,&/W"@H<
M<(X^Q2M5EHH_58#=K+P@*N82=ZU'%;\92I. 3*WE$&25A3DF*U_(! S;;<H?
M<(OUZJ3C6J[4<N7[)QU?9.E$@AJXYHF9-?G6Y.MF'!,!PY'"J8):G?TM"$,/
M$PK7G9KK-..:67\09JW3C._4D4!G&T]!U[_5,V.3@D#^568KY,X43#*T"0^E
MO%V3;XB940C?;[,.M2)ODZ(H>W&HX!\C!<0 NT8/7%LG0\%)0YE,E-@H)=D4
M82B\9"ZQ%P VQS.H'V(.LCJB-&23?TR Y)4M$8IYQ87<9!H=)46?TRH=+_F,
MO$1<2QI%,>&2LI\%IT<;(LNA2M8SW:,6K;5H_=8-"$ F?5$2)*$"*%V\?,<\
MR 6> =KKL98,^(#Y5B_K?*L-E'\_9KX5JB;B?4O\)*-(PL<:XNCHZ%OF7$WU
MAYV4J\)/=<95G7&U.N.JX)EN;^*$^Z92H-SD9+-FN>&Y94[6E7A.6_IB(^?Y
M0^30Y=HZ&:&GMH"G3JA[:@EUW3JAKDZH6R\[I/;#?"L_3 Z+_!OZ5:L071U7
M<XZ<#%_$=MGBHV201M'/$^PPQ4,7IPX#5>4F*<,HZNRRT&2OY1_OC>!@"<CQ
M6L)N-B/0L*[ZV8+G)X:AQ5QE%T1P1EU9M.7UA'RM&;-F3#/"WS0J,I>!DZ,2
MXS63V!/'P5@.N.-P8@$<B0$K,)*3$M=U7KUZJ=,F=PHIJ2MXW>1:[N</(7=*
M+PX#N.PE) )B>*(/FEDBPUN9=RU9KT[6K(7-CRML>O-8>N*20(\IM)V4X&![
MYQ>'E+I9>:"[69L1G+*A\-$RC#6,,K]1RY]>-LF2M,9.KGGE$7GEHB,N^B=E
M3&/XB6AX'JLK4'))BXSEE8PR*?R%CUD&.2Q#PK(Y82@5BX=FGC7D[!8S[%42
MM'B.V0T(I";GDEPP-N*X](INU[Q"Z*=?U%Q0<\$:GAA4U3,./INZI#*OG7TX
M^H.8#8D?]4N-OY=0 0^JB'E2?UE%S<N.NMOU&5%SQ]/CCH'TN%*M8)V9^L,<
M9/_\E+4JY I@CF"&>65ISAY#PB6NX!#M[MB]H99E)A%(G[&VBF4M9=YEU@TB
MPWB\[W692VV1U1+D>TF0GUL'NL@E+P= SCX)_&DP\2)Q[%V+@3]5*EQ+)JUI
MN:9EZUUHO:?CY5QABK6O:]?/8\Q>24'8U@4O=<%+S:GKP*GW*7C)4[!1Q<0G
M[U38L@R)FP-2.X4D.71]UY248-6#C *L"LG=-$YRMX:VKTC/IMJ,@N.R&M;>
M2TV,Q6!A3[$V!95Q7:R"2-9V9#MM5[/F:@PO# ./ C/X5^P%2>&1OW5@(' +
M2#T8[D@.6=F7\!:$U>;H"XQD58K%&HC#6EX\+7D!G'G78C%D3>N M.5=#!/O
M@#D_6,X ,4QRTR.6'?.R,. ;&)&/@+CBVDORBBD8I,6ES\NW4"2,[:N=8BZG
M3(RFO/\F<6JSUHCA'K!JH_BN#Y?5A1.^Q,+ 4NE$X=GIN!FK:_CQE:FBL*-]
M>D4AU3,K_8A"35R>]9& J^M([EA5(I;HH\&I?0UDL6!<D=?G9/#I5$YG,K5\
M?N+R^9'UN?O@CFM%KJIB>$7!G>XW!#*9\JT40I-79(18O8K;"Z%^9PI[=7L#
M. 4^G#6$1/D<$*KYLC)6/(@"#>2&+VC@83#U1@SBHYL@P "6JFE3VVT\99[#
M$Z/J)(CS-?#&8R^(^;2:TFK":U46$PI;%OGZO*A5M5H4K+<H>.Q.)L#6Q:9@
M#]A\) S&\!I.>LO;CM1<5W/=6G/=2:R;@IC:TG);D/MC<+C-0=:2_NOOU-^I
MO_,TOO- ?H5.^TE:_C4<1 T'4=%^)X2S6ERTQ+$7)S)JB/-IZZ#U+?$@0OJP
M@P;A_%!C03Q)+(B]W'EGZ["W]UPM]D&P(-QTY-U-G.\/!)*PB?.K80,V!39@
MOUW#!CQZ@E -&U#[M;[8KV6:LC3R"'U#Q]KS"+Z)M3-(Z1BE)$?>>__)@BCR
MIN*\W X'L\6IC*J8&511"XA^*@<*E:+NV*Z!>K]3Z*5W/&B(7O@7&'\S&9OH
M"Y<8*RJ<C606JY&<4$B)ACP*$NDELJH"BW $;)'(V@B(FG.>%N<\IBE2R95Y
MXLPR9P+3=%ZVB\6YQZUS8D$_#")BOB3U)E+,LL3/0I5\DJ'$:.\HSB8%!BQ6
MD0##; O, 0I%D":F8(0PB;E"I1D&"::\X?<+H -!Y&+-K9?[N6:VFMER9D.>
M(K)-,2Q9..Y6IK$!QUW $>+%_I1N/"@>88,Y1F^.I3<N,*5S,!(D.+,N<-Q0
M=Z$S[!ABMOLB[S=G>+&M$3;6L^JJ9JN:K8IL=<;)DM'$<%7CRUB* ?RU&PMN
M_&DQBCWQ/E ZW.]PUC!0MVN=^L##@6'W+Q>$@E@P9[GVMF:Y^B2K66Z]66Z
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M//,ZSWR]=(#:'''-D7,O3B,#:?V3A -[>CB:2'$47<F$4.B%OB5IB./C?D.
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M"M01C6;E0#-J^(S!8;^AV[G 9B8:FE'E8+;GL?J\P$8[?%ILRGH-)&)>T\F
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M]_!83DB:<T6X"C/=Y#9A#R25C8$ERZX"?!W"*%-TC3?</K(QWB'8#JIMS)W
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MHW$"DLJ)E'@7_%UO*)&:'&\T0F<:7F3 5N4KV1O!_2G4-C.:--25UPMFV+I
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MIQ]@)-"C#!\SQ8^3"2LKY+ G9-R0/HE:EI%032O'.S-CCMXU2.H\&3S#6H*
M6W_*V\Q$##C$[1$[P71D'?1K_\T7NH(K:+[/U/.+RQ(I%M["+^+$^"^TT?X;
M/3_]O1/\<^)<Y',[5W-3W\$J:TK^V9M+9Z0$$ON*@2SV\+X$H\8C/TZP6 YD
MFC^5J2!D%.@;Y7*19YX<&7'U!)V^?J[:%-(=EJ!Y_E#=0/ Y#55.OGE%Q=CC
MNO<J2KW_9H(3'Q+=%\*91IQ=R5_D0? >0\**#?,>NN:%!??3+-=\8J)(55$/
M2!V]$HS*FZ6MW&$VAR&3)3'R6D?V@*T.PZN\7:1)!I9[LOSF*4\,\)PPH] \
MS%DG09<[5\\5P>J<@')ZB?B!Z<R"+F)*<(CKI"N4:BRI]'$HDD'L]Q$!!EN!
MPOHX!9NRF623"96+2CT3D'91'U0S9SLT^*31-5=L9%=R/8*^>)%774:'L:I[
MSGSFE.6HM@JXU$]TB@.,XF,2E8G7@N4=1WC'Q2B:NMLR;??,1/I6"*.*56HC
M^#8D'3[H'%@F'E71] N'@U.3"\GL$NU']>N5&<YNH9)(=VHV@,,;SGD0R#HC
MAO7+JWI<ZOWE8Z-E3Y>\49G1!)@Y5895$7!(22%9_(H7OH6Z*LD1] ;9'YJ+
M@C!)C TY#-?GN2Z4,2V+A_-L$P,2U)AD;^G4\-VHG&,L&8'I_8E7 )?P?G](
MQ8%?5,\/R:H>"IT$A!PNP!"TA1?"&D-I#M"4<8 I6!612NJ[$B%BE)8'XY*X
M?$BSW.Y?L"Y;+#R7>=)IVJ2:_4VJN0-41,64SG.A6#03[XXIU0^U3N[XR ^_
MX:.:AU:YX"[<B&\L/D,+]@DG$UG@1\4]>C[I7P7A7NEI@_JF6*[BF'Z4IM'D
M_I-YV%5]47)U.S]O;B(YML]6/* [T@/^\":B</<_7((9M+DE5T2+*K(A-K;7
ME1&D79*=DG18W-2#^G:'-[_#';O#^[S#/X/=C>F5.]_>BGO*'6G/-JI/]9\*
M_;DY"@#]%P>9>4<67@RT-JJ][[SXV.QP/RT;J5>Z+2&C;Y.C]\Z.7? ]JN80
M1K>Q-_W%2>/,<(TJ/;PG2_R#VNN3=L]MVKVNS7!;W_!NX[@VF_US#95;LP=Z
MK7T&_^EN7;E]]D&AB<#YO2&1DZQ.VQK;GW3=GI5SA['79U:GU6DXJ],.R&%[
M[U&Y2@X,:'7:UMB^>^:>6#EW&'O=.W//[%[79CBKTP[(3SL/0^%\ENDC5I]M
MB^4[)Z?NL95Q!['7W6ZSCCY:DDT7"+8TFK["/+,CF0+48LR YZT7KU_"4WO.
M+#50B*U>HS[L4M:(594>G-RS8KW47&[.PZ9Y:N38&1E \VE"RU$O'CZ).<5<
MMA?P7*E=VU#&C3'NHBRW!U"U<*6\' OE_M)D^1WS,AIB0=1^$/%3Z'P0_3C#
M;+T"QF\.)8G8]BND\19:#ZR3U-M'M$G,C:<V0'DB(>5]R%'2R/FIVVRY[6:3
MX,IU+JYKC(G)S9SDR]4/Z^;X,LB>3EL^P[X,>0)U89IFWC'-C35M8YZE]K=*
M[;6OZAW?8;WC6VI]4:?"H(<N\!L7E474,JNR)&B^[3CU&J6S4%$9)#/OJ?PN
MKQ'%$YR7[^3%DW/E0@33"6^DW@(IXN::/=MRI#2NY%$@EI7Y_GGYIM$:)_#J
MTX=B0V4;%ZI::DS 9[)+BJI_(8[U)E2+H[%Q&;-S&;HNU]ST@6@$+*O[[U&-
M#)'=3["V*&;P>]4(#5.ML,M 7C6C*Y0,<6+TU='%%EP"4B@1T]U>"FZS8B1&
MJQMR(67G^&=DG>[QSXLJ([0TS6LD7 G9S2,AR%J,E6B%%Q/:<8PB%E>N%Z,>
MP=GEU5BD$A0@^S1*?%GFM*3,*M^2Q%RUN6WSU2QSQ:;3L1]$230=S^:+LHR6
M5;*:2Q>HEHNZ\LX(W-S!51V8L##++;=;4,UO^B*]%0([8?V 49_S%G.#)>)<
M-%Z?TX)>L$0PI\[$H7VI7'JABH@VR,,_(JK=#D ,=E1S8"J?;Y+S:E1VL)>U
M!CLN+ #1> ;_WSII;C$FJ8G;_GD[)OKJ2JPB?;;ZRK&>50B=9^ &W/+/K:75
M9ANCZEQ4XM%WL&IYI5WMK[6Q/^.N.O!#-%(_5>3$]^V.[\V.GY.:5YOMZ9]8
MR]VY[36Z1GJTU(C=BNF[$^F7'<W#B6!O[]!7!,>?O3E=[XYWFR+IYQKMQ-:6
MVNJM=O6UQ=$K^:#7.EF[XF*;S%#;TJ/FL;[U[^VUN%Z0&FZE] ZD=-=*:2NE
M84+M=@=O>6K##+65T@=C5"](=K92VDKINNS$X4GI5LOM'M>'&6HKI0_&EJY(
MW[42NMX2NKUU"?V0W*S:;.+!"??626NMM.'M\I%3E8CW@.R_=HG#;'*I32ZU
MR:5;(>)7@3E0!&9=E7EEY$0M3AZ-1NOF<2Y.POP_]G3L^'2T[>FH.AT>]TK%
MM.7Y1*^JK#U.O5-XQG!&"H<GS^=;/POZ2:4P;RA+])SAUXO9==3-!%,%8^%@
M8WM$AL\"SQ](#/8I-K>-PB69HF:'99$D*ED77$].PNUG"1R1A)'#\TQ)1O?/
MH>@=;X2=B%5B8Z!QWG72Z=(LRARG7B+F8X_Y,:8*XAP6M"7&CQ#WW0L")U(\
M4OZ2:D5,$/9^/U/8VC)G'M,JJ6_+. I@?.?&"S*"CM?X]>6L20W4C_FPA#>>
M9TE7MU_ U,>&\P6IM"1C%Y-_S?Q>ZCR@QG"Q>W%.).H<K:':S6TQMX0.(;83
MD,T/C*_E?13*=%$$5;T8S!<BHC[UJ^9=+7*#9B2#',2>M4G7+I_#=4=Y[2_*
MZ;ST9E&6)OM45W"^X#RG*MMWY"?8#A>/]K+&&$:&>-[#794#L'R_T$4(4KR[
M>2L)TB$&"QJ=(X [96MM8%<O*376*#]%'#M7[N \CZCI3CKVI) T&#FZ#<VW
MO& )AGTQ@"!P2+EK>]X503:2RI=SE4TF6'RCFOZD?AH4._X #3XP'?\?YN43
M8=\JB7N9CVWV[,%32PT8.)U:207J;,12@ZEG.P 4.@"T; > _>T 4.#*O#9%
M@!H/_!LZ'$D:1]BV2]L2W,J+M:!L-03?@MGZ(!K@W4;5$1D1AH4AU6?%X5_:
MW^M>I[U<! *F'Y;SD-@R.B0EKNQBAY45\+T[:RL>2N4-M8=D_J83M<;L5NS_
MV.G=$3ZM\ CEA.YVO1Y*P.?^B[4\3 XI;G-&^6%1%:58:WHCPHR#'U+E$]^"
M2CVADJV?6KU>X\2!"014DI5SJGP=_H@=Q+"CEVZ_A>^D$L.?6LVV>A@/T9=S
ML*9\['P7>M>R]U?H7 =1'\\="+QTK*R'SU$8W<"4'+3BR0S^CSQ]^-<(7'BP
M6R;D2"I+UX=AP2^*,F#6HZ%_[:/C"BHDU">[,,([>#'\,01!)FL>Z?6@#(ZB
MJ1_YP_FAISAY\!:&V2!]M9:;:D_0^B>H=D=(&LO2<@T\K$941NOEQ<5O>%&0
M&*;T_W?T[1:,8M +/YBWKF9)*B:N%.1YG6?Q5>JQMWY$M;Z)#YYIZ1UXFOZG
MA:>URP> C"4ZW'!L1QE8";)^,!;<I%(7Z<+JQ4WTF0,W\"/,&:S9<921CWP.
M^@[<83 XTID<RW+ZUCF]AJP>HI C&()OLRGX3LY$".J-JEV^#^_/93UW>!W)
MUH*"JE4QFJ<*3PV/3C>4Q"?S[JP8?HE0':'H'01^B"MEN0SL-TU4RT@IL/_=
MN&K@TUG@I1$X8 P0X06J/C;ZKA_#YHX)Z+=IA.6Y/A?/3T3,X28O3D'J)V-_
MRI6L\OW2V*-A\(T)'*!!ZIPG0"QYJ!)[)+9])&[N<R)\[&/J:0$M6Q/."T+\
M]!,PZW7L@Y3[-$'@@51)NXJ&V793-[*I]]K3;<X(]>0,5&>,>9W,-)=CY)%/
MGSXY6A*E,8H+E!"_SKP@&H%J9+GG$6(%^H$3, D)5B 6DMN45,)>D1,_2?3%
M21]L[^]'J&2SZS&8T3=X+3(4Z)NR@B<1%0Y8H)*&O_>-2,%CK[Z86.&JZ='"
MDG\);<;@LA61Q\(+TO%,0QHD8]!$SMB[01*QZ81;(#S$PH M)1M'6NF(FJ#<
M_TH_1;HE9-E/M%OBPL_#//Q&1QW>>(V &O@$''/\4;7\Q0$_O_]J:B79!)G#
MB/#$109:3I1\%;J*& *3I=PC68PPWJ 5'C9/QB'XW@*=-@)EV)<H])=0;>G2
MYLM&LV&"-KD=^[ ;MTBQ5$9P\[;Q>00HOP6Y%4623[SO0D6,U(V(O@G3NYS&
M7IC@RPE@!6^CXFO@L/_U&)R$;EY\@LFAUK37XU1I%FT.@=$S2!G*8Q!'B.,3
M3?R!<Q,!CU #:'GO-@K80P6V(<B6+%9H'X9;ZR=QIB%8<#[P%[[<B1@XBESB
M&2*OP(1"L+ZB^'OB##/RT?.8F3^DRT1Y*J@#-=EY9DB=KL$2I.D 1#*^+X'=
M"T2<@P\EVHW.DC2:2/"J2SYU!O$O!3@3S/?OLB#-$& (/VR 047W@*ONO8<1
M!%\:<?$TB@GEA-,XZ(8&)W1&;8AQ'V2V1WZW%^"9' 6\6!T>5+)!.F*Y!'!2
MX4VD -Y1O]WM73=_\,,\!X:OMPH7FGSY8+96IYO!B6IX3,=MP76,V=C=NP;>
M2=*YRTG=DI["2>1DQ CK0UW5U0EV#6/=-42K]'=ERV?0&-<ZEJ3;QL/^^T$D
M>] 7;X?T#5"A%[M/)RZ_;S)O3I,[KDX;SA?^T,T)./9T4-HDCCR-R&J$U43G
M-H]*![-\8*&AMPJW])77Y9J?26,.Q00F3?%MZ@<.9XEW ]MI"V_(/H\3@@+%
M7N]R/D49!4J53WZJ&HM[ S!H*4@FY:&2E+I_^RH"/**K[9F6*Q2+Q-G!@M!V
M5K?\!,\$XBEGO!QM2!YW_#5_314O2G GYG,%"J7YUP#ZDSAZBKXPE:I\#()#
MPV0,F36C+N40%XI\ 6J<7A=1<0_MO"+LD7$W_AYT8$)'9!7$HXTOW2(<[07"
M$?9@WG7]R--&.&I;C)M[8MR0'%L3V.;1]M=B)CTY?M(H6>?2M:@/-UEIL5EI
M<0GV8"UVMT;5I@>#"7#80%M/HXRPWGA+^\41-2U&/ENWP=8V]_\@ "-.=BD+
M3A;QP?%IQP62U(85:JO #P8NXB"AUYZ&WJXW M=^<41=]?9QHU>;_;=Z>V=Z
MN]WJN)W>:6U8H;9Z^V <[X,$XWLB>KO6F&S[Q1%6;UN]76>]W6R[K=-.;5BA
MMGK[8/SM@X-G?!HZ>UVH/:NS]T]G=QJMVNR_U=D[T]FMX[/ZZ^P:8H"5AKD/
M]-#OV WW&W;#O?AO1C5I(>8K8 ;L):;9>I-:]37>4!HZ)N>F8S_>1G=CH!GF
M[(*Y)3BO73!A?4U8K-U:T/>8&ZS.]3ZF\X()OWYL5#@86>>Z-)8J84625TD8
M,&0(YK&TCW)5:^0;2K/E5&M<?2RHHA5)DL58/9LTG'_?M59:Q\2;.7W!]"'D
M%)B8$TTYT1UK  A\!%.H:?+R503VE9@ $+B\V!_D[^"OT RST,?**R,56[9L
M+[V-TM_YX>DTQGH:6A())%C0A?EM)YU-T4"'_<'=RMO"I[(V((9/$BP%R["6
M;T$NNBQBAK'S[3:2\D=^G*3.?S,O1H"L0EOE:Z C9WO+=^A" IC(#RPUI4;L
M<XV9RR!7\+,?\2;.T\<D3#Y!M5=B-&).4ZA_?'BHVE\7"0P]/!\2*(:XP0O#
M"//Y%8_E)02$-J4>5#4$*LT^1SO@%LL&)IA%GRJ@3[4M^M0309_:H.*2T*A2
M($]R62F/LE1 N0!!J664PBQO\9[IVM)[M!)? 1#4#V7=Y'^RX74.HY-ZWR60
M0T18>+A"JO4Q43=I1BG7YTSFFI1/L3R:*K149>'=A6*5CZU3@I77((5"EAFE
M*<Z)_@[*$HN$4B_@JAUM.G M;PA_2+$*B<JO\K6)\,:/(U;-M^/(&< WL227
MJQG]B00@(@+I:E%9'BJAALK88N(''B%!5<Q2MZ/F_B!%+J*NP &@=1+3)$NK
M(Q%5-(<ZA=EG2;&0LTKK%@R9>4.%R__8CHERV!C3?JE-B=.&3K.&E%N"6NG<
M JVU'BY:,4A'+M$&8K$]B=].IH$O*U#!/. *5*PY#V8:&V5^JXKFF"PO4_(%
MT07\;(+Z>##W7?E',(=:K2;5P(X\L%/E 97SX_?1.L!02)F34Z#B$1R&M-*L
M(UNNX7PALQ"YPP#]1';6-<DY #0>%J0 U1F'%<"<,$DR7V!@;:MCB>= ^&32
M.0G84XBGP#0$,O#\)1#HNXLO.;S,W9.G19J2ATE=>'(IW0G[SYL(M0%'51O
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M5]ED@O0MY!-^R_N!X-8/?2 G)H/FB:OSRRV]V4^XJ\CBWF__QPK@'0O@MA7
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M,?>A5U7KM3]V!?7L$(-8I%Z\)H#MOAH4]NHCO^IMVZL/4R*<==WCLQ-+#Z5
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MG3VW<[9C06J-SL<2I0MP7&VPTTHV:Z)NVD0]=D_.#LI@.U@3=1$>=)TCG0]
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M .&6%+P.:>* OS(D6#1R&W(*SONF68@Z0ZL&*?;&(A@J,%8E8,E^]>B5"Y"
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M4_V-A(--?CIS3]?%;=U?&Z'=[KK-UN(^L7^#?_O1< ;\G7K]0+SYV]]>TP]
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MOYRMAQ.=1G'*[_SC_.K]^?_@#-Z+@:!)D^7>;'?@Y< YO/XI3&) QTG\$/'
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MW&$9#/ZE,S ?+.%Y8'0'[-J)#HI[9QUN\;[1-71G3*-[L +7AC$]')/SXZ"
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M,8Q&-\%$BC02?TBF?=R[9X-"1H[5:$Y)U< C/:./%1;B<-N>&QW1K7_G*-;
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MUD?XJ>=%FS0QQS=E<:@3%DL3A7>Y0PP?3#.9NDO;'/KFHQXI;\;F*S!WV#E
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M60<8;'A[4KM?H99718F59MX;]Q^!9KFK@S:IW;+;VA_U]O^>%%],[74B!_[
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MUD']?@3(P\,#/0:5Y..31!V7/8[Z/^?H)4"(&T %4$% )0"'$! D!#SJ!"@
M $ P\-\!_$> '"!.,!>$FX?WV*^!!D$ !Q $XN $@<&<G+^ZT;_Z $XAL/!Q
M;3,N$><K$"6R*.I&>A&WLOG3#C&7@6T8VI,2Q\,K+B$I):VBJJ:N =?1U3NI
M;V!H<<;2RMK&]JPK!HMS.^^.)WAY^_A>)?H%AX2&A4=$4O^.3[AYZY_$I(S,
MK.R[]W+NYQ:7/'I<6E9>45GWK+[A.;VQJ?G5Z\XN!K.[IW=P:'AD=&Q\8G)N
M?F%Q:7EE]=/:EYW=/=;^UV_L@]\N(  $_,_\CRZA7RX.3DX0)^2W"\@1_GM
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M;4T%%Q4JM78NF%4\3=MXQ,Y.+_35LH/3\Q73%N]GIZK-M+Q3V(SU<5<:J4;
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M$S\$_QB?RL'(X,:A>,=EA>"/@DO]R7 =J.92*0_)83+.VIVF,$IT"$=YGL&
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M9](3SY33$ZP3UA$'UYE/NM,8Q*+BRGQO!<R3-W3X-P2@?/_  "C?;P HCQJ
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MLR^[^)^^1+*:SO)R#O,2#/]4/O>:S<OJF> NAS3AV>^*\II*0YUV5OK!DNK
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M\S6$XW[=E9LD5Z@:C+EIH(I"Z]?H9*2)!X&YK_@0M#6TUQ-,0$OT#GZI^[
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MK[RAAKVWNN6!*)KV'@NI45ZF_0U02P,$%     @ #$::6 &0F*EG!   CA0
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M9&.-),R1WRT70M$R1X 4__(<\C]02P,$%     @ #$::6(4;7G#S"P  > P
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M)]9HX:MZ3^K1MGM%)L?O_PY02P,$%     @ #$::6-TPCT Z20  !$P   H
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MZ/T<T;JZ1$W)6L\[;K52 &D)+(^@"/HB8*4-''$[3NIG)494==WB^>C0;)K
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M0N"[J%,_2"Z> /AGK"":[#'N+R;LB@=\);,_+#_MTQQ??5WOWDT^/3U6$'*
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M+7]W)CK\6= F"2[@I;]HTF2LF]U2!)_"XHN(#3ZL2IK,V\GH1&S;2%^/T,6
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MLK>J'M+1B/GH<,Z,?#OLF)V&:H*K!$%D;X"NW?]_G?__&K]/_AM02P,$%
M  @ #$::6,P(" J&J@  + T!  H   !G<F%P:#(N:G!G[+T'6)--TS!ZAPZ"
M* )6!!%0Z0%"%1"1)B(U5 $IH4/H32%V! 0$I LH74(1D"(M-D2Z= $%:0E%
M1!.*P9"<F^CS/#[E?;_W_.<]_W_.=;%>.]F=G=F9G9V]=^\A62GO*!^!76<U
M=30!" T$(@H1!0#*Y&Y&C6!7)P#0TP.$ 0!@ A@A'  M6(* _P#( 8">6@8
M>\C!W\MND.,_:6A  -V"P"$P^T*DJ&5.,,=&N )T/^GSP/P6$'O]# ".[?KM
M4\T1:8_@,W!!^B/]7)#>?.K&4GQFKEZ.R" _0$I22D914D91"L8'A2E**BC"
MH& 7 .T#R!^Z/:#YK7\:\P>TOY4AYL"/Q "A_4G+\.LX((?_& =$Z-=QT$!^
M[T.<YO>^V7M_]J?]<RS43\JOMMS"@5C*$L!*'9.MNAY(\1G82:T!CE>H'&/
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M?Y1%J30_RJ>VRHZ>7HY@>4MG;T=/QZWR*[!\.S!@ZZ(SVG-@^5:@*R((+ ^
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M-S+A<PCP#?S11KWYCQY@ =@!3F _<!@X"AP'Q  I0 Y0 DX!&L!90!\P 2P
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MZ5#NH<Y#JSR'>;1XO'G2>%[R?#K,??C48;?#]PXW'Y[GW<.KPNO*>X\7P[O
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MRKH<ETMT(Q#27W;:U-Y+FO&T;3^0?)OPA'OC?L?)^ MA]DRFFAKF>>?M'[#
M3<;P_61? L&YN]F>-$9Z--R8/RLA2@X*MPI9UL3GQR6=J\6/NBF&YWWN6ZBH
M$)$KJ.E5?M'KLFNGK8>AV=R7O\8X;"E]?W^W:4:0%D&[.^ GL+C[C=>)I04A
MT4:D>M(,J=29 M"%V\V?8/U\MZ-CH*KY29TQSV!5A+>#H![/,Y\W@V8/7,:U
M" L+O8MD#U)/X@5,?PFNIE<F4_K<@?-QG,,L7&5E'BV#G;5&19RGU@]Q<D]=
MC>-#8WO:,<072[9XDW!'"M#^E+0^M!*)DJEN:VS%[LC(9-=N3&#31!G?&W)R
MN1V5]7!JGR1O&-PI' GJ>!I?GM'80%04(H17(XBYQ+U2MB%["#$<0]8FX\D<
M%]I0K/'[Q!WJ[_JE2SW@T.>HEB]V92=-PS"I%$".5$C\0'R)G28FX7@[T*YB
M&+$G#6$*,C%[-4.>K2YS=.H'" Q+[6)_)#IK&OV<L^B(63490;8B:A&"WF0Y
MD>H(V.3ZUJ23(XYKEDV1]C'/B^!3=[T2-#\JRG\PIX&:==3'D28_EV(EVF-X
MR3Z$+MO,].Y:XOZ\,*,^?8F"-'?W<MOY Y?CVYSSQQ<-GYK>DN:XUFO9*G(<
M:!M(LD!EHG"<)Q]ALSOUB:W9*G,;LSV)8BC<@:GTB3?A!OV>8NG/'];%'A>(
M0AGX3<^]*'K(-+U6?%[XZ_+&,>1='"F!U$I*'KB\638Q&K+<74C8H4?0?^C.
MMA93GAY.?G>FN"R#Z^/85R?(5;Z;MM;A-B&TG>'6;R>K2*V$I5;L1"KW\8LI
MU@,RW]V9Y*W0PC*FDH08@7!X$I';[^-#$^$,LAV1E^1'1&'C.K[KZ9.D$=A2
MX66-QN::FECGJ+Z-O=?L6+W@7-\4IK3Y>.9\S#H4G4D?:^/!0PF.JYJ=^"K3
MN2N]##,C*ZTWNQEH+C8Y*/,]3<+64.?E:V6%<T$[M>GIS295Y(L+,S&XW2<G
MP87,J#I3GH7!\9,Z2L;KYP,KB,T\BD-#<A5]>3N3UT/]?3F?2@-T/0+5OL6N
MI^!)ZN:H[MTCYHL3A(31.M+ 8'XMZ":9^*;"%'"J_#NXW(5JJ]RYGS[QAW#N
MR[LK<%KRT9NPLJ-<82>(@D0+9^(Q(GRFO#U3R>(I@2%MQAU2,%]?.N/3XB/*
M]*EW [V+N0U>-P"Q-"L3)@X3KI.]:_H)*,)1@G1/?0JVIB'?(AP1;JU+O.0S
MF[HDYN707SKK,N/ZR3FKE*4Q7J3C /TJN[C^:0".9B>^Z#@.'J!QG*N7ECN7
MC+Z;@$KJ]V7HXDLB"RW5=^8E:'!59=0]=[)]?SK^2IR!FGU+K' +/_AX"@DY
M2#:IQ;+/?)C ,C2$[+W?N QNXWNU"':UU5'K&@2FAWNY.PX4*WIH,4Q$2[(*
M,\$7;)/!YTVTG(T>:6,(A>-O["*6HD.F>[+L\:7E2=4=SOTE_ILJYJ7)D$4!
M272CXQ/(%0Y/8Z-WZ#%5>0H@KCKK1;8,:<5W>P8BQ>>;@_L^/_%T-JJYIO"9
MNQLO=,N.Z=X7,^$Q*$/6/O0.T@/2[3C\)?SI'KS<64+ >$7.W(8U-OZ!>VWR
M8\'91KE;3F+"K=JSCJZ1O"S7 ,96KLNSLRCB>FT2Z=%L.7B>$G&E .D'2.DH
MTG1$1OG)Z1FB8%6%U ?K\0^MP5]M)$\=@/E?E+\IXX5A:K%9)X+VDY\N##]'
MM@L/#K<S#VDP(-#C<&7U61<)#"E!2#J#D0]: I^BW7H!$DVW281 .JWE,)>=
M[3T,(5**?#8$US,:=Q<C&] D@2\G,':*84MU\4D>2W56;KZ2(2KH1PE.L<PL
M-X-?P.\*$_+=T+:)O%M\&L2,[LB9N*X8MV%\1/=A^Y0N6WQ15^;CV!Z#M*3\
M6+;S!78>)"[+7=<3BA_Y??6%KW:5I12^JU).SO9TZ99O4&/1U/XB>*K%5G0.
M18AZZY)-2&RVVPJQV'8>_%XN1\S6T!=?R+*]M /1C])\+79-X!0OW)$7KM[Y
M=!S#Q@8UJ<(ODWWX]=M1G<N=V;+AMN$>B^'6I ;2T+#JJW$/$CJJ>R37VJ16
M 5$U$+E:.IU6$\\E;#:)/9XGC)< 9[.G_M/E27:LT7AXH#L%L"(L8V-2L#')
M#WT*+"[T. 0Y"FI_RDMZI^-'Y]/Q0E \<A_-[7#AX@TE\)P7,V3)2)I)24?A
M!/4S86SJG39(?%/MO55]<1UWC^33?>^L.!/D-#B869.?MY6J\#^A247W8A10
M8HPXQMGL^RC18\-.>&P:+E,<ISE4+>)RM*[.2JEN],0-?N/G%] >KV GH6;M
M*J ELB^'6Q/1>%K\.I[7BA#^^"4^816I*J8*_?2QMGK8O[[;.8FNF-5+0"AB
MDA=Q<.FX//KXUI%&?:@$](85B1[D\? @=Q53TJN4#NYQ(U+/  70L+#1P$:+
M&$3SO/IR%LY7OX,C_*NZF*'V*04&.&$YN_$A3@%<B3/9*7N(NH:#3W3#1/!&
M832JG2(?Q*UMVF!'E5?:Z#_UA1JVB;PZ<X,Y/K*P!<.!'FU\"@KDF8D3#)'
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M'(U[;E6XIC.RO)]S#*NC>A:W2ZJ9XWRNO'OP0++.=Y#G!=%AMIX,^FH5QWO
M)"$;M#%2-G-1ZO/2W$M(:PX<\*"5]C0F!;NF%>??%PU/WX(BA-6&<A8ASK!X
MGMT<NX!N,W'=[DOAY%!(\<@$&RN.5IRTZ=ZG!*T>W?3][S?(?7,:U_(^E%I)
MD&*SN P@1C4EF^<!XCB6'-U!"_8L#JGDH1J<58YG3 TJO3]V V_2-7NQ(,)+
MW!$G]?C@@6];ZN"K!*R2&]\72"*Z]E67YVSCV7 *T#B_$?.:'G<9'U^.3.,K
MJ2!UJ9-QHJDN;./7H_M?YIJ\(IYG ZR-,0#$<A!E)'6,!"K:3>5RD$G#U85I
M]-09D9!HJM!P'1ER3=>$#7KA3XR?IF\4"OP,VO-AYX+&U>39%6P+"-8<X(B2
MY ('P2K7(@,&XA3H2E$.+K"83U1L?S=ZP%K-+OIRUM-?)(3'6K@:=F^(&=Q0
M<!#T 6- (V?P(T/-:01K,^Q<D9CA\N;=M]9MRI@XC[UF5AM,@]-][.>,:4*!
M21"1F@-S0!"2B@(]F4@J4@9#U>.6OR]STT.]YJ:S]WSY-KE3QRV[Y?N<U93?
MZ18)S/$$W3>6M2X/7+::"MU )T*&"4^DQ\,Y4387N-F<"J8 +O IP]J571@X
MQARVL)8=&65NO[M&8;>962U-3OM49>43:5WM(Y9/U.1,7,%!2/!F\".HDL:[
MR+LR;(7QNP:I.X0[SPFFQKL%TD4SM#/,)EY/BKW\$/Q(EYQYYLT[D[WQR93K
MB9Z2V1R>/_86UA@R/Q1H#($HJHU#":<S FQEJ*2@V=1.FLG._I&)@8XG5?+F
M: W[=R<_O;C088W:K_-Y+J@ ]9)GA<6 -6P.>['5%^#$6F3C?< LEHP7NIC]
M!G1O<@(,G)>NQ$^[?RI.L(U#=D6G;WDJDON+L+\M,4>V;'G:J!4]"ARW'$0/
M3UKHNF#1%1]274\<--J4B"@0##.W.VBV6^WT<#G91@#2L2/XD1D)MD2"S;,G
ML>Z8=PU&/8I4^9&IK6=2LC*R"G99N"CM?:^52JA)U!9YV#CC-R@40,('+C.0
M%,3)*;%[G";BWD>,H/5'@XRNOY0S6W&^MBG^R69I]N7<M!V9ML2MO226'.E(
M*5(*I'74WZ#-SLLHL<<ZGHX3U2_XY%@=B$"8QE5J'IR[^&;/P;CUMPQU SU1
M3A!/!,0=V'BF8U).GX^:\B ;9Q5*2;W;A9BO(5B;J.E.=ZM(W;MMKQEO4N,L
MJ-$8:--[EK 7FIR[7#8'S\QA"7 9R.C UH.GOL!C;6R[2F<EWO7)V ,'18*3
M*_9H8\P/JAS-11W:\L :"L^16%>L/]8>BP8Z#;&7L.86(*&%[81/4@X>+D\?
M/_#C>'FOFS?!WK8ZUJ*DL[A5M>CLL=<A!?.:,C6CQ&P(UP)*@3'@@?$@;6A!
M[&;/&K!#HA1V3B9F924OTDV7VA^>&#&;[AJ^4B,9G[7F2)WG]4>K^;+[W%KV
M=%;A2);ZJQR3WGD#88I)GOUAG&EO8,.FU'<THPWA\J6.,=SS6I)6N60S8&7[
M[+AWJD$7=\J>*96B1;.NX&QO2DD?M-#UT4*?;.J>RN\K$"28']G]*3&E\FXN
MV8*&9)U"'E$X@*34+$>>'J%;\FZ#_LOM=-S6'&<_6O3D=W\?4I_[[I$3-YVW
MM<5F:FKL/I\MN0@<QY3H<EBQM64LZ\WN,5H<FR2W_ F=((]CA2T5-1'VSPS6
MI:EZD(-1P1?(YF?^'O;S)!*08X\(0+L\KP#U22/M'Z!@ HT#/" B: +O^T'H
M";WP.X$F2G,;N5GO5;E]U?E#5JMG930M*2-^W=2L(*>5N)=7]/:O9 8]F=!'
M/7!")_)LV;($^W$J5<7,NR:I=3T)!YPN%'X>D9\((YQ#SDJSJLL$O^?XH+4S
M"/G5.]L^"=YPV:2VZ>A?"?K/*7+W\G=HR5"I';/@6S!P&22!IF "8[8#H>@<
MGXKBD*E)W*Y7:%?<7<V=E6O"G#R/");:CD:0^G^XZJ.$5S,]1CD#8*1.L4AA
M'K>\"ZDRBU23]N8)+%"[_<YH"797]O3LU+S;=%/B"/EB<U/9;=1\#IX/DW'G
MPTYQNQB7%\)7R;!,J3G.C(/ =9]1LIC)<3Q2GK!^\&MVYT<^#&NG>%JWN.])
M@:@IE:<+68U^'[<0G' &<9ZL1QC&\)Y.=0RG' \[S8NJJ^34[CU5G^+?N&ZI
M[FF9G>CF<;7#Y'O0W' 9%=RQ4!; FB$R98Y2L*[L.APCO@QTRP6Q/9<^J)>M
M[Q6[E<J6>N*1%6"&G]KE?]5?MXAK*]V]:?A',HK)L_WM?.9'C@8X^7VJ71W5
M,\-= -=D80TI;H(5T=K.0;;?:G%O.ZH3#JON6Y_F'GH;I=U)YP0CDXR;F15L
M; 4C8#"RW0-LGH*WTA7)!*L1RZSG&5F:@E=<]KIM+\TV<[C<<N*SN4B$B9 5
MZKM#*"AUC,8=X\->\&'' S\RM^M=KF5W!K]RKN#=8,>GG\'?E2V]%1(],+Q^
MMV3)N^U;YA7.$IA FP?8"'0B6]"20*>V!N@*IKL!+%(G7-':Q>8*3;45 V!<
ML\R&3ES%^,&S+8)T+KA?"\(=/G>[5+(^&!J>![>2V\LM9ZM!4%*A3.#XY$[G
M*=&<N-+(XQ]'!B8F7(121RU+\O0\56E*QBVS"A&'F4:2=V509L@D$FO? ET%
ML[%C<R$FNQ?KBJEHA]AMF8S#\+%(74NTC,M5FPFL3=@1_?";@E<%U09,,6T?
M*FV)E[AIW!>5; &&7TI@*-&U(\^:=V.JWI56AG';&H0VXL,$;:RLZK(B<R6/
M5IC?7_>@M0JYJ^V!:6/J):BW^[B#W;,DUL%2 <6I$9.85O0+GA6T9F47W&0G
M.?.I.7;,LGBI@,I/\;3N$+.QEWLUCL+:G!I/C1)6-TG7\F&GRV;!IFDCGB>]
M4QB)\_?APV(+XBEL*B?I<DFJ@?N2BLH"Z77D59U#1OE-6??TBRE*:DG3:UM-
MRWBWL9#\SO,\+-8,B_IB@ZUE2\1S)\8!).C1J=SSA4,?^FB=?3_Z:25%IM9H
MTEKA?GYLYHTK)7WIICCP$>]. $?%@DUG%H7#$P/+UC<S);CCXLB4,S'RUK'E
M;YX;79GHOB926H8ZV-Q0188B[1F@<S/6<7(*Q#/5CG;4FX=V*N>PLD@L/\8(
MWK_B]$2D^*Z.M<[*Q?-ZP4X,'ON8"_QCMN0RM96G3_.>I00!FO5L4JQJ$A,N
MKQ&DV/2(<79 37(K@>*YRUEVVTZUAI(MM4V"$C>;/^>AYH2A-?(9SO1X40"P
M=K@Y<+3CRX0A3=] JQ2]Z5(<LC/AP_9*YPE\H%P,0I[7,671RB673'F>:)XG
MQY@; Y5T[P(.UZX$9&/2^B/<!U$U/8\IKG[.!2-60V\\$U"T3U5R4=,6LV&U
MRSS/03:<4\+S#&T361RGQGC4$ED(RN,^]P4X!5":$O;SK8Z/<,V]W-WA&I1#
M=A7W<Y @9&BK!E+$+FR0C.9Y )U2V)L\6Z!3]PL^Y6T@CHF4^L*[B&^IX!G0
M4MDG%=?5R+?*?+[GQKR\7_RE($S.1G';]A/YCF -Y*O>@GB0G(FUPBQ;<7P?
M90/03!J!(QYG,5L"S%@QE'#G*<V&2\FUKEX3.MM+ YFC5GH=<?<J=A*.])!8
M8JIT%AULG94%.O6Q'KS0KG%N*7OY"S*.CAL0[:T.NZ V0%GHT%U:<@TP=*>;
M>3]7" L[6^RN(:1/8B$@8W5'LL1K*])!LPE_-7)Y;&+P2 IS\\R,PHJC5E^8
MYA*$1 VJ'Y[$/50F]1WQR0QO?KHC_R(Q;=Y-N$-$@%$?SJ!$&"*4, V7W\MX
M#PY[7/$KC[Q2%_+Q<#S3!!6'Z[UC]=60#S.4!%78PKP[@T9L(N3R8I$L.!^F
MHHE/3F-K%0)Y$P,YN 498X/G?K55E94F7NOBW^1=N',ES\'8T-K3]#7/AV>"
MF80F:-:$FP=-:6!?*?T8)GJ[,D6/79Y15$I[,?AQ4$\X;W^J?77LY9L7\^2E
MWI3M"SQ_"C5W'%I99X^"502,'6>Y[201@]1_P^WG4MBSS W!]W BSZ9O5SMN
M=B^4V/W..E)A](VP@S_.7[381(^%!]^2VI%G!H'.R_2WS(@-/9;<+FX+1,C1
M+V129@Q*A6UL''YI,/84D-W3U.CU1$Q&X^+Z+<1T:"&+(8\!<DC9U67".H8\
MS5V0O5^,O3?EKU68.6$AT]'18RZ;<JNO0W!6K79-N/!D1IEOX2\%*NT0;(]
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M+T9I8V+0V*IG^A2SHQ:#/O]X"T&X^%E>U@_DQ&$(PCU;0*SM&%.U&YH%K2J
M!03TLXX %.GM/F&(SWX#I7\LO(KW(KT@P =III<$ 3XDM^LWP#<#(3Y+TA(.
M\JN9H1#BDX,07[,:M0< ?R6>T6-23V!O#.G9QF^@6E<\O2I^^NZ&+I',%R>3
MA<MW?NJ(7,J911CTRX\^AI24OICM.0/^)"$2PH=UZDYV?0&B\ DBI:\5VWV5
M;T1]NBCTTG]NRR^^HEYN_5=':;9B0/JOT_(6SGB)T69ND3625R ,L)61$ZF%
MG\06(^9"5_L^05^X6<.'14'A7#]P[4C]*:COUBJ\ J7?2D;>#Z U[8"P*B4'
M^! RR]/67I'[)N#_XRV=7>4]N_0:HNTM7_BP; %*ZL+<HWE'WAV5SKT\MQY
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M*C IK/QD!5>ZUWHB-?]M,N2Q*F2%:UBKM12:18672<W&"%^_3HYB9E3M![;
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M)C\E/F>4D)4_1>LJE)#?D)4=?O_[J]I_WW/Y[RGK_P>B*9/_"U!+ P04
M"  ,1II8/'I-]Z7"  #1+0$ "@   &=R87!H,RYJ<&?LO7=85$G3.'K(.0L2
M!8DJ<<A!&)$L BH91(1A@&& 08:,@&&%%00$) NHY"Q90!@5!)6<DXA*SDIT
M"#/W,+JNN^^^W_?>WWWO?>X?M'9-=75U5W5UG:;/TWVZ\</XCP#C.6T];8"(
MF(A(C$@, /"?N+]H^2$< <#  #@%   E0$'$#)" &!'X#R#B!,@(. #8$W']
MQ%V(3OS@(08!Y  "W&#T))(FX$? &!6& $A_\&>!L1L0;WD! "*,?_RJ.Z#L
MX7P7G%%>*+0SRH-/PUB:SQSA[H#R10/24M*RRE*RRM)R?! Y92EY96D(6 5
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M*/6J\OTL&UPNSBF;@VUC^=- !3Q>?B_0K;I-K6M^,C@..]%]:H37VI.GS]#
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M!PTC>3/?'F5>2.*Z("DR.#976Z]3A^E5Z*_!UF%>\5L/*1O(4R^_@UW1;^;
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M@G.;&%P\.VH"LZ$6/SB\J*J !VZ!;ZUSL7H&[JEQ[N9&K6]K'R>,6U_9JO$
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M[,=<?"M&#+O@/M"!=_M"(84[@6\%<],JGGCWNN<4?7R/7"Y?6^[<M-J^LEL
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MI$2^ZT,-_+'F1DPHN?EC/5+2T1',<04A^8]2WRF/DU-^4J0)T.I@/?0'18X
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MJ $&X C  1P#!( 3@#@@#2@ *L 90 LX!Q@!)H E< 6  <Z &^ )^ +7@9M
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M>O1CR?SN2UZ&<NI8+MIZ!8.,9O890]T1E8!@:KF1KQX<+R@YCZ$L>KU7)77
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M)]A<7>:!XV?6C9NUVW7BYC-RU]@[)5BNOYU>":"8[9I.G('&/V\%_:]CME3
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MSU S9Y2H<@Z)F2L5]L]'@.2ZUF>W[_W57HN=( KH>2C]R=E@#YWUK3L6@3^
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MC= P?T<K%TDLOR'W^K7FJC^EO[/DSDIO<T6C_-9JY?;IZ*_!+;81\2)Y*>Q
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MCJ*>LE>33;2,?J6%ATUYJ(7RETUQ,GN+[7W[/BPF5Y8Y=V %CR5TT#\\NYA
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MUXOCN/=%CSXLPUF*"IL4EM_%TUB.34/++(?/D=J[-"U?.K*&/ DESHWE \F
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MEJU_]NZ)DEGW_)"M>XFK*(BU8\,XSDC&'.$([(\%S5DY9YL$B53!S1Y_E-%
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MV[2*9)?+7!M;GF,\T62SD#^ O7\FI=MBDN(.V67,2H7P62E<D@I.T:K?HUJ
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M]EUOM$@/7ROF[:?^_]055V K __7"XCT(/Z.1@8%ER4.H@,[NSBDT0RH%@P
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M5K=#I92MOL)=;@US"B!59D^N_Z;])?OO8/?^+]F_8/]V?0"X6$&_GL<* _2
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MTV9NE-Z:0SPRK)V..WS_=U!+ P04    "  ,1II8CN+R5;(+   ]#   "@
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MR:3E"R:W;:[3S,0D\*U"(4?8" J@75D1*,9HK:W6!R_TM!I*GNRM&6;KYI1
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M""AG(4./8U0HP.[84$K[KM+KLO-,$W'#@& .PNSB()@R_C=02P,$%     @
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M#H[S*A(B$BK_9]'> =S,0"00"09) G3<(# WB-8+B $ B 'TCX#_$(@.3,_
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MH _91XO3EYV=^;<#TF_Y5TR=('3)?'R\=59\_5CUI %A65S,C5P61TAIX]?
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MH2^I2OG+L>X,],11>0^RO)SS76'J5_*7YR?5L9E>-LZCX-//_P!02P,$%
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M_?^; %!+ 0(4 Q0    (  Q&FEA4L..M9@,  &\-   1              "
M 0    !A;FEK+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    (  Q&FEC< 1@;%@8
M $Q    5              "  94#  !A;FEK+3(P,C,Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    "  ,1II8]H0:7?D'  #75P  %0              @ '>"0
M86YI:RTR,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ #$::6+_Y(\2S!0
MKT,  !4              ( !"A(  &%N:6LM,C R,S$R,S%?<')E+GAM;%!+
M 0(4 Q0    (  Q&FEAM\#G 6 $! .=V"@ 5              "  ? 7  !A
M;FEK,C R,S$R,S%?,3!K82YH=&U02P$"% ,4    "  ,1II8VR 7C34,  "Y
M#   #0              @ %[&0$ 8FQA;F-H87)D+FIP9U!+ 0(4 Q0    (
M  Q&FEB1K4F^]PL  '\,   *              "  =LE 0!C;VYL97DN:G!G
M4$L! A0#%     @ #$::6.B+8#L>/P  PX !  T              ( !^C$!
M &5X7S8U.34R,2YH=&U02P$"% ,4    "  ,1II8]\-HN$4_   HA0$ #0
M            @ %#<0$ 97A?-C4Y-3(R+FAT;5!+ 0(4 Q0    (  Q&FEAI
M^#.$800  %,3   -              "  ;.P 0!E>%\V-3DU.#,N:'1M4$L!
M A0#%     @ #$::6 &0F*EG!   CA0   T              ( !/[4! &5X
M7S8U.34X-"YH=&U02P$"% ,4    "  ,1II8A1M></,+  !X#   #0
M        @ '1N0$ 9FES8VAE='1I+FIP9U!+ 0(4 Q0    (  Q&FEC=,(]
M.DD   1,   *              "  >_% 0!G<F%P:#$N:G!G4$L! A0#%
M  @ #$::6,P(" J&J@  + T!  H              ( !40\" &=R87!H,BYJ
M<&=02P$"% ,4    "  ,1II8/'I-]Z7"  #1+0$ "@              @ '_
MN0( 9W)A<&@S+FIP9U!+ 0(4 Q0    (  Q&FEAV=.3Y^ H  ((+   ,
M          "  <Q\ P!H96YN96UA;BYJ<&=02P$"% ,4    "  ,1II8CN+R
M5;(+   ]#   "@              @ 'NAP, ;&%R<V5N+FIP9U!+ 0(4 Q0
M   (  Q&FEB4O +CF@H  !X+   +              "  <B3 P!R:6-H87)D
M+FIP9U!+ 0(4 Q0    (  Q&FEB^HH[IVPP  'H-   ,              "
M 8N> P!T:&]M<'-O;BYJ<&=02P$"% ,4    "  ,1II8FAA%%=(,  !4#0
M"               @ &0JP, =F]G="YJ<&=02P$"% ,4    "  ,1II80=>I
MXW<!  #+ 0  "P              @ &(N , >&)U;&QE="YJ<&=02P4&
/ !4 %0#A!   *+H#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>anik20231231_10ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="anik-20231231.xsd" xlink:type="simple"/>
    <context id="d202410KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000898437</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d202410KABYX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000898437</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d202410KAWEJ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000898437</identifier>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag contextRef="d202410KA" id="ixv-6612">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d202410KA" id="ixv-6613">0000898437</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="d202410KA" id="ixv-6637">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d202410KA" id="ixv-6638">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d202410KA" id="ixv-6639">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentType contextRef="d202410KA" id="ixv-17">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d202410KA" id="ixv-6640">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d202410KA" id="ixv-43">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d202410KA" id="ixv-6641">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d202410KA" id="ixv-68">001-14027</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d202410KA" id="ixv-72">Anika Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d202410KA" id="ixv-83">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d202410KA" id="ixv-89">04-3145961</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d202410KA" id="ixv-96">32 Wiggins Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d202410KA" id="ixv-98">Bedford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d202410KA" id="ixv-100">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d202410KA" id="ixv-102">01730</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d202410KA" id="ixv-109">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d202410KA" id="ixv-111">457-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d202410KA" id="ixv-6642">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d202410KA" id="ixv-6643">ANIK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d202410KA" id="ixv-6644">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d202410KA" id="ixv-6645">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d202410KA" id="ixv-6646">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d202410KA" id="ixv-6647">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d202410KA" id="ixv-6648">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d202410KA" id="ixv-6649">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d202410KA" id="ixv-6650">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d202410KA" id="ixv-6651">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d202410KA" id="ixv-6652">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d202410KA" id="ixv-6653">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d202410KA" id="ixv-6654">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="d202410KABYX"
      decimals="0"
      id="ixv-6655"
      unitRef="USD">370427535</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="d202410KAWEJ"
      decimals="0"
      id="ixv-6656"
      unitRef="Share">14828456</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription contextRef="d202410KA" id="ixv-200">This Amendment No. 1 on Form 10-K/A, or the Amendment, amends the Annual Report on Form 10-K of Anika Therapeutics, Inc., a Delaware corporation, or we, our, us, Anika, or the Company, for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission, or the SEC, on March 15, 2024, or the Original Filing. This Amendment is being filed to amend Part III of the Original Filing to include the information required by and not included in Part III of the Original Filing. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 4 and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.

&#160;

Except for the matters described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing other than as expressly indicated in this Amendment. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company&#x2019;s other filings made with the SEC on or subsequent to March 15, 2024.

</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
